0	[CLS]	O
0	p	O
0	##k	O
0	-	O
0	p	O
0	##d	O
0	analysis	O
0	of	O
0	h	O
0	##r	O
0	changes	O
0	induced	O
0	by	O
0	s	O
0	-	O
0	carved	O
0	##ilo	O
0	##l	O
0	showed	O
0	a	O
0	greater	O
0	ma	O
0	##ximal	O
0	bra	O
0	##dy	O
0	##card	O
0	##ic	O
0	response	O
0	to	O
0	carved	O
0	##ilo	O
0	##l	O
0	in	O
0	s	O
0	##h	O
0	rats	O
0	(	O
0	e	B-PK
0	(	I-PK
0	ma	I-PK
0	##x	I-PK
0	)	I-PK
0	,	O
0	-	O
0	27	O
0	.	O
0	6	O
0	±	O
0	3	O
0	.	O
0	9	O
0	%	O
0	;	O
0	p	O
0	<	O
0	0	O
0	.	O
0	05	O
0	)	O
0	compared	O
0	with	O
0	w	O
0	##ky	O
0	group	O
0	(	O
0	e	B-PK
0	(	I-PK
0	ma	I-PK
0	##x	I-PK
0	)	I-PK
0	,	O
0	-	O
0	13	O
0	.	O
0	4	O
0	±	O
0	2	O
0	.	O
0	5	O
0	%	O
0	)	O
0	.	O
0	[SEP]	O
1	[CLS]	O
1	residues	O
1	were	O
1	re	O
1	##con	O
1	##stituted	O
1	with	O
1	2	O
1	m	O
1	##l	O
1	of	O
1	65	O
1	%	O
1	met	O
1	##han	O
1	##ol	O
1	and	O
1	cent	O
1	##ri	O
1	##fu	O
1	##ged	O
1	at	O
1	10	O
1	,	O
1	000	O
1	×	O
1	g	O
1	for	O
1	8	O
1	min	O
1	.	O
1	[SEP]	O
2	[CLS]	O
2	this	O
2	study	O
2	documents	O
2	that	O
2	a	O
2	ta	O
2	##f	O
2	+	O
2	e	O
2	##v	O
2	##g	O
2	n	O
2	##p	O
2	provides	O
2	sustained	O
2	release	O
2	,	O
2	which	O
2	can	O
2	overcome	O
2	patient	O
2	non	O
2	-	O
2	ad	O
2	##herence	O
2	to	O
2	dos	O
2	##ing	O
2	and	O
2	may	O
2	facilitate	O
2	prediction	O
2	of	O
2	appropriate	O
2	protective	O
2	drug	O
2	concentration	O
2	for	O
2	hi	O
2	##v	O
2	prop	O
2	##hyl	O
2	##ax	O
2	##is	O
2	.	O
2	[SEP]	O
3	[CLS]	O
3	the	O
3	mobile	O
3	phase	O
3	composed	O
3	of	O
3	ace	O
3	##ton	O
3	##it	O
3	##ril	O
3	##e	O
3	-	O
3	0	O
3	.	O
3	1	O
3	m	O
3	am	O
3	##mon	O
3	##ium	O
3	ace	O
3	##tate	O
3	(	O
3	15	O
3	:	O
3	85	O
3	,	O
3	v	O
3	/	O
3	v	O
3	)	O
3	was	O
3	delivered	O
3	at	O
3	a	O
3	flow	O
3	rate	O
3	of	O
3	1	O
3	.	O
3	0	O
3	m	O
3	##l	O
3	/	O
3	min	O
3	.	O
3	[SEP]	O
4	[CLS]	O
4	in	O
4	a	O
4	second	O
4	phase	O
4	,	O
4	the	O
4	same	O
4	animals	O
4	were	O
4	treated	O
4	with	O
4	the	O
4	alternate	O
4	test	O
4	article	O
4	according	O
4	to	O
4	the	O
4	same	O
4	protocol	O
4	.	O
4	[SEP]	O
5	[CLS]	O
5	the	O
5	bio	O
5	##ad	O
5	##hesion	O
5	of	O
5	each	O
5	component	O
5	in	O
5	the	O
5	m	O
5	##z	O
5	-	O
5	c	O
5	##r	O
5	formulation	O
5	was	O
5	evaluated	O
5	individually	O
5	in	O
5	order	O
5	to	O
5	el	O
5	##uc	O
5	##ida	O
5	##te	O
5	the	O
5	contribution	O
5	of	O
5	each	O
5	component	O
5	to	O
5	bio	O
5	##ad	O
5	##hesion	O
5	.	O
5	[SEP]	O
6	[CLS]	O
6	mean	O
6	)	O
6	and	O
6	young	O
6	subjects	O
6	(	O
6	15	O
6	.	O
6	7	O
6	+	O
6	-	O
6	2	O
6	.	O
6	1	O
6	)	O
6	,	O
6	whereas	O
6	total	B-PK
6	clearance	I-PK
6	of	O
6	o	O
6	##xi	O
6	##pur	O
6	##ino	O
6	##l	O
6	was	O
6	significantly	O
6	reduced	O
6	in	O
6	the	O
6	aged	O
6	(	O
6	0	O
6	.	O
6	24	O
6	+	O
6	-	O
6	0	O
6	.	O
6	03	O
6	)	O
6	compared	O
6	with	O
6	young	O
6	controls	O
6	(	O
6	0	O
6	.	O
6	37	O
6	+	O
6	-	O
6	0	O
6	.	O
6	05	O
6	)	O
6	as	O
6	was	O
6	the	O
6	distribution	B-PK
6	volume	I-PK
6	of	O
6	o	O
6	##xi	O
6	##pur	O
6	##ino	O
6	##l	O
6	(	O
6	0	O
6	.	O
6	60	O
6	+	O
6	-	O
6	0	O
6	.	O
6	09	O
6	and	O
6	0	O
6	.	O
6	84	O
6	+	O
6	-	O
6	0	O
6	.	O
6	07	O
6	l	O
6	kg	O
6	-	O
6	1	O
6	,	O
6	respectively	O
6	)	O
6	.	O
6	[SEP]	O
7	[CLS]	O
7	p	O
7	##har	O
7	##ma	O
7	##co	O
7	##kin	O
7	##etic	O
7	parameters	O
7	were	O
7	derived	O
7	by	O
7	using	O
7	a	O
7	non	O
7	##com	O
7	##par	O
7	##tment	O
7	##al	O
7	method	O
7	within	O
7	win	O
7	##non	O
7	##lin	O
7	pro	O
7	(	O
7	version	O
7	5	O
7	.	O
7	2	O
7	)	O
7	.	O
7	[SEP]	O
8	[CLS]	O
8	the	O
8	initial	O
8	elevation	O
8	in	O
8	il	O
8	-	O
8	10	O
8	did	O
8	not	O
8	co	O
8	##rrel	O
8	##ate	O
8	with	O
8	clinical	O
8	response	O
8	or	O
8	with	O
8	the	O
8	development	O
8	of	O
8	toxicity	O
8	.	O
8	[SEP]	O
9	[CLS]	O
9	to	O
9	accomplish	O
9	this	O
9	goal	O
9	,	O
9	a	O
9	series	O
9	of	O
9	genetically	O
9	engineered	O
9	derivatives	O
9	of	O
9	ma	O
9	##b	O
9	ch	O
9	##t	O
9	##nt	O
9	-	O
9	3	O
9	including	O
9	the	O
9	single	O
9	-	O
9	chain	O
9	f	O
9	##v	O
9	,	O
9	di	O
9	##ab	O
9	##ody	O
9	,	O
9	t	O
9	##ria	O
9	##body	O
9	,	O
9	f	O
9	##ab	O
9	,	O
9	and	O
9	f	O
9	(	O
9	a	O
9	##b	O
9	'	O
9	)	O
9	(	O
9	2	O
9	)	O
9	were	O
9	generated	O
9	and	O
9	expressed	O
9	in	O
9	n	O
9	##s	O
9	##0	O
9	my	O
9	##elo	O
9	##ma	O
9	cells	O
9	using	O
9	the	O
9	g	O
9	##lut	O
9	##amine	O
9	s	O
9	##ynth	O
9	##eta	O
9	##se	O
9	am	O
9	##p	O
9	##lification	O
9	system	O
9	.	O
9	[SEP]	O
10	[CLS]	O
10	to	O
10	conduct	O
10	a	O
10	phase	O
10	i	O
10	study	O
10	determining	O
10	the	O
10	safety	O
10	,	O
10	p	O
10	##har	O
10	##ma	O
10	##co	O
10	##kin	O
10	##etics	O
10	and	O
10	preliminary	O
10	efficacy	O
10	of	O
10	e	O
10	##p	O
10	-	O
10	100	O
10	,	O
10	a	O
10	novel	O
10	anti	O
10	##can	O
10	##cer	O
10	drug	O
10	consisting	O
10	of	O
10	natural	O
10	l	O
10	##ute	O
10	##ini	O
10	##zing	O
10	-	O
10	hormone	O
10	-	O
10	releasing	O
10	hormone	O
10	(	O
10	l	O
10	##hr	O
10	##h	O
10	)	O
10	l	O
10	##igan	O
10	##d	O
10	linked	O
10	to	O
10	a	O
10	cat	O
10	##ion	O
10	##ic	O
10	membrane	O
10	-	O
10	disrupt	O
10	##ing	O
10	p	O
10	##eptide	O
10	.	O
10	[SEP]	O
11	[CLS]	O
11	the	O
11	in	O
11	##hibition	O
11	effect	O
11	of	O
11	r	O
11	##hein	O
11	on	O
11	tumor	O
11	cell	O
11	growth	O
11	was	O
11	measured	O
11	by	O
11	the	O
11	percentage	O
11	of	O
11	in	O
11	##hibit	O
11	##ed	O
11	cell	O
11	growth	O
11	.	O
11	[SEP]	O
12	[CLS]	O
12	the	O
12	ed	B-PK
12	##50	I-PK
12	values	O
12	(	O
12	95	O
12	%	O
12	confidence	O
12	interval	O
12	)	O
12	were	O
12	<	O
12	1	O
12	.	O
12	0	O
12	mg	O
12	/	O
12	kg	O
12	p	O
12	.	O
12	o	O
12	.	O
12	and	O
12	<	O
12	0	O
12	.	O
12	3	O
12	mg	O
12	/	O
12	kg	O
12	s	O
12	.	O
12	c	O
12	.	O
12	for	O
12	anti	O
12	-	O
12	em	O
12	##etic	O
12	activity	O
12	,	O
12	9	O
12	.	O
12	45	O
12	(	O
12	4	O
12	.	O
12	09	O
12	,	O
12	47	O
12	.	O
12	79	O
12	)	O
12	mg	O
12	/	O
12	kg	O
12	p	O
12	.	O
12	o	O
12	.	O
12	and	O
12	0	O
12	.	O
12	52	O
12	(	O
12	0	O
12	.	O
12	10	O
12	,	O
12	1	O
12	.	O
12	08	O
12	)	O
12	mg	O
12	/	O
12	kg	O
12	s	O
12	.	O
12	c	O
12	.	O
12	for	O
12	anti	O
12	-	O
12	con	O
12	##st	O
12	##ip	O
12	##ation	O
12	activity	O
12	,	O
12	and	O
12	>	O
12	300	O
12	mg	O
12	/	O
12	kg	O
12	p	O
12	.	O
12	o	O
12	.	O
12	and	O
12	>	O
12	30	O
12	mg	O
12	/	O
12	kg	O
12	s	O
12	.	O
12	c	O
12	.	O
12	for	O
12	anti	O
12	-	O
12	anal	O
12	##ges	O
12	##ic	O
12	activity	O
12	.	O
12	[SEP]	O
13	[CLS]	O
13	extra	O
13	##he	O
13	##pa	O
13	##tic	O
13	metabolism	O
13	of	O
13	4	O
13	-	O
13	met	O
13	##hyl	O
13	##um	O
13	##bell	O
13	##ifer	O
13	##one	O
13	and	O
13	lid	O
13	##oc	O
13	##aine	O
13	in	O
13	the	O
13	an	O
13	##he	O
13	##pa	O
13	##tic	O
13	rabbit	O
13	.	O
13	[SEP]	O
14	[CLS]	O
14	the	O
14	challenge	O
14	in	O
14	developing	O
14	oral	O
14	drug	O
14	delivery	O
14	systems	O
14	of	O
14	poorly	O
14	soluble	O
14	basic	O
14	drugs	O
14	is	O
14	primarily	O
14	due	O
14	to	O
14	their	O
14	p	O
14	##h	O
14	dependent	O
14	so	O
14	##lub	O
14	##ility	O
14	.	O
14	[SEP]	O
15	[CLS]	O
15	of	O
15	the	O
15	48	O
15	and	O
15	24	O
15	subjects	O
15	who	O
15	met	O
15	all	O
15	entry	O
15	criteria	O
15	and	O
15	were	O
15	enrolled	O
15	in	O
15	the	O
15	sad	O
15	and	O
15	mad	O
15	protocols	O
15	,	O
15	respectively	O
15	,	O
15	all	O
15	completed	O
15	the	O
15	study	O
15	and	O
15	were	O
15	included	O
15	in	O
15	the	O
15	final	O
15	analyses	O
15	.	O
15	[SEP]	O
16	[CLS]	O
16	in	O
16	dissolution	O
16	tests	O
16	,	O
16	all	O
16	cu	O
16	##rc	O
16	##umi	O
16	##n	O
16	formulation	O
16	##s	O
16	exhibited	O
16	marked	O
16	improvement	O
16	in	O
16	the	O
16	dissolution	O
16	behavior	O
16	when	O
16	compared	O
16	with	O
16	crystal	O
16	##line	O
16	cu	O
16	##rc	O
16	##umi	O
16	##n	O
16	.	O
16	[SEP]	O
17	[CLS]	O
17	the	O
17	parameter	O
17	estimates	O
17	and	O
17	model	O
17	fit	O
17	for	O
17	models	O
17	with	O
17	body	O
17	weight	O
17	effect	O
17	estimated	O
17	or	O
17	fixed	O
17	to	O
17	zero	O
17	were	O
17	very	O
17	similar	O
17	.	O
17	[SEP]	O
18	[CLS]	O
18	to	O
18	obtain	O
18	tissue	O
18	and	O
18	plasma	O
18	samples	O
18	,	O
18	five	O
18	pigs	O
18	which	O
18	received	O
18	the	O
18	in	O
18	##tra	O
18	##mus	O
18	##cular	O
18	injection	O
18	were	O
18	randomly	O
18	killed	O
18	at	O
18	2	O
18	,	O
18	6	O
18	,	O
18	10	O
18	,	O
18	24	O
18	,	O
18	48	O
18	,	O
18	72	O
18	,	O
18	and	O
18	96	O
18	h	O
18	,	O
18	respectively	O
18	,	O
18	whereas	O
18	those	O
18	in	O
18	control	O
18	group	O
18	were	O
18	sacrificed	O
18	at	O
18	96	O
18	h	O
18	.	O
18	samples	O
18	of	O
18	plasma	O
18	and	O
18	tissues	O
18	,	O
18	including	O
18	muscle	O
18	,	O
18	lung	O
18	,	O
18	heart	O
18	,	O
18	kidney	O
18	,	O
18	liver	O
18	,	O
18	and	O
18	muscle	O
18	at	O
18	the	O
18	injection	O
18	site	O
18	,	O
18	were	O
18	collected	O
18	from	O
18	each	O
18	animal	O
18	.	O
18	[SEP]	O
19	[CLS]	O
19	inspection	O
19	of	O
19	the	O
19	raw	O
19	data	O
19	showed	O
19	that	O
19	148	O
19	of	O
19	the	O
19	163	O
19	error	O
19	codes	O
19	were	O
19	not	O
19	applicable	O
19	to	O
19	the	O
19	four	O
19	primary	O
19	rot	O
19	##em	O
19	parameters	O
19	evaluated	O
19	in	O
19	this	O
19	study	O
19	.	O
19	[SEP]	O
20	[CLS]	O
20	at	O
20	48	O
20	h	O
20	post	O
20	-	O
20	administration	O
20	,	O
20	p	O
20	##t	O
20	##x	O
20	was	O
20	still	O
20	detected	O
20	in	O
20	the	O
20	tumor	O
20	in	O
20	the	O
20	dual	O
20	-	O
20	n	O
20	##ps	O
20	group	O
20	,	O
20	however	O
20	,	O
20	p	O
20	##t	O
20	##x	O
20	levels	O
20	were	O
20	below	O
20	the	O
20	limit	O
20	of	O
20	detection	O
20	in	O
20	the	O
20	tumor	O
20	in	O
20	the	O
20	free	O
20	p	O
20	##t	O
20	##x	O
20	+	O
20	ever	O
20	group	O
20	.	O
20	[SEP]	O
21	[CLS]	O
21	eight	O
21	adult	O
21	volunteers	O
21	with	O
21	severe	O
21	stable	O
21	c	O
21	##ri	O
21	(	O
21	mean	O
21	c	O
21	##rea	O
21	##tin	O
21	##ine	O
21	clearance	O
21	,	O
21	0	O
21	.	O
21	28	O
21	m	O
21	##l	O
21	/	O
21	s	O
21	;	O
21	range	O
21	,	O
21	0	O
21	.	O
21	15	O
21	to	O
21	0	O
21	.	O
21	47	O
21	m	O
21	##l	O
21	/	O
21	s	O
21	)	O
21	were	O
21	recruited	O
21	from	O
21	the	O
21	out	O
21	##patient	O
21	ne	O
21	##ph	O
21	##rol	O
21	##ogy	O
21	clinics	O
21	of	O
21	in	O
21	##dian	O
21	##a	O
21	university	O
21	medical	O
21	center	O
21	.	O
21	[SEP]	O
22	[CLS]	O
22	f	O
22	##gt	O
22	##1	O
22	behave	O
22	##s	O
22	like	O
22	natural	O
22	functional	O
22	fi	O
22	##bri	O
22	##no	O
22	##gen	O
22	,	O
22	and	O
22	its	O
22	p	O
22	##har	O
22	##ma	O
22	##co	O
22	##kin	O
22	##etic	O
22	properties	O
22	are	O
22	in	O
22	line	O
22	with	O
22	those	O
22	expected	O
22	from	O
22	a	O
22	fi	O
22	##bri	O
22	##no	O
22	##gen	O
22	concentrate	O
22	.	O
22	[SEP]	O
23	[CLS]	O
23	overall	O
23	,	O
23	most	O
23	compounds	O
23	reached	O
23	their	O
23	maximum	B-PK
23	concentrations	I-PK
23	within	O
23	2	O
23	h	O
23	,	O
23	whereas	O
23	slow	O
23	absorption	O
23	was	O
23	observed	O
23	for	O
23	the	O
23	four	O
23	di	O
23	##ter	O
23	##pen	O
23	##e	O
23	##quin	O
23	##oned	O
23	##eri	O
23	##vat	O
23	##ives	O
23	(	O
23	t	B-PK
23	##max	I-PK
23	,	O
23	8	O
23	h	O
23	)	O
23	.	O
23	[SEP]	O
24	[CLS]	O
24	as	O
24	previously	O
24	shown	O
24	for	O
24	im	O
24	##ati	O
24	##ni	O
24	##b	O
24	,	O
24	therapeutic	O
24	drug	O
24	monitoring	O
24	(	O
24	t	O
24	##d	O
24	##m	O
24	)	O
24	of	O
24	ve	O
24	##mura	O
24	##fen	O
24	##ib	O
24	should	O
24	be	O
24	important	O
24	to	O
24	measure	O
24	efficacy	O
24	of	O
24	the	O
24	treatment	O
24	in	O
24	me	O
24	##lan	O
24	##oma	O
24	patient	O
24	.	O
24	[SEP]	O
25	[CLS]	O
25	animal	O
25	bio	O
25	##dis	O
25	##tribution	O
25	data	O
25	and	O
25	serial	O
25	micro	O
25	##pet	O
25	images	O
25	demonstrated	O
25	rapid	O
25	tumor	O
25	up	O
25	##take	O
25	and	O
25	rapid	O
25	clearance	B-PK
25	from	O
25	the	O
25	blood	O
25	and	O
25	all	O
25	tissues	O
25	except	O
25	kidney	O
25	.	O
25	[SEP]	O
26	[CLS]	O
26	treatment	O
26	of	O
26	ex	O
26	##uda	O
26	##tive	O
26	age	O
26	-	O
26	related	O
26	mac	O
26	##ular	O
26	de	O
26	##gene	O
26	##ration	O
26	with	O
26	a	O
26	designed	O
26	an	O
26	##ky	O
26	##rin	O
26	repeat	O
26	protein	O
26	that	O
26	binds	O
26	vascular	O
26	end	O
26	##oth	O
26	##eli	O
26	##al	O
26	growth	O
26	factor	O
26	:	O
26	a	O
26	phase	O
26	i	O
26	/	O
26	ii	O
26	study	O
26	.	O
26	[SEP]	O
27	[CLS]	O
27	experiments	O
27	in	O
27	a	O
27	co	O
27	##lla	O
27	##gen	O
27	-	O
27	induced	O
27	art	O
27	##hr	O
27	##itis	O
27	mouse	O
27	model	O
27	demonstrated	O
27	that	O
27	the	O
27	magnitude	O
27	##s	O
27	of	O
27	therapeutic	O
27	effects	O
27	,	O
27	as	O
27	judged	O
27	by	O
27	clinical	O
27	scores	O
27	and	O
27	his	O
27	##tology	O
27	,	O
27	were	O
27	significantly	O
27	enhanced	O
27	by	O
27	the	O
27	sustained	O
27	delivery	O
27	of	O
27	p	O
27	##eg	O
27	-	O
27	trail	O
27	,	O
27	with	O
27	the	O
27	order	O
27	of	O
27	na	O
27	##no	O
27	##com	O
27	##plex	O
27	in	O
27	1	O
27	%	O
27	ha	O
27	>	O
27	na	O
27	##no	O
27	##com	O
27	##plex	O
27	in	O
27	p	O
27	##bs	O
27	>	O
27	p	O
27	##eg	O
27	-	O
27	trail	O
27	in	O
27	p	O
27	##bs	O
27	.	O
27	[SEP]	O
28	[CLS]	O
28	a	O
28	##es	O
28	were	O
28	coded	O
28	by	O
28	using	O
28	the	O
28	medical	O
28	dictionary	O
28	for	O
28	drug	O
28	regulatory	O
28	activities	O
28	(	O
28	me	O
28	##dd	O
28	##ra	O
28	;	O
28	v	O
28	12	O
28	.	O
28	0	O
28	)	O
28	.	O
28	[SEP]	O
29	[CLS]	O
29	the	O
29	predict	O
29	##ive	O
29	performance	O
29	of	O
29	the	O
29	final	O
29	model	O
29	was	O
29	evaluated	O
29	with	O
29	a	O
29	population	O
29	prediction	O
29	-	O
29	corrected	O
29	visual	O
29	predict	O
29	##ive	O
29	check	O
29	(	O
29	p	O
29	##c	O
29	##v	O
29	##p	O
29	##c	O
29	)	O
29	through	O
29	1000	O
29	simulation	O
29	##s	O
29	of	O
29	the	O
29	data	O
29	##set	O
29	[	O
29	24	O
29	]	O
29	.	O
29	[SEP]	O
30	[CLS]	O
30	the	O
30	c	O
30	##s	O
30	##f	O
30	penetration	O
30	of	O
30	p	O
30	##ex	O
30	##ida	O
30	##rt	O
30	##ini	O
30	##b	O
30	after	O
30	single	O
30	-	O
30	dose	O
30	oral	O
30	administration	O
30	to	O
30	n	O
30	##hp	O
30	##s	O
30	was	O
30	limited	O
30	.	O
30	[SEP]	O
31	[CLS]	O
31	c	O
31	##t	O
31	##x	O
31	and	O
31	the	O
31	internal	O
31	standard	O
31	(	O
31	w	O
31	##ogo	O
31	##nin	O
31	)	O
31	were	O
31	detected	O
31	using	O
31	a	O
31	tandem	O
31	mass	O
31	s	O
31	##pect	O
31	##rome	O
31	##ter	O
31	in	O
31	positive	O
31	multiple	O
31	reaction	O
31	monitoring	O
31	mode	O
31	.	O
31	[SEP]	O
32	[CLS]	O
32	there	O
32	was	O
32	also	O
32	a	O
32	rapid	O
32	de	O
32	##ple	O
32	##tion	O
32	in	O
32	c	O
32	##d	O
32	##19	O
32	+	O
32	b	O
32	-	O
32	cells	O
32	after	O
32	the	O
32	first	O
32	o	O
32	##bin	O
32	##ut	O
32	##uz	O
32	##uma	O
32	##b	O
32	in	O
32	##fusion	O
32	(	O
32	i	O
32	.	O
32	e	O
32	.	O
32	b	O
32	-	O
32	cell	O
32	de	O
32	##ple	O
32	##tion	O
32	;	O
32	supplement	O
32	##ary	O
32	data	O
32	,	O
32	fi	O
32	##g	O
32	.	O
32	4	O
32	)	O
32	.	O
32	[SEP]	O
33	[CLS]	O
33	ve	O
33	##nous	O
33	blood	O
33	was	O
33	collected	O
33	by	O
33	ve	O
33	##ni	O
33	##pu	O
33	##nc	O
33	##ture	O
33	at	O
33	t	O
33	##0	O
33	in	O
33	a	O
33	non	O
33	-	O
33	fast	O
33	##ing	O
33	state	O
33	to	O
33	measure	O
33	the	O
33	o	O
33	##me	O
33	##ga	O
33	-	O
33	3	O
33	index	O
33	,	O
33	and	O
33	at	O
33	t	O
33	##1	O
33	and	O
33	t	O
33	##8	O
33	after	O
33	an	O
33	overnight	O
33	fast	O
33	to	O
33	measure	O
33	pre	O
33	##de	O
33	##fine	O
33	##d	O
33	bio	O
33	##chemical	O
33	parameters	O
33	as	O
33	shown	O
33	in	O
33	table	O
33	2	O
33	.	O
33	[SEP]	O
34	[CLS]	O
34	the	O
34	ass	O
34	##ays	O
34	were	O
34	valid	O
34	##ated	O
34	over	O
34	the	O
34	concentration	O
34	range	O
34	of	O
34	3	O
34	.	O
34	5	O
34	-	O
34	143	O
34	##36	O
34	.	O
34	0	O
34	ng	O
34	x	O
34	m	O
34	##l	O
34	(	O
34	-	O
34	1	O
34	)	O
34	in	O
34	human	O
34	plasma	O
34	.	O
34	[SEP]	O
35	[CLS]	O
35	the	O
35	protocol	O
35	was	O
35	approved	O
35	by	O
35	the	O
35	institutional	O
35	review	O
35	board	O
35	of	O
35	kn	O
35	##uh	O
35	.	O
35	[SEP]	O
36	[CLS]	O
36	to	O
36	assess	O
36	the	O
36	p	O
36	##har	O
36	##ma	O
36	##co	O
36	##kin	O
36	##etic	O
36	and	O
36	p	O
36	##har	O
36	##ma	O
36	##co	O
36	##dynamic	O
36	dose	O
36	-	O
36	responses	O
36	of	O
36	continuous	O
36	in	O
36	##fusion	O
36	regime	O
36	##ns	O
36	of	O
36	la	O
36	##nso	O
36	##pra	O
36	##zo	O
36	##le	O
36	.	O
36	[SEP]	O
37	[CLS]	O
37	a	O
37	good	O
37	correlation	O
37	of	O
37	drug	O
37	absorption	O
37	in	O
37	v	O
37	##ivo	O
37	and	O
37	drug	O
37	release	O
37	in	O
37	v	O
37	##it	O
37	##ro	O
37	(	O
37	r	O
37	(	O
37	2	O
37	)	O
37	=	O
37	0	O
37	.	O
37	978	O
37	##5	O
37	)	O
37	was	O
37	observed	O
37	.	O
37	[SEP]	O
38	[CLS]	O
38	the	O
38	subjects	O
38	were	O
38	assessed	O
38	throughout	O
38	the	O
38	study	O
38	to	O
38	determine	O
38	if	O
38	they	O
38	were	O
38	experiencing	O
38	adverse	O
38	events	O
38	.	O
38	[SEP]	O
39	[CLS]	O
39	almost	O
39	all	O
39	of	O
39	the	O
39	g	O
39	##ra	O
39	##vid	O
39	##ae	O
39	described	O
39	the	O
39	o	O
39	##bs	O
39	##te	O
39	##tric	O
39	anal	O
39	##ges	O
39	##ia	O
39	as	O
39	good	O
39	or	O
39	adequate	O
39	.	O
39	[SEP]	O
40	[CLS]	O
40	residual	O
40	g	O
40	##z	O
40	-	O
40	de	O
40	levels	O
40	in	O
40	di	O
40	##st	O
40	##ille	O
40	##d	O
40	water	O
40	were	O
40	79	O
40	.	O
40	3	O
40	%	O
40	±	O
40	3	O
40	.	O
40	0	O
40	%	O
40	at	O
40	10	O
40	hours	O
40	(	O
40	figure	O
40	4	O
40	##a	O
40	)	O
40	and	O
40	83	O
40	.	O
40	7	O
40	%	O
40	±	O
40	9	O
40	.	O
40	8	O
40	%	O
40	by	O
40	one	O
40	day	O
40	(	O
40	figure	O
40	4	O
40	##c	O
40	)	O
40	after	O
40	in	O
40	##cu	O
40	##bation	O
40	at	O
40	37	O
40	##°	O
40	##c	O
40	.	O
40	[SEP]	O
41	[CLS]	O
41	the	O
41	m	O
41	##t	O
41	##d	O
41	for	O
41	schedule	O
41	4	O
41	/	O
41	2	O
41	and	O
41	the	O
41	c	O
41	##dd	O
41	schedule	O
41	was	O
41	sun	O
41	##iti	O
41	##ni	O
41	##b	O
41	37	O
41	.	O
41	5	O
41	mg	O
41	/	O
41	d	O
41	plus	O
41	cape	O
41	##ci	O
41	##ta	O
41	##bine	O
41	1	O
41	,	O
41	000	O
41	mg	O
41	/	O
41	m	O
41	(	O
41	2	O
41	)	O
41	twice	O
41	per	O
41	day	O
41	;	O
41	the	O
41	m	O
41	##t	O
41	##d	O
41	for	O
41	schedule	O
41	2	O
41	/	O
41	1	O
41	was	O
41	sun	O
41	##iti	O
41	##ni	O
41	##b	O
41	50	O
41	mg	O
41	/	O
41	d	O
41	plus	O
41	cape	O
41	##ci	O
41	##ta	O
41	##bine	O
41	1	O
41	,	O
41	000	O
41	mg	O
41	/	O
41	m	O
41	(	O
41	2	O
41	)	O
41	twice	O
41	per	O
41	day	O
41	.	O
41	[SEP]	O
42	[CLS]	O
42	effects	O
42	of	O
42	and	O
42	##ros	O
42	##tero	O
42	##ne	O
42	on	O
42	the	O
42	protective	O
42	action	O
42	of	O
42	various	O
42	anti	O
42	##ep	O
42	##ile	O
42	##ptic	O
42	drugs	O
42	against	O
42	ma	O
42	##ximal	O
42	electro	O
42	##sh	O
42	##ock	O
42	-	O
42	induced	O
42	seizure	O
42	##s	O
42	in	O
42	mice	O
42	.	O
42	[SEP]	O
43	[CLS]	O
43	the	O
43	average	O
43	number	O
43	of	O
43	nod	O
43	##aga	O
43	molecules	O
43	per	O
43	protein	O
43	was	O
43	q	O
43	##uant	O
43	##ified	O
43	by	O
43	is	O
43	##oto	O
43	##pic	O
43	di	O
43	##lution	O
43	as	O
43	previously	O
43	described	O
43	[	O
43	19	O
43	]	O
43	and	O
43	was	O
43	1	O
43	.	O
43	4	O
43	.	O
43	[SEP]	O
44	[CLS]	O
44	at	O
44	180	O
44	mg	O
44	/	O
44	m	O
44	##2	O
44	,	O
44	cm	B-PK
44	##ax	I-PK
44	was	O
44	2	O
44	.	O
44	9	O
44	+	O
44	-	O
44	1	O
44	.	O
44	2	O
44	micro	O
44	##g	O
44	/	O
44	m	O
44	##l	O
44	,	O
44	t	B-PK
44	##1	I-PK
44	/	I-PK
44	2	I-PK
44	78	O
44	.	O
44	7	O
44	+	O
44	-	O
44	24	O
44	.	O
44	4	O
44	h	O
44	,	O
44	c	B-PK
44	##lt	I-PK
44	##ot	I-PK
44	25	O
44	.	O
44	3	O
44	+	O
44	-	O
44	4	O
44	.	O
44	6	O
44	m	O
44	##l	O
44	/	O
44	min	O
44	and	O
44	au	B-PK
44	##c	I-PK
44	203	O
44	+	O
44	-	O
44	71	O
44	.	O
44	5	O
44	h	O
44	x	O
44	micro	O
44	##g	O
44	/	O
44	m	O
44	##l	O
44	.	O
44	[SEP]	O
45	[CLS]	O
45	a	O
45	q	O
45	##uad	O
45	##ratic	O
45	re	O
45	##gression	O
45	(	O
45	weighted	O
45	1	O
45	/	O
45	concentration	O
45	)	O
45	was	O
45	used	O
45	to	O
45	fit	O
45	ca	O
45	##li	O
45	##bra	O
45	##tion	O
45	curves	O
45	over	O
45	the	O
45	concentration	O
45	range	O
45	1	O
45	.	O
45	01	O
45	-	O
45	220	O
45	##0	O
45	ng	O
45	/	O
45	m	O
45	##l	O
45	with	O
45	an	O
45	equation	O
45	y	O
45	=	O
45	a	O
45	##x	O
45	##2	O
45	+	O
45	b	O
45	##x	O
45	+	O
45	c	O
45	for	O
45	free	O
45	payload	O
45	.	O
45	[SEP]	O
46	[CLS]	O
46	the	O
46	p	O
46	##har	O
46	##ma	O
46	##co	O
46	##kin	O
46	##etic	O
46	data	O
46	obtained	O
46	after	O
46	single	O
46	in	O
46	##tra	O
46	##per	O
46	##ito	O
46	##nea	O
46	##l	O
46	injection	O
46	##s	O
46	were	O
46	calculated	O
46	according	O
46	to	O
46	a	O
46	two	O
46	-	O
46	compartment	O
46	model	O
46	using	O
46	j	O
46	##mp	O
46	7	O
46	.	O
46	0	O
46	.	O
46	1	O
46	(	O
46	sa	O
46	##s	O
46	institute	O
46	in	O
46	##c	O
46	.	O
46	)	O
46	software	O
46	for	O
46	approximation	O
46	fit	O
46	of	O
46	the	O
46	concentration	O
46	curves	O
46	.	O
46	[SEP]	O
47	[CLS]	O
47	reproductive	O
47	toxicity	O
47	studies	O
47	,	O
47	p	O
47	##har	O
47	##ma	O
47	##co	O
47	##kin	O
47	##etic	O
47	studies	O
47	,	O
47	single	O
47	-	O
47	and	O
47	repeat	O
47	-	O
47	dose	O
47	in	O
47	##tra	O
47	##per	O
47	##ito	O
47	##nea	O
47	##l	O
47	or	O
47	in	O
47	##tra	O
47	##ven	O
47	##ous	O
47	toxicity	O
47	studies	O
47	in	O
47	mice	O
47	,	O
47	rats	O
47	and	O
47	monkeys	O
47	were	O
47	conducted	O
47	to	O
47	assess	O
47	the	O
47	toxicity	O
47	of	O
47	l	O
47	##hr	O
47	##h	O
47	-	O
47	p	O
47	##e	O
47	##40	O
47	.	O
47	[SEP]	O
48	[CLS]	O
48	after	O
48	trans	O
48	##fusion	O
48	with	O
48	flu	O
48	##oso	O
48	##l	O
48	da	O
48	20	O
48	%	O
48	or	O
48	s	O
48	##trom	O
48	##a	O
48	-	O
48	free	O
48	hem	O
48	##og	O
48	##lo	O
48	##bin	O
48	the	O
48	p	O
48	##har	O
48	##ma	O
48	##co	O
48	##kin	O
48	##etics	O
48	of	O
48	anti	O
48	##py	O
48	##rine	O
48	,	O
48	di	O
48	##az	O
48	##ep	O
48	##am	O
48	,	O
48	and	O
48	pen	O
48	##ici	O
48	##llin	O
48	were	O
48	unchanged	O
48	when	O
48	compared	O
48	to	O
48	control	O
48	animals	O
48	.	O
48	[SEP]	O
49	[CLS]	O
49	the	O
49	p	O
49	##t	O
49	##c	O
49	##l	O
49	sub	O
49	##type	O
49	was	O
49	diagnosed	O
49	in	O
49	each	O
49	institution	O
49	from	O
49	les	O
49	##ion	O
49	bio	O
49	##psy	O
49	specimens	O
49	and	O
49	confirmed	O
49	by	O
49	an	O
49	independent	O
49	path	O
49	##ology	O
49	review	O
49	committee	O
49	.	O
49	[SEP]	O
50	[CLS]	O
50	human	O
50	est	O
50	##rogen	O
50	receptor	O
50	‐	O
50	α	O
50	(	O
50	er	O
50	##α	O
50	)	O
50	and	O
50	est	O
50	##rogen	O
50	receptor	O
50	‐	O
50	β	O
50	(	O
50	er	O
50	##β	O
50	)	O
50	expressed	O
50	in	O
50	s	O
50	##f	O
50	##9	O
50	insect	O
50	cells	O
50	were	O
50	prepared	O
50	individually	O
50	in	O
50	modified	O
50	t	O
50	##ris	O
50	–	O
50	h	O
50	##c	O
50	##l	O
50	buffer	O
50	p	O
50	##h	O
50	7	O
50	.	O
50	4	O
50	.	O
50	[SEP]	O
51	[CLS]	O
51	these	O
51	include	O
51	nearly	O
51	complete	O
51	enter	O
51	##al	O
51	absorption	O
51	and	O
51	virtual	O
51	absence	O
51	of	O
51	liver	O
51	first	O
51	-	O
51	pass	O
51	metabolism	O
51	,	O
51	both	O
51	resulting	O
51	in	O
51	high	O
51	bio	B-PK
51	##ava	I-PK
51	##ila	I-PK
51	##bility	I-PK
51	,	O
51	long	O
51	plasma	B-PK
51	half	I-PK
51	-	I-PK
51	life	I-PK
51	,	O
51	p	O
51	##har	O
51	##ma	O
51	##co	O
51	##kin	O
51	##etics	O
51	that	O
51	are	O
51	linear	O
51	over	O
51	a	O
51	wide	O
51	dose	O
51	range	O
51	and	O
51	independent	O
51	of	O
51	age	O
51	,	O
51	food	O
51	intake	O
51	and	O
51	h	O
51	##ydro	O
51	##xy	O
51	##lator	O
51	status	O
51	,	O
51	low	O
51	plasma	O
51	protein	O
51	binding	O
51	,	O
51	and	O
51	a	O
51	1	O
51	:	O
51	1	O
51	ratio	O
51	of	O
51	he	O
51	##pa	O
51	##tic	O
51	meta	O
51	##bol	O
51	##ization	O
51	to	O
51	re	O
51	##nal	O
51	elimination	O
51	of	O
51	the	O
51	un	O
51	##altered	O
51	substance	O
51	.	O
51	[SEP]	O
52	[CLS]	O
52	seventy	O
52	subjects	O
52	were	O
52	randomly	O
52	assigned	O
52	to	O
52	8	O
52	in	O
52	##cre	O
52	##mental	O
52	dos	O
52	##age	O
52	groups	O
52	(	O
52	2	O
52	,	O
52	5	O
52	,	O
52	10	O
52	,	O
52	25	O
52	,	O
52	50	O
52	,	O
52	100	O
52	,	O
52	200	O
52	and	O
52	400	O
52	µ	O
52	##g	O
52	)	O
52	.	O
52	[SEP]	O
53	[CLS]	O
53	peak	B-PK
53	plasma	I-PK
53	levels	I-PK
53	and	O
53	au	B-PK
53	##c	I-PK
53	##0	I-PK
53	–	I-PK
53	24	I-PK
53	##h	I-PK
53	showed	O
53	no	O
53	clear	O
53	increase	O
53	after	O
53	repeated	O
53	dos	O
53	##ing	O
53	,	O
53	but	O
53	mean	O
53	t	B-PK
53	##rough	I-PK
53	plasma	I-PK
53	levels	I-PK
53	increased	O
53	with	O
53	increasing	O
53	numbers	O
53	of	O
53	injection	O
53	##s	O
53	up	O
53	to	O
53	at	O
53	least	O
53	the	O
53	first	O
53	20	O
53	weeks	O
53	of	O
53	treatment	O
53	,	O
53	indicating	O
53	continued	O
53	tissue	O
53	exposure	O
53	at	O
53	once	O
53	-	O
53	weekly	O
53	dos	O
53	##ing	O
53	intervals	O
53	.	O
53	[SEP]	O
54	[CLS]	O
54	the	O
54	f	O
54	##e	O
54	-	O
54	b	O
54	##lf	O
54	or	O
54	tax	O
54	##ol	O
54	-	O
54	loaded	O
54	n	O
54	##cs	O
54	indicated	O
54	as	O
54	a	O
54	##ec	O
54	-	O
54	c	O
54	##p	O
54	-	O
54	f	O
54	##e	O
54	-	O
54	b	O
54	##lf	O
54	or	O
54	a	O
54	##ec	O
54	-	O
54	c	O
54	##p	O
54	-	O
54	tax	O
54	##ol	O
54	n	O
54	##cs	O
54	,	O
54	respectively	O
54	,	O
54	were	O
54	made	O
54	by	O
54	combination	O
54	of	O
54	ion	O
54	##ic	O
54	gel	O
54	##ation	O
54	and	O
54	na	O
54	##no	O
54	##p	O
54	##re	O
54	##ci	O
54	##pit	O
54	##ation	O
54	.	O
54	[SEP]	O
55	[CLS]	O
55	the	O
55	radio	O
55	##chemical	O
55	purity	O
55	of	O
55	the	O
55	compound	O
55	was	O
55	determined	O
55	to	O
55	be	O
55	higher	O
55	##than	O
55	95	O
55	%	O
55	.	O
55	[SEP]	O
56	[CLS]	O
56	patients	O
56	were	O
56	randomly	O
56	assigned	O
56	to	O
56	once	O
56	-	O
56	daily	O
56	l	O
56	##y	O
56	##21	O
56	##9	O
56	##60	O
56	##44	O
56	(	O
56	final	O
56	doses	O
56	of	O
56	125	O
56	or	O
56	250	O
56	mg	O
56	/	O
56	d	O
56	)	O
56	or	O
56	place	O
56	##bo	O
56	.	O
56	[SEP]	O
57	[CLS]	O
57	the	O
57	parameters	O
57	of	O
57	the	O
57	final	O
57	model	O
57	are	O
57	presented	O
57	in	O
57	table	O
57	3	O
57	.	O
57	[SEP]	O
58	[CLS]	O
58	to	O
58	test	O
58	whether	O
58	13	O
58	##cis	O
58	##ra	O
58	results	O
58	in	O
58	a	O
58	decrease	O
58	in	O
58	c	O
58	##y	O
58	##p	O
58	##2	O
58	##d	O
58	##6	O
58	activity	O
58	in	O
58	the	O
58	clinic	O
58	,	O
58	a	O
58	d	O
58	##di	O
58	study	O
58	was	O
58	conducted	O
58	using	O
58	de	O
58	##x	O
58	##trom	O
58	##eth	O
58	##or	O
58	##pha	O
58	##n	O
58	as	O
58	a	O
58	probe	O
58	.	O
58	[SEP]	O
59	[CLS]	O
59	the	O
59	en	O
59	##cap	O
59	##sul	O
59	##ated	O
59	c	O
59	##f	O
59	in	O
59	the	O
59	three	O
59	batch	O
59	##es	O
59	was	O
59	measured	O
59	after	O
59	pu	O
59	##rification	O
59	of	O
59	the	O
59	lip	O
59	##oso	O
59	##mes	O
59	.	O
59	[SEP]	O
60	[CLS]	O
60	the	O
60	per	O
60	-	O
60	oral	O
60	administration	O
60	of	O
60	[	O
60	3	O
60	##h	O
60	]	O
60	di	O
60	##os	O
60	##gen	O
60	##in	O
60	yielded	O
60	12	O
60	%	O
60	of	O
60	the	O
60	given	O
60	dose	O
60	distributed	O
60	throughout	O
60	:	O
60	liver	O
60	,	O
60	s	O
60	##ple	O
60	##en	O
60	,	O
60	e	O
60	##pid	O
60	##idy	O
60	##mal	O
60	fat	O
60	,	O
60	brain	O
60	and	O
60	car	O
60	##cas	O
60	##s	O
60	of	O
60	the	O
60	rat	O
60	.	O
60	[SEP]	O
61	[CLS]	O
61	the	O
61	disposition	O
61	of	O
61	[	O
61	14	O
61	##c	O
61	]	O
61	sa	O
61	##lm	O
61	##eter	O
61	##ol	O
61	x	O
61	##ina	O
61	##fo	O
61	##ate	O
61	,	O
61	a	O
61	new	O
61	inhaled	O
61	beta	O
61	2	O
61	-	O
61	ad	O
61	##ren	O
61	##oc	O
61	##ept	O
61	##or	O
61	ago	O
61	##nist	O
61	with	O
61	both	O
61	br	O
61	##on	O
61	##cho	O
61	##di	O
61	##lator	O
61	and	O
61	anti	O
61	##in	O
61	##f	O
61	##lam	O
61	##mat	O
61	##ory	O
61	activity	O
61	,	O
61	has	O
61	been	O
61	studied	O
61	in	O
61	laboratory	O
61	animals	O
61	and	O
61	humans	O
61	following	O
61	in	O
61	##tra	O
61	##ven	O
61	##ous	O
61	and	O
61	oral	O
61	administration	O
61	.	O
61	[SEP]	O
62	[CLS]	O
62	phase	O
62	i	O
62	study	O
62	of	O
62	s	O
62	-	O
62	1	O
62	and	O
62	bi	O
62	##week	O
62	##ly	O
62	do	O
62	##ce	O
62	##ta	O
62	##xe	O
62	##l	O
62	combination	O
62	ch	O
62	##em	O
62	##otherapy	O
62	for	O
62	advanced	O
62	and	O
62	re	O
62	##current	O
62	gas	O
62	##tric	O
62	cancer	O
62	.	O
62	[SEP]	O
63	[CLS]	O
63	1	O
63	##h	O
63	nm	O
63	##r	O
63	(	O
63	500	O
63	m	O
63	##h	O
63	##z	O
63	,	O
63	d	O
63	##ms	O
63	##o	O
63	-	O
63	d	O
63	##6	O
63	)	O
63	:	O
63	δ	O
63	10	O
63	.	O
63	37	O
63	(	O
63	s	O
63	,	O
63	1	O
63	##h	O
63	,	O
63	n	O
63	##h	O
63	)	O
63	,	O
63	8	O
63	.	O
63	94	O
63	(	O
63	d	O
63	,	O
63	j	O
63	=	O
63	4	O
63	.	O
63	0	O
63	h	O
63	##z	O
63	,	O
63	1	O
63	##h	O
63	,	O
63	a	O
63	##r	O
63	-	O
63	h	O
63	)	O
63	,	O
63	8	O
63	.	O
63	52	O
63	(	O
63	s	O
63	,	O
63	1	O
63	##h	O
63	,	O
63	a	O
63	##r	O
63	-	O
63	h	O
63	)	O
63	,	O
63	8	O
63	.	O
63	34	O
63	(	O
63	d	O
63	,	O
63	j	O
63	=	O
63	15	O
63	.	O
63	5	O
63	h	O
63	##z	O
63	,	O
63	1	O
63	##h	O
63	,	O
63	al	O
63	##ken	O
63	##e	O
63	hydrogen	O
63	)	O
63	,	O
63	8	O
63	.	O
63	33	O
63	(	O
63	br	O
63	##s	O
63	,	O
63	1	O
63	##h	O
63	,	O
63	a	O
63	##r	O
63	-	O
63	h	O
63	)	O
63	,	O
63	8	O
63	.	O
63	16	O
63	(	O
63	d	O
63	,	O
63	j	O
63	=	O
63	8	O
63	.	O
63	5	O
63	h	O
63	##z	O
63	,	O
63	1	O
63	##h	O
63	,	O
63	a	O
63	##r	O
63	-	O
63	h	O
63	)	O
63	,	O
63	8	O
63	.	O
63	08	O
63	(	O
63	m	O
63	,	O
63	2	O
63	##h	O
63	,	O
63	a	O
63	##r	O
63	-	O
63	h	O
63	)	O
63	,	O
63	7	O
63	.	O
63	91	O
63	(	O
63	d	O
63	,	O
63	j	O
63	=	O
63	4	O
63	.	O
63	0	O
63	h	O
63	##z	O
63	,	O
63	1	O
63	##h	O
63	,	O
63	a	O
63	##r	O
63	-	O
63	h	O
63	)	O
63	,	O
63	7	O
63	.	O
63	83	O
63	(	O
63	m	O
63	,	O
63	1	O
63	##h	O
63	,	O
63	a	O
63	##r	O
63	-	O
63	h	O
63	)	O
63	,	O
63	7	O
63	.	O
63	60	O
63	(	O
63	m	O
63	,	O
63	1	O
63	##h	O
63	,	O
63	a	O
63	##r	O
63	-	O
63	h	O
63	)	O
63	,	O
63	7	O
63	.	O
63	28	O
63	(	O
63	d	O
63	,	O
63	j	O
63	=	O
63	15	O
63	.	O
63	5	O
63	h	O
63	##z	O
63	,	O
63	1	O
63	##h	O
63	,	O
63	al	O
63	##ken	O
63	##e	O
63	hydrogen	O
63	)	O
63	,	O
63	7	O
63	.	O
63	27	O
63	(	O
63	m	O
63	,	O
63	1	O
63	##h	O
63	,	O
63	a	O
63	##r	O
63	-	O
63	h	O
63	)	O
63	,	O
63	3	O
63	.	O
63	79	O
63	–	O
63	3	O
63	.	O
63	63	O
63	(	O
63	m	O
63	,	O
63	5	O
63	##h	O
63	,	O
63	o	O
63	##ch	O
63	##3	O
63	+	O
63	ch	O
63	##2	O
63	)	O
63	,	O
63	3	O
63	.	O
63	48	O
63	(	O
63	t	O
63	,	O
63	j	O
63	=	O
63	6	O
63	.	O
63	5	O
63	h	O
63	##z	O
63	,	O
63	2	O
63	##h	O
63	,	O
63	ch	O
63	##2	O
63	)	O
63	,	O
63	1	O
63	.	O
63	94	O
63	(	O
63	m	O
63	,	O
63	2	O
63	##h	O
63	,	O
63	ch	O
63	##2	O
63	)	O
63	,	O
63	1	O
63	.	O
63	89	O
63	–	O
63	1	O
63	.	O
63	81	O
63	(	O
63	m	O
63	,	O
63	2	O
63	##h	O
63	,	O
63	ch	O
63	##2	O
63	)	O
63	.	O
63	[SEP]	O
64	[CLS]	O
64	for	O
64	plasma	O
64	levels	O
64	of	O
64	s	O
64	##met	O
64	,	O
64	s	O
64	##ve	O
64	##g	O
64	##f	O
64	##r	O
64	##2	O
64	,	O
64	ve	O
64	##g	O
64	##fa	O
64	and	O
64	h	O
64	##g	O
64	##f	O
64	,	O
64	marker	O
64	base	O
64	##line	O
64	and	O
64	changes	O
64	from	O
64	base	O
64	##line	O
64	were	O
64	analyzed	O
64	at	O
64	each	O
64	time	O
64	point	O
64	using	O
64	analysis	O
64	of	O
64	variance	O
64	,	O
64	and	O
64	their	O
64	relationships	O
64	with	O
64	plasma	O
64	fore	O
64	##tin	O
64	##ib	O
64	concentrations	O
64	and	O
64	clinical	O
64	outcome	O
64	(	O
64	sum	O
64	of	O
64	longest	O
64	diameter	O
64	[	O
64	s	O
64	##ld	O
64	]	O
64	,	O
64	p	O
64	##fs	O
64	and	O
64	re	O
64	##cist	O
64	response	O
64	)	O
64	were	O
64	examined	O
64	using	O
64	spear	O
64	##man	O
64	analysis	O
64	.	O
64	[SEP]	O
65	[CLS]	O
65	capsule	O
65	##s	O
65	were	O
65	taken	O
65	with	O
65	240	O
65	m	O
65	##l	O
65	of	O
65	water	O
65	while	O
65	subjects	O
65	were	O
65	fast	O
65	##ed	O
65	.	O
65	[SEP]	O
66	[CLS]	O
66	the	O
66	trial	O
66	is	O
66	conducted	O
66	in	O
66	accordance	O
66	with	O
66	the	O
66	ethical	O
66	principles	O
66	laid	O
66	down	O
66	in	O
66	the	O
66	declaration	O
66	of	O
66	he	O
66	##ls	O
66	##ink	O
66	##i	O
66	(	O
66	as	O
66	revised	O
66	in	O
66	1983	O
66	)	O
66	,	O
66	the	O
66	guide	O
66	##line	O
66	for	O
66	good	O
66	clinical	O
66	practice	O
66	(	O
66	chin	O
66	##a	O
66	,	O
66	2003	O
66	and	O
66	exposure	O
66	draft	O
66	in	O
66	2017	O
66	)	O
66	,	O
66	and	O
66	local	O
66	laws	O
66	.	O
66	[SEP]	O
67	[CLS]	O
67	protein	O
67	binding	O
67	of	O
67	ma	O
67	##rb	O
67	##of	O
67	##lo	O
67	##xa	O
67	##cin	O
67	was	O
67	not	O
67	significantly	O
67	different	O
67	in	O
67	healthy	O
67	and	O
67	disease	O
67	##d	O
67	ca	O
67	##lves	O
67	.	O
67	[SEP]	O
68	[CLS]	O
68	parasite	O
68	slope	O
68	half	B-PK
68	-	I-PK
68	life	I-PK
68	for	O
68	each	O
68	patient	O
68	was	O
68	calculated	O
68	from	O
68	log	O
68	##e	O
68	(	O
68	2	O
68	)	O
68	/	O
68	k	O
68	=	O
68	0	O
68	.	O
68	69	O
68	##3	O
68	,	O
68	where	O
68	k	B-PK
68	is	O
68	the	O
68	clearance	B-PK
68	rate	I-PK
68	constant	I-PK
68	[	O
68	15	O
68	]	O
68	.	O
68	[SEP]	O
69	[CLS]	O
69	this	O
69	consent	O
69	extended	O
69	to	O
69	the	O
69	use	O
69	of	O
69	biological	O
69	,	O
69	his	O
69	##top	O
69	##ath	O
69	##ological	O
69	,	O
69	radio	O
69	##logical	O
69	,	O
69	bio	O
69	##chemical	O
69	,	O
69	and	O
69	clinical	O
69	data	O
69	for	O
69	scientific	O
69	purposes	O
69	.	O
69	[SEP]	O
70	[CLS]	O
70	the	O
70	total	B-PK
70	clearance	I-PK
70	,	I-PK
70	c	I-PK
70	##lt	I-PK
70	##ot	I-PK
70	;	O
70	he	B-PK
70	##pa	I-PK
70	##tic	I-PK
70	extraction	I-PK
70	ratio	I-PK
70	,	I-PK
70	eh	I-PK
70	;	O
70	and	O
70	liver	B-PK
70	-	I-PK
70	to	I-PK
70	-	I-PK
70	plasma	I-PK
70	concentration	I-PK
70	ratio	I-PK
70	,	I-PK
70	k	I-PK
70	##p	I-PK
70	values	O
70	,	O
70	decreased	O
70	as	O
70	the	O
70	in	O
70	##fusion	O
70	rate	O
70	increased	O
70	.	O
70	[SEP]	O
71	[CLS]	O
71	following	O
71	su	O
71	##gam	O
71	##made	O
71	##x	O
71	16	O
71	mg	O
71	/	O
71	kg	O
71	in	O
71	##fusion	O
71	,	O
71	peak	B-PK
71	su	I-PK
71	##gam	I-PK
71	##made	I-PK
71	##x	I-PK
71	concentration	I-PK
71	was	O
71	197	O
71	μ	O
71	##g	O
71	/	O
71	m	O
71	##l	O
71	,	O
71	clearance	B-PK
71	was	O
71	99	O
71	.	O
71	7	O
71	m	O
71	##l	O
71	/	O
71	min	O
71	,	O
71	and	O
71	apparent	B-PK
71	volume	I-PK
71	of	I-PK
71	distribution	I-PK
71	at	I-PK
71	equilibrium	I-PK
71	was	O
71	10	O
71	.	O
71	5	O
71	l	O
71	.	O
71	plasma	O
71	su	O
71	##gam	O
71	##made	O
71	##x	O
71	concentrations	O
71	showed	O
71	a	O
71	p	O
71	##oly	O
71	##ex	O
71	##po	O
71	##nent	O
71	##ial	O
71	decline	O
71	over	O
71	time	O
71	,	O
71	with	O
71	an	O
71	overall	O
71	geometric	O
71	mean	O
71	(	O
71	c	O
71	##v	O
71	%	O
71	)	O
71	terminal	B-PK
71	half	I-PK
71	-	I-PK
71	life	I-PK
71	of	O
71	145	O
71	minutes	O
71	(	O
71	17	O
71	.	O
71	9	O
71	%	O
71	)	O
71	(	O
71	139	O
71	minutes	O
71	(	O
71	17	O
71	.	O
71	7	O
71	%	O
71	)	O
71	for	O
71	males	O
71	;	O
71	152	O
71	minutes	O
71	(	O
71	18	O
71	.	O
71	6	O
71	%	O
71	)	O
71	for	O
71	females	O
71	)	O
71	.	O
71	[SEP]	O
72	[CLS]	O
72	the	O
72	car	O
72	##box	O
72	##yl	O
72	and	O
72	amino	O
72	functional	O
72	m	O
72	##oi	O
72	##eti	O
72	##es	O
72	present	O
72	on	O
72	the	O
72	link	O
72	##er	O
72	portions	O
72	of	O
72	p	O
72	##da	O
72	and	O
72	p	O
72	##d	O
72	##b	O
72	,	O
72	respectively	O
72	,	O
72	may	O
72	facilitate	O
72	their	O
72	con	O
72	##ju	O
72	##gation	O
72	to	O
72	na	O
72	##no	O
72	##par	O
72	##tic	O
72	##les	O
72	to	O
72	tail	O
72	##or	O
72	m	O
72	##or	O
72	##phine	O
72	p	O
72	##har	O
72	##ma	O
72	##co	O
72	##kin	O
72	##etics	O
72	and	O
72	specific	O
72	targeting	O
72	.	O
72	[SEP]	O
73	[CLS]	O
73	reduced	O
73	-	O
73	intensity	O
73	transplant	O
73	##s	O
73	can	O
73	also	O
73	achieve	O
73	cure	O
73	and	O
73	result	O
73	in	O
73	less	O
73	treatment	O
73	-	O
73	related	O
73	mortality	O
73	but	O
73	higher	O
73	re	O
73	##lap	O
73	##se	O
73	rates	O
73	.	O
73	[SEP]	O
74	[CLS]	O
74	aggressive	O
74	amino	O
74	##gly	O
74	##cos	O
74	##ide	O
74	dos	O
74	##ing	O
74	immediately	O
74	followed	O
74	by	O
74	individual	O
74	##ized	O
74	p	O
74	##har	O
74	##ma	O
74	##co	O
74	##kin	O
74	##etic	O
74	monitoring	O
74	would	O
74	ensure	O
74	that	O
74	cm	B-PK
74	##ax	I-PK
74	/	I-PK
74	mi	I-PK
74	##c	I-PK
74	targets	O
74	are	O
74	achieved	O
74	early	O
74	in	O
74	therapy	O
74	.	O
74	[SEP]	O
75	[CLS]	O
75	the	O
75	error	O
75	in	O
75	fitted	O
75	p	O
75	##har	O
75	##ma	O
75	##co	O
75	##kin	O
75	##etic	O
75	parameters	O
75	,	O
75	k	B-PK
75	(	I-PK
75	trans	I-PK
75	)	I-PK
75	and	O
75	v	B-PK
75	(	I-PK
75	e	I-PK
75	)	I-PK
75	,	O
75	was	O
75	calculated	O
75	.	O
75	[SEP]	O
76	[CLS]	O
76	this	O
76	was	O
76	an	O
76	open	O
76	-	O
76	label	O
76	,	O
76	random	O
76	##ized	O
76	,	O
76	single	O
76	-	O
76	dose	O
76	,	O
76	two	O
76	-	O
76	way	O
76	crossover	O
76	study	O
76	in	O
76	healthy	O
76	male	O
76	subjects	O
76	.	O
76	[SEP]	O
77	[CLS]	O
77	the	O
77	most	O
77	frequent	O
77	drug	O
77	-	O
77	related	O
77	non	O
77	##hem	O
77	##ato	O
77	##log	O
77	##ic	O
77	toxic	O
77	##ities	O
77	included	O
77	di	O
77	##ar	O
77	##r	O
77	##hea	O
77	(	O
77	16	O
77	patients	O
77	)	O
77	,	O
77	nausea	O
77	(	O
77	8	O
77	patients	O
77	)	O
77	,	O
77	and	O
77	al	O
77	##ope	O
77	##cia	O
77	(	O
77	7	O
77	patients	O
77	)	O
77	.	O
77	[SEP]	O
78	[CLS]	O
78	ve	O
78	##nous	O
78	blood	O
78	samples	O
78	were	O
78	taken	O
78	before	O
78	cocaine	O
78	application	O
78	and	O
78	15	O
78	,	O
78	30	O
78	,	O
78	45	O
78	,	O
78	60	O
78	,	O
78	90	O
78	,	O
78	120	O
78	,	O
78	150	O
78	,	O
78	180	O
78	,	O
78	240	O
78	min	O
78	later	O
78	.	O
78	[SEP]	O
79	[CLS]	O
79	the	O
79	study	O
79	employed	O
79	an	O
79	open	O
79	-	O
79	label	O
79	,	O
79	two	O
79	-	O
79	co	O
79	##hor	O
79	##t	O
79	,	O
79	parallel	O
79	design	O
79	.	O
79	[SEP]	O
80	[CLS]	O
80	further	O
80	##more	O
80	,	O
80	based	O
80	on	O
80	predictions	O
80	from	O
80	the	O
80	b	O
80	##l	O
80	##rm	O
80	,	O
80	the	O
80	m	O
80	##t	O
80	##d	O
80	was	O
80	more	O
80	than	O
80	700	O
80	mg	O
80	once	O
80	daily	O
80	,	O
80	with	O
80	a	O
80	low	O
80	probability	O
80	of	O
80	over	O
80	##dos	O
80	##e	O
80	at	O
80	the	O
80	600	O
80	mg	O
80	once	O
80	-	O
80	daily	O
80	dose	O
80	.	O
80	[SEP]	O
81	[CLS]	O
81	data	O
81	were	O
81	split	O
81	into	O
81	an	O
81	index	O
81	and	O
81	a	O
81	valid	O
81	##ation	O
81	data	O
81	set	O
81	.	O
81	[SEP]	O
82	[CLS]	O
82	the	O
82	p	O
82	##har	O
82	##ma	O
82	##co	O
82	##kin	O
82	##etic	O
82	properties	O
82	of	O
82	anti	O
82	##mal	O
82	##aria	O
82	##l	O
82	drugs	O
82	are	O
82	often	O
82	affected	O
82	by	O
82	pregnancy	O
82	,	O
82	resulting	O
82	in	O
82	lower	O
82	drug	O
82	concentrations	O
82	and	O
82	a	O
82	consequently	O
82	higher	O
82	risk	O
82	of	O
82	treatment	O
82	failure	O
82	.	O
82	[SEP]	O
83	[CLS]	O
83	when	O
83	these	O
83	samples	O
83	were	O
83	re	O
83	-	O
83	analyzed	O
83	,	O
83	the	O
83	average	O
83	total	O
83	serum	O
83	f	O
83	##olate	O
83	was	O
83	21	O
83	.	O
83	3	O
83	nm	O
83	(	O
83	s	O
83	.	O
83	d	O
83	.	O
83	±	O
83	5	O
83	.	O
83	2	O
83	)	O
83	by	O
83	the	O
83	micro	O
83	##bio	O
83	##logical	O
83	ass	O
83	##ay	O
83	,	O
83	and	O
83	serum	O
83	5	O
83	-	O
83	m	O
83	##th	O
83	##f	O
83	was	O
83	18	O
83	.	O
83	1	O
83	nm	O
83	(	O
83	s	O
83	.	O
83	d	O
83	.	O
83	±	O
83	4	O
83	.	O
83	2	O
83	)	O
83	by	O
83	hp	O
83	##l	O
83	##c	O
83	(	O
83	85	O
83	%	O
83	of	O
83	total	O
83	f	O
83	##olate	O
83	)	O
83	.	O
83	[SEP]	O
84	[CLS]	O
84	it	O
84	was	O
84	found	O
84	that	O
84	micro	O
84	##em	O
84	##ul	O
84	##sions	O
84	with	O
84	x	O
84	##1	O
84	and	O
84	x	O
84	##3	O
84	at	O
84	low	O
84	levels	O
84	and	O
84	x	O
84	##2	O
84	at	O
84	high	O
84	levels	O
84	had	O
84	a	O
84	shortened	O
84	la	B-PK
84	##g	I-PK
84	time	I-PK
84	.	O
84	[SEP]	O
85	[CLS]	O
85	thus	O
85	,	O
85	30	O
85	patients	O
85	(	O
85	66	O
85	.	O
85	7	O
85	%	O
85	female	O
85	)	O
85	underwent	O
85	analysis	O
85	after	O
85	receiving	O
85	p	O
85	##y	O
85	##c	O
85	##no	O
85	##gen	O
85	##ol	O
85	##®	O
85	(	O
85	“	O
85	p	O
85	+	O
85	”	O
85	;	O
85	9	O
85	females	O
85	,	O
85	6	O
85	males	O
85	)	O
85	or	O
85	no	O
85	treatment	O
85	as	O
85	the	O
85	control	O
85	group	O
85	(	O
85	“	O
85	co	O
85	”	O
85	;	O
85	11	O
85	females	O
85	,	O
85	4	O
85	males	O
85	)	O
85	.	O
85	[SEP]	O
86	[CLS]	O
86	the	O
86	far	O
86	-	O
86	reaching	O
86	effects	O
86	that	O
86	result	O
86	from	O
86	pace	O
86	##4	O
86	in	O
86	##hibition	O
86	are	O
86	consistent	O
86	with	O
86	the	O
86	role	O
86	of	O
86	pace	O
86	##4	O
86	as	O
86	a	O
86	hub	O
86	protein	O
86	for	O
86	the	O
86	activation	O
86	of	O
86	cancer	O
86	promoting	O
86	factors	O
86	in	O
86	pro	O
86	##state	O
86	cancer	O
86	.	O
86	[SEP]	O
87	[CLS]	O
87	four	O
87	other	O
87	groups	O
87	of	O
87	animals	O
87	received	O
87	the	O
87	same	O
87	pre	O
87	##tre	O
87	##at	O
87	##ment	O
87	and	O
87	non	O
87	-	O
87	labeled	O
87	do	O
87	##x	O
87	##or	O
87	##ubi	O
87	##cin	O
87	.	O
87	[SEP]	O
88	[CLS]	O
88	the	O
88	geometric	O
88	mean	O
88	ratios	O
88	(	O
88	90	O
88	%	O
88	confidence	O
88	interval	O
88	)	O
88	of	O
88	g	O
88	##p	O
88	##20	O
88	##15	O
88	/	O
88	et	O
88	##n	O
88	for	O
88	cm	B-PK
88	##ax	I-PK
88	(	O
88	1	O
88	.	O
88	11	O
88	[	O
88	1	O
88	.	O
88	05	O
88	–	O
88	1	O
88	.	O
88	17	O
88	]	O
88	)	O
88	,	O
88	au	B-PK
88	##c	I-PK
88	##0	I-PK
88	–	I-PK
88	t	I-PK
88	##last	I-PK
88	(	O
88	0	O
88	.	O
88	98	O
88	[	O
88	0	O
88	.	O
88	94	O
88	–	O
88	1	O
88	.	O
88	02	O
88	]	O
88	)	O
88	and	O
88	au	B-PK
88	##c	I-PK
88	##0	I-PK
88	–	I-PK
88	in	I-PK
88	##f	I-PK
88	(	O
88	0	O
88	.	O
88	96	O
88	[	O
88	0	O
88	.	O
88	93	O
88	–	O
88	1	O
88	.	O
88	00	O
88	]	O
88	)	O
88	were	O
88	within	O
88	the	O
88	pre	O
88	##de	O
88	##fine	O
88	##d	O
88	bio	O
88	##e	O
88	##qui	O
88	##valence	O
88	range	O
88	of	O
88	0	O
88	.	O
88	80	O
88	–	O
88	1	O
88	.	O
88	25	O
88	.	O
88	[SEP]	O
89	[CLS]	O
89	according	O
89	to	O
89	the	O
89	who	O
89	report	O
89	in	O
89	2016	O
89	,	O
89	there	O
89	was	O
89	a	O
89	growing	O
89	number	O
89	of	O
89	tram	O
89	##ado	O
89	##l	O
89	abuse	O
89	##rs	O
89	alone	O
89	or	O
89	in	O
89	combination	O
89	with	O
89	ps	O
89	##ych	O
89	##oa	O
89	##ctive	O
89	substances	O
89	such	O
89	as	O
89	m	O
89	##d	O
89	##ma	O
89	in	O
89	particular	O
89	in	O
89	some	O
89	middle	O
89	east	O
89	countries	O
89	.	O
89	[SEP]	O
90	[CLS]	O
90	the	O
90	limited	O
90	data	O
90	suggest	O
90	that	O
90	the	O
90	volume	B-PK
90	of	I-PK
90	distribution	I-PK
90	of	O
90	do	O
90	##but	O
90	##amine	O
90	was	O
90	related	O
90	to	O
90	the	O
90	extent	O
90	of	O
90	ed	O
90	##ema	O
90	.	O
90	[SEP]	O
91	[CLS]	O
91	we	O
91	previously	O
91	reported	O
91	a	O
91	phase	O
91	i	O
91	study	O
91	of	O
91	the	O
91	safety	O
91	and	O
91	p	O
91	##har	O
91	##ma	O
91	##co	O
91	##kin	O
91	##etics	O
91	of	O
91	sat	O
91	##rap	O
91	##lat	O
91	##in	O
91	in	O
91	patients	O
91	with	O
91	re	O
91	##fra	O
91	##ctor	O
91	##y	O
91	solid	O
91	tumors	O
91	and	O
91	varying	O
91	degrees	O
91	of	O
91	re	O
91	##nal	O
91	imp	O
91	##air	O
91	##ment	O
91	.	O
91	[SEP]	O
92	[CLS]	O
92	the	O
92	u	O
92	##v	O
92	detection	O
92	wavelength	O
92	was	O
92	248	O
92	nm	O
92	,	O
92	and	O
92	the	O
92	sample	O
92	injection	O
92	volume	O
92	was	O
92	8	O
92	μ	O
92	##l	O
92	.	O
92	[SEP]	O
93	[CLS]	O
93	healthy	O
93	men	O
93	and	O
93	women	O
93	(	O
93	of	O
93	non	O
93	-	O
93	child	O
93	-	O
93	bearing	O
93	potential	O
93	or	O
93	those	O
93	using	O
93	an	O
93	acceptable	O
93	con	O
93	##tra	O
93	##ceptive	O
93	)	O
93	aged	O
93	≥	O
93	##18	O
93	years	O
93	and	O
93	weighing	O
93	50	O
93	–	O
93	100	O
93	kg	O
93	(	O
93	110	O
93	–	O
93	220	O
93	lbs	O
93	)	O
93	were	O
93	recruited	O
93	.	O
93	[SEP]	O
94	[CLS]	O
94	p	O
94	##har	O
94	##ma	O
94	##co	O
94	##kin	O
94	##etics	O
94	of	O
94	oral	O
94	i	O
94	##va	O
94	##bra	O
94	##dine	O
94	in	O
94	healthy	O
94	cats	O
94	.	O
94	[SEP]	O
95	[CLS]	O
95	the	O
95	f	B-PK
95	,	O
95	d	O
95	,	O
95	and	O
95	v	B-PK
95	##d	I-PK
95	represent	O
95	the	O
95	bio	B-PK
95	##ava	I-PK
95	##ila	I-PK
95	##bility	I-PK
95	,	O
95	dose	O
95	,	O
95	and	O
95	volume	B-PK
95	of	I-PK
95	distribution	I-PK
95	,	O
95	respectively	O
95	.	O
95	[SEP]	O
96	[CLS]	O
96	p	O
96	##har	O
96	##ma	O
96	##co	O
96	##kin	O
96	##etic	O
96	(	O
96	p	O
96	##k	O
96	)	O
96	and	O
96	p	O
96	##har	O
96	##ma	O
96	##co	O
96	##dynamic	O
96	(	O
96	p	O
96	##d	O
96	)	O
96	models	O
96	were	O
96	developed	O
96	to	O
96	assess	O
96	dose	O
96	selection	O
96	,	O
96	identify	O
96	significant	O
96	a	O
96	##ed	O
96	drug	O
96	interactions	O
96	,	O
96	and	O
96	q	O
96	##uant	O
96	##itate	O
96	relationships	O
96	between	O
96	exposure	O
96	and	O
96	safety	O
96	and	O
96	efficacy	O
96	outcomes	O
96	from	O
96	phase	O
96	3	O
96	trials	O
96	of	O
96	ad	O
96	##junct	O
96	##ive	O
96	es	O
96	##l	O
96	.	O
96	[SEP]	O
97	[CLS]	O
97	serial	O
97	blood	O
97	sampling	O
97	for	O
97	total	O
97	plasma	O
97	g	O
97	##aa	O
97	activity	O
97	and	O
97	protein	O
97	following	O
97	a	O
97	##a	O
97	in	O
97	##fusion	O
97	was	O
97	performed	O
97	for	O
97	24	O
97	h	O
97	##r	O
97	on	O
97	day	O
97	1	O
97	of	O
97	periods	O
97	1	O
97	and	O
97	2	O
97	at	O
97	pre	O
97	-	O
97	dose	O
97	(	O
97	time	O
97	0	O
97	)	O
97	and	O
97	at	O
97	1	O
97	,	O
97	2	O
97	,	O
97	3	O
97	,	O
97	4	O
97	,	O
97	5	O
97	,	O
97	6	O
97	,	O
97	7	O
97	,	O
97	8	O
97	,	O
97	9	O
97	,	O
97	10	O
97	,	O
97	12	O
97	,	O
97	and	O
97	24	O
97	h	O
97	##r	O
97	after	O
97	initiation	O
97	of	O
97	in	O
97	##fusion	O
97	.	O
97	[SEP]	O
98	[CLS]	O
98	tumor	O
98	volume	O
98	(	O
98	v	O
98	)	O
98	was	O
98	calculated	O
98	by	O
98	the	O
98	following	O
98	formula	O
98	:	O
98	v	O
98	=	O
98	(	O
98	w	O
98	##2	O
98	##×	O
98	##l	O
98	)	O
98	/	O
98	2	O
98	,	O
98	[	O
98	1	O
98	]	O
98	[SEP]	O
99	[CLS]	O
99	the	O
99	combination	O
99	of	O
99	c	O
99	##is	O
99	##p	O
99	##lat	O
99	##in	O
99	and	O
99	5	O
99	-	O
99	flu	O
99	##oro	O
99	##ura	O
99	##ci	O
99	##l	O
99	(	O
99	5	O
99	-	O
99	f	O
99	##u	O
99	)	O
99	is	O
99	considered	O
99	to	O
99	be	O
99	the	O
99	standard	O
99	treatment	O
99	in	O
99	induction	O
99	ch	O
99	##em	O
99	##otherapy	O
99	for	O
99	patients	O
99	with	O
99	sq	O
99	##ua	O
99	##mous	O
99	cell	O
99	car	O
99	##cin	O
99	##oma	O
99	of	O
99	the	O
99	head	O
99	and	O
99	neck	O
99	.	O
99	[SEP]	O
100	[CLS]	O
100	in	O
100	##tra	O
100	##vi	O
100	##tre	O
100	##al	O
100	injection	O
100	of	O
100	anti	O
100	-	O
100	ve	O
100	##g	O
100	##f	O
100	(	O
100	vascular	O
100	end	O
100	##oth	O
100	##eli	O
100	##al	O
100	growth	O
100	factor	O
100	)	O
100	antibodies	O
100	or	O
100	anti	O
100	##body	O
100	fragments	O
100	has	O
100	been	O
100	shown	O
100	to	O
100	be	O
100	a	O
100	highly	O
100	effective	O
100	treatment	O
100	for	O
100	neo	O
100	##vas	O
100	##cular	O
100	age	O
100	-	O
100	related	O
100	mac	O
100	##ular	O
100	de	O
100	##gene	O
100	##ration	O
100	(	O
100	wet	O
100	am	O
100	##d	O
100	)	O
100	.	O
100	[SEP]	O
101	[CLS]	O
101	dry	O
101	em	O
101	##ul	O
101	##sions	O
101	consisting	O
101	of	O
101	red	O
101	##is	O
101	##pers	O
101	##ed	O
101	freeze	O
101	-	O
101	dried	O
101	drug	O
101	-	O
101	milk	O
101	formulation	O
101	##s	O
101	have	O
101	been	O
101	evaluated	O
101	using	O
101	re	O
101	##con	O
101	##st	O
101	##itution	O
101	in	O
101	v	O
101	##it	O
101	##ro	O
101	to	O
101	obtain	O
101	an	O
101	o	O
101	/	O
101	w	O
101	em	O
101	##ul	O
101	##sion	O
101	before	O
101	administration	O
101	for	O
101	di	O
101	##cum	O
101	##aro	O
101	##l	O
101	(	O
101	an	O
101	anti	O
101	##coa	O
101	##gu	O
101	##lant	O
101	)	O
101	(	O
101	mac	O
101	##her	O
101	##as	O
101	and	O
101	re	O
101	##ppa	O
101	##s	O
101	1986	O
101	##a	O
101	)	O
101	and	O
101	ni	O
101	##tro	O
101	##fu	O
101	##rant	O
101	##oi	O
101	##n	O
101	(	O
101	a	O
101	b	O
101	##act	O
101	##eri	O
101	##oc	O
101	##idal	O
101	)	O
101	(	O
101	mac	O
101	##her	O
101	##as	O
101	and	O
101	re	O
101	##ppa	O
101	##s	O
101	1986	O
101	##b	O
101	)	O
101	respectively	O
101	.	O
101	[SEP]	O
102	[CLS]	O
102	the	O
102	effects	O
102	of	O
102	na	O
102	##lo	O
102	##xon	O
102	##e	O
102	h	O
102	##ydro	O
102	##ch	O
102	##lor	O
102	##ide	O
102	(	O
102	na	O
102	##l	O
102	)	O
102	and	O
102	other	O
102	op	O
102	##iate	O
102	antagonist	O
102	##s	O
102	on	O
102	blood	O
102	-	O
102	ethanol	O
102	concentration	O
102	(	O
102	be	O
102	##c	O
102	)	O
102	in	O
102	acute	O
102	##ly	O
102	-	O
102	ethanol	O
102	-	O
102	into	O
102	##xi	O
102	##cated	O
102	rats	O
102	were	O
102	examined	O
102	.	O
102	[SEP]	O
103	[CLS]	O
103	p	O
103	##har	O
103	##ma	O
103	##co	O
103	##kin	O
103	##etics	O
103	,	O
103	p	O
103	##har	O
103	##ma	O
103	##co	O
103	##dynamic	O
103	##s	O
103	and	O
103	der	O
103	##mal	O
103	distribution	O
103	of	O
103	5	O
103	-	O
103	met	O
103	##ho	O
103	##xy	O
103	##ps	O
103	##oral	O
103	##en	O
103	based	O
103	on	O
103	a	O
103	physiological	O
103	##ly	O
103	based	O
103	p	O
103	##har	O
103	##ma	O
103	##co	O
103	##kin	O
103	##etic	O
103	model	O
103	to	O
103	support	O
103	p	O
103	##hy	O
103	##to	O
103	##ther	O
103	##ap	O
103	##y	O
103	using	O
103	br	O
103	##os	O
103	##im	O
103	##um	O
103	g	O
103	##aud	O
103	##ich	O
103	##aud	O
103	##ii	O
103	.	O
103	[SEP]	O
104	[CLS]	O
104	no	O
104	##ci	O
104	##ceptive	O
104	threshold	O
104	to	O
104	mechanical	O
104	all	O
104	##ody	O
104	##nia	O
104	was	O
104	determined	O
104	using	O
104	electronic	O
104	von	O
104	f	O
104	##rey	O
104	pressure	O
104	al	O
104	##go	O
104	##meter	O
104	(	O
104	model	O
104	239	O
104	##0	O
104	;	O
104	ii	O
104	##t	O
104	##c	O
104	life	O
104	science	O
104	in	O
104	##c	O
104	.	O
104	,	O
104	woodland	O
104	hills	O
104	,	O
104	ca	O
104	,	O
104	u	O
104	.	O
104	s	O
104	.	O
104	a	O
104	.	O
104	)	O
104	on	O
104	7	O
104	,	O
104	14	O
104	and	O
104	21st	O
104	day	O
104	.	O
104	[SEP]	O
105	[CLS]	O
105	we	O
105	used	O
105	p	O
105	##os	O
105	##it	O
105	##ron	O
105	emission	O
105	to	O
105	##mo	O
105	##graphy	O
105	(	O
105	pet	O
105	)	O
105	and	O
105	[	O
105	(	O
105	11	O
105	)	O
105	c	O
105	]	O
105	-	O
105	labeled	O
105	l	O
105	##igan	O
105	##ds	O
105	to	O
105	q	O
105	##uant	O
105	##ify	O
105	s	O
105	##tri	O
105	##ata	O
105	##l	O
105	and	O
105	extra	O
105	-	O
105	s	O
105	##tri	O
105	##ata	O
105	##l	O
105	do	O
105	##pa	O
105	##mine	O
105	-	O
105	2	O
105	(	O
105	d	O
105	(	O
105	2	O
105	)	O
105	)	O
105	,	O
105	and	O
105	co	O
105	##rt	O
105	##ical	O
105	se	O
105	##rot	O
105	##oni	O
105	##n	O
105	-	O
105	2	O
105	##a	O
105	(	O
105	5	O
105	-	O
105	h	O
105	##t	O
105	(	O
105	2	O
105	##a	O
105	)	O
105	)	O
105	receptor	O
105	o	O
105	##cc	O
105	##up	O
105	##ancy	O
105	in	O
105	healthy	O
105	subjects	O
105	after	O
105	a	O
105	single	O
105	dose	O
105	,	O
105	and	O
105	in	O
105	patients	O
105	chronic	O
105	##ally	O
105	treated	O
105	for	O
105	ps	O
105	##ych	O
105	##osis	O
105	.	O
105	[SEP]	O
106	[CLS]	O
106	accordingly	O
106	,	O
106	these	O
106	results	O
106	indicated	O
106	that	O
106	op	O
106	##ti	O
106	##mized	O
106	at	O
106	##r	O
106	s	O
106	##ned	O
106	##ds	O
106	and	O
106	n	O
106	##s	O
106	formulation	O
106	##s	O
106	improved	O
106	the	O
106	p	O
106	##har	O
106	##ma	O
106	##co	O
106	##kin	O
106	##etic	O
106	parameters	O
106	of	O
106	the	O
106	water	O
106	ins	O
106	##ol	O
106	##ub	O
106	##le	O
106	drug	O
106	at	O
106	##r	O
106	.	O
106	[SEP]	O
107	[CLS]	O
107	bio	O
107	##chemistry	O
107	:	O
107	sodium	O
107	,	O
107	potassium	O
107	,	O
107	chloride	O
107	,	O
107	ma	O
107	##gnesium	O
107	,	O
107	bi	O
107	##car	O
107	##bon	O
107	##ate	O
107	,	O
107	c	O
107	##rea	O
107	##tin	O
107	##ine	O
107	,	O
107	u	O
107	##rea	O
107	,	O
107	la	O
107	##ct	O
107	##ate	O
107	de	O
107	##hy	O
107	##dr	O
107	##ogen	O
107	##ase	O
107	(	O
107	l	O
107	##dh	O
107	)	O
107	,	O
107	as	O
107	##par	O
107	##tate	O
107	amino	O
107	##tra	O
107	##ns	O
107	##fer	O
107	##ase	O
107	(	O
107	as	O
107	##t	O
107	)	O
107	,	O
107	al	O
107	##ani	O
107	##ne	O
107	amino	O
107	##tra	O
107	##ns	O
107	##fer	O
107	##ase	O
107	(	O
107	al	O
107	##t	O
107	)	O
107	,	O
107	gamma	O
107	-	O
107	g	O
107	##lut	O
107	##am	O
107	##yl	O
107	##tra	O
107	##ns	O
107	##fer	O
107	##ase	O
107	(	O
107	γ	O
107	##gt	O
107	)	O
107	,	O
107	al	O
107	##kal	O
107	##ine	O
107	p	O
107	##hos	O
107	##pha	O
107	##tase	O
107	,	O
107	total	O
107	bi	O
107	##li	O
107	##ru	O
107	##bin	O
107	,	O
107	album	O
107	##in	O
107	,	O
107	g	O
107	##lo	O
107	##bul	O
107	##in	O
107	,	O
107	total	O
107	protein	O
107	,	O
107	calcium	O
107	,	O
107	p	O
107	##hos	O
107	##phorus	O
107	,	O
107	glucose	O
107	,	O
107	u	O
107	##ric	O
107	acid	O
107	,	O
107	total	O
107	g	O
107	##ly	O
107	##cer	O
107	##ides	O
107	,	O
107	high	O
107	-	O
107	density	O
107	lip	O
107	##op	O
107	##rote	O
107	##in	O
107	(	O
107	h	O
107	##dl	O
107	)	O
107	,	O
107	low	O
107	-	O
107	density	O
107	lip	O
107	##op	O
107	##rote	O
107	##in	O
107	(	O
107	l	O
107	##dl	O
107	)	O
107	and	O
107	total	O
107	ch	O
107	##ole	O
107	##ster	O
107	##ol	O
107	.	O
107	[SEP]	O
108	[CLS]	O
108	the	O
108	bio	O
108	-	O
108	analytical	O
108	method	O
108	described	O
108	above	O
108	was	O
108	used	O
108	to	O
108	determine	O
108	to	O
108	##l	O
108	##va	O
108	##pta	O
108	##n	O
108	concentrations	O
108	in	O
108	plasma	O
108	followed	O
108	by	O
108	oral	O
108	administration	O
108	to	O
108	healthy	O
108	rabbits	O
108	.	O
108	[SEP]	O
109	[CLS]	O
109	the	O
109	method	O
109	is	O
109	cost	O
109	-	O
109	saving	O
109	in	O
109	that	O
109	it	O
109	allows	O
109	about	O
109	30	O
109	analyses	O
109	a	O
109	day	O
109	to	O
109	be	O
109	performed	O
109	without	O
109	automatic	O
109	in	O
109	##te	O
109	##gra	O
109	##tors	O
109	,	O
109	and	O
109	about	O
109	50	O
109	analyses	O
109	a	O
109	day	O
109	with	O
109	these	O
109	in	O
109	##te	O
109	##gra	O
109	##tors	O
109	.	O
109	[SEP]	O
110	[CLS]	O
110	eighteen	O
110	patients	O
110	with	O
110	various	O
110	ma	O
110	##li	O
110	##gna	O
110	##ncies	O
110	and	O
110	re	O
110	##fra	O
110	##ctor	O
110	##y	O
110	ma	O
110	##li	O
110	##gnant	O
110	as	O
110	##cite	O
110	##s	O
110	consent	O
110	##ed	O
110	to	O
110	enter	O
110	this	O
110	trial	O
110	.	O
110	[SEP]	O
111	[CLS]	O
111	for	O
111	analysis	O
111	using	O
111	im	O
111	##scope	O
111	,	O
111	α	O
111	-	O
111	ch	O
111	##ca	O
111	was	O
111	v	O
111	##ap	O
111	##our	O
111	-	O
111	deposited	O
111	at	O
111	250	O
111	°	O
111	##c	O
111	onto	O
111	the	O
111	surface	O
111	of	O
111	the	O
111	t	O
111	##umour	O
111	tissue	O
111	sections	O
111	as	O
111	previously	O
111	described	O
111	##19	O
111	,	O
111	and	O
111	then	O
111	50	O
111	%	O
111	ace	O
111	##ton	O
111	##it	O
111	##ril	O
111	##e	O
111	containing	O
111	7	O
111	mg	O
111	/	O
111	m	O
111	##l	O
111	α	O
111	-	O
111	ch	O
111	##ca	O
111	,	O
111	1	O
111	µ	O
111	##g	O
111	/	O
111	m	O
111	##l	O
111	er	O
111	##lot	O
111	##ini	O
111	##b	O
111	d	O
111	##6	O
111	,	O
111	and	O
111	0	O
111	.	O
111	2	O
111	%	O
111	t	O
111	##fa	O
111	was	O
111	applied	O
111	by	O
111	using	O
111	the	O
111	image	O
111	##p	O
111	##re	O
111	##p	O
111	matrix	O
111	deposition	O
111	device	O
111	(	O
111	br	O
111	##uke	O
111	##r	O
111	)	O
111	according	O
111	to	O
111	manufacturer	O
111	’	O
111	s	O
111	standard	O
111	method	O
111	for	O
111	α	O
111	-	O
111	ch	O
111	##ca	O
111	.	O
111	[SEP]	O
112	[CLS]	O
112	the	O
112	multi	O
112	##disciplinary	O
112	meeting	O
112	should	O
112	determine	O
112	that	O
112	complete	O
112	re	O
112	##section	O
112	of	O
112	the	O
112	c	O
112	##rl	O
112	##m	O
112	is	O
112	feasible	O
112	.	O
112	[SEP]	O
113	[CLS]	O
113	in	O
113	phase	O
113	2	O
113	,	O
113	16	O
113	patients	O
113	(	O
113	eight	O
113	h	O
113	##gg	O
113	and	O
113	eight	O
113	dip	O
113	##g	O
113	)	O
113	were	O
113	enrolled	O
113	;	O
113	11	O
113	were	O
113	e	O
113	##val	O
113	##ua	O
113	##ble	O
113	for	O
113	response	O
113	and	O
113	five	O
113	withdrew	O
113	(	O
113	three	O
113	due	O
113	to	O
113	an	O
113	##aph	O
113	##yla	O
113	##xi	O
113	##s	O
113	)	O
113	.	O
113	[SEP]	O
114	[CLS]	O
114	secondary	O
114	p	O
114	##har	O
114	##ma	O
114	##co	O
114	##dynamic	O
114	end	O
114	‐	O
114	points	O
114	were	O
114	derived	O
114	from	O
114	the	O
114	individual	O
114	g	O
114	##ir	O
114	(	O
114	smoothed	O
114	)	O
114	and	O
114	blood	O
114	glucose	O
114	profiles	O
114	at	O
114	steady	O
114	state	O
114	.	O
114	[SEP]	O
115	[CLS]	O
115	twelve	O
115	men	O
115	and	O
115	four	O
115	women	O
115	,	O
115	mean	O
115	age	O
115	,	O
115	38	O
115	.	O
115	6	O
115	+	O
115	-	O
115	6	O
115	.	O
115	9	O
115	years	O
115	,	O
115	received	O
115	a	O
115	single	O
115	600	O
115	-	O
115	mg	O
115	oral	O
115	dose	O
115	of	O
115	r	O
115	##if	O
115	##ap	O
115	##ent	O
115	##ine	O
115	in	O
115	an	O
115	open	O
115	-	O
115	label	O
115	,	O
115	random	O
115	##ized	O
115	two	O
115	-	O
115	way	O
115	,	O
115	complete	O
115	crossover	O
115	study	O
115	.	O
115	[SEP]	O
116	[CLS]	O
116	thirty	O
116	-	O
116	two	O
116	patients	O
116	were	O
116	included	O
116	in	O
116	a	O
116	dose	O
116	-	O
116	response	O
116	study	O
116	,	O
116	in	O
116	which	O
116	the	O
116	patients	O
116	received	O
116	one	O
116	of	O
116	four	O
116	doses	O
116	of	O
116	mi	O
116	##va	O
116	##cu	O
116	##rium	O
116	.	O
116	[SEP]	O
117	[CLS]	O
117	/	O
117	=	O
117	30	O
117	%	O
117	dose	O
117	es	O
117	##cal	O
117	##ation	O
117	for	O
117	i	O
117	##rino	O
117	##teca	O
117	##n	O
117	,	O
117	when	O
117	administered	O
117	in	O
117	a	O
117	combination	O
117	regime	O
117	##n	O
117	with	O
117	c	O
117	##is	O
117	##p	O
117	##lat	O
117	##in	O
117	.	O
117	[SEP]	O
118	[CLS]	O
118	p	O
118	##har	O
118	##ma	O
118	##co	O
118	##kin	O
118	##etics	O
118	,	O
118	safety	O
118	,	O
118	and	O
118	to	O
118	##ler	O
118	##ability	O
118	of	O
118	bay	O
118	12	O
118	-	O
118	95	O
118	##6	O
118	##6	O
118	and	O
118	non	O
118	##ster	O
118	##oid	O
118	##al	O
118	anti	O
118	-	O
118	inflammatory	O
118	agents	O
118	(	O
118	nap	O
118	##ro	O
118	##xen	O
118	,	O
118	i	O
118	##bu	O
118	##p	O
118	##ro	O
118	##fen	O
118	)	O
118	during	O
118	co	O
118	##ad	O
118	##mini	O
118	##stra	O
118	##tion	O
118	in	O
118	patients	O
118	with	O
118	o	O
118	##ste	O
118	##oar	O
118	##th	O
118	##rit	O
118	##is	O
118	.	O
118	[SEP]	O
119	[CLS]	O
119	this	O
119	was	O
119	mostly	O
119	due	O
119	to	O
119	a	O
119	slower	O
119	rate	O
119	constant	O
119	of	O
119	##ass	O
119	##oc	O
119	##iation	O
119	(	O
119	k	O
119	##on	O
119	)	O
119	,	O
119	in	O
119	line	O
119	with	O
119	a	O
119	hampered	O
119	diffusion	O
119	##th	O
119	##rough	O
119	the	O
119	surface	O
119	matrix	O
119	of	O
119	the	O
119	sensor	O
119	##chi	O
119	##p	O
119	.	O
119	[SEP]	O
120	[CLS]	O
120	f	O
120	##am	O
120	##ci	O
120	##c	O
120	##lov	O
120	##ir	O
120	was	O
120	administered	O
120	oral	O
120	##ly	O
120	or	O
120	re	O
120	##ct	O
120	##ally	O
120	in	O
120	accordance	O
120	with	O
120	an	O
120	incomplete	O
120	crossover	O
120	design	O
120	.	O
120	[SEP]	O
121	[CLS]	O
121	the	O
121	concentrations	O
121	of	O
121	cm	O
121	##nx	O
121	transferred	O
121	to	O
121	the	O
121	u	O
121	##ter	O
121	##us	O
121	and	O
121	its	O
121	app	O
121	##end	O
121	##ages	O
121	after	O
121	cm	O
121	##nx	O
121	1	O
121	g	O
121	in	O
121	##tra	O
121	##ven	O
121	##ous	O
121	injection	O
121	were	O
121	maintained	O
121	above	O
121	12	O
121	.	O
121	5	O
121	micro	O
121	##gram	O
121	##s	O
121	/	O
121	g	O
121	during	O
121	first	O
121	3	O
121	hours	O
121	or	O
121	more	O
121	.	O
121	[SEP]	O
122	[CLS]	O
122	more	O
122	##over	O
122	the	O
122	p	O
122	##h	O
122	of	O
122	the	O
122	formulation	O
122	is	O
122	in	O
122	the	O
122	required	O
122	range	O
122	for	O
122	the	O
122	in	O
122	##tra	O
122	##ven	O
122	##ous	O
122	administration	O
122	[	O
122	25	O
122	]	O
122	.	O
122	[SEP]	O
123	[CLS]	O
123	in	O
123	these	O
123	studies	O
123	,	O
123	me	O
123	##man	O
123	##tine	O
123	was	O
123	not	O
123	actively	O
123	transported	O
123	by	O
123	o	O
123	##ct	O
123	##1	O
123	,	O
123	but	O
123	appeared	O
123	to	O
123	be	O
123	a	O
123	substrate	O
123	of	O
123	o	O
123	##ct	O
123	##2	O
123	and	O
123	o	O
123	##at	O
123	##p	O
123	##2	O
123	##b	O
123	##1	O
123	,	O
123	with	O
123	an	O
123	accumulation	O
123	of	O
123	me	O
123	##man	O
123	##tine	O
123	in	O
123	transport	O
123	##er	O
123	-	O
123	trans	O
123	##fected	O
123	cells	O
123	>	O
123	[SEP]	O
124	[CLS]	O
124	the	O
124	separation	O
124	of	O
124	the	O
124	ben	O
124	##zo	O
124	##yl	O
124	derivatives	O
124	was	O
124	achieved	O
124	on	O
124	a	O
124	l	O
124	##una	O
124	o	O
124	##me	O
124	##ga	O
124	c	O
124	##18	O
124	ps	O
124	column	O
124	,	O
124	150	O
124	×	O
124	2	O
124	.	O
124	1	O
124	mm	O
124	,	O
124	1	O
124	.	O
124	6	O
124	μ	O
124	##m	O
124	(	O
124	p	O
124	##hen	O
124	##ome	O
124	##nex	O
124	)	O
124	.	O
124	[SEP]	O
125	[CLS]	O
125	all	O
125	patients	O
125	improved	O
125	clinical	O
125	##ly	O
125	over	O
125	16	O
125	+	O
125	-	O
125	10	O
125	months	O
125	.	O
125	[SEP]	O
126	[CLS]	O
126	the	O
126	z	O
126	##eta	O
126	potential	O
126	changed	O
126	ins	O
126	##ign	O
126	##ificant	O
126	##ly	O
126	(	O
126	p	O
126	>	O
126	0	O
126	.	O
126	00	O
126	##2	O
126	)	O
126	as	O
126	it	O
126	depends	O
126	on	O
126	the	O
126	formulation	O
126	composition	O
126	that	O
126	remained	O
126	un	O
126	##altered	O
126	.	O
126	[SEP]	O
127	[CLS]	O
127	a	O
127	total	O
127	of	O
127	40	O
127	##7	O
127	samples	O
127	were	O
127	collected	O
127	.	O
127	[SEP]	O
128	[CLS]	O
128	we	O
128	conclude	O
128	that	O
128	the	O
128	spatial	O
128	resolution	O
128	of	O
128	our	O
128	to	O
128	##mo	O
128	##graph	O
128	reduces	O
128	the	O
128	apparent	O
128	magnitude	O
128	of	O
128	k	O
128	(	O
128	3	O
128	)	O
128	(	O
128	d	O
128	)	O
128	in	O
128	s	O
128	##tri	O
128	##at	O
128	##um	O
128	.	O
128	[SEP]	O
129	[CLS]	O
129	the	O
129	purpose	O
129	of	O
129	this	O
129	study	O
129	was	O
129	to	O
129	assess	O
129	the	O
129	multiple	O
129	-	O
129	dose	O
129	clinical	O
129	p	O
129	##har	O
129	##ma	O
129	##cology	O
129	of	O
129	to	O
129	##l	O
129	##cap	O
129	##one	O
129	,	O
129	a	O
129	novel	O
129	cat	O
129	##ech	O
129	##ol	O
129	-	O
129	o	O
129	-	O
129	met	O
129	##hyl	O
129	##tra	O
129	##ns	O
129	##fer	O
129	##ase	O
129	(	O
129	com	O
129	##t	O
129	)	O
129	inhibitor	O
129	,	O
129	in	O
129	elderly	O
129	subjects	O
129	.	O
129	[SEP]	O
130	[CLS]	O
130	this	O
130	was	O
130	followed	O
130	by	O
130	a	O
130	forward	O
130	inclusion	O
130	and	O
130	backward	O
130	elimination	O
130	procedure	O
130	,	O
130	with	O
130	significance	O
130	levels	O
130	of	O
130	5	O
130	and	O
130	0	O
130	.	O
130	1	O
130	%	O
130	(	O
130	log	O
130	-	O
130	likelihood	O
130	ratio	O
130	test	O
130	,	O
130	ch	O
130	##i	O
130	square	O
130	distribution	O
130	)	O
130	,	O
130	respectively	O
130	.	O
130	[SEP]	O
131	[CLS]	O
131	the	O
131	maternal	O
131	plasma	O
131	profile	O
131	following	O
131	single	O
131	sub	O
131	##cut	O
131	##aneous	O
131	dose	O
131	of	O
131	50	O
131	mg	O
131	/	O
131	kg	O
131	on	O
131	both	O
131	g	O
131	##d	O
131	##14	O
131	and	O
131	g	O
131	##d	O
131	##21	O
131	showed	O
131	a	O
131	mon	O
131	##oe	O
131	##x	O
131	##po	O
131	##nent	O
131	##ial	O
131	elimination	O
131	pattern	O
131	.	O
131	[SEP]	O
132	[CLS]	O
132	din	O
132	##ac	O
132	##ic	O
132	##li	O
132	##b	O
132	(	O
132	m	O
132	##k	O
132	-	O
132	79	O
132	##65	O
132	,	O
132	formerly	O
132	s	O
132	##ch	O
132	72	O
132	##7	O
132	##9	O
132	##65	O
132	,	O
132	me	O
132	##rc	O
132	##k	O
132	,	O
132	white	O
132	##house	O
132	station	O
132	,	O
132	n	O
132	##j	O
132	)	O
132	;	O
132	p	O
132	##ac	O
132	##lit	O
132	##ax	O
132	##el	O
132	(	O
132	l	O
132	##c	O
132	laboratories	O
132	,	O
132	w	O
132	##ob	O
132	##urn	O
132	,	O
132	ma	O
132	)	O
132	;	O
132	trip	O
132	##to	O
132	##lide	O
132	(	O
132	si	O
132	##gma	O
132	)	O
132	;	O
132	na	O
132	##vi	O
132	##to	O
132	##c	O
132	##lax	O
132	(	O
132	a	O
132	##bt	O
132	-	O
132	26	O
132	##3	O
132	)	O
132	(	O
132	sell	O
132	##eck	O
132	chemicals	O
132	)	O
132	;	O
132	k	O
132	##dr	O
132	inhibitor	O
132	b	O
132	[	O
132	19	O
132	]	O
132	(	O
132	me	O
132	##rc	O
132	##k	O
132	,	O
132	white	O
132	##house	O
132	station	O
132	,	O
132	n	O
132	##j	O
132	)	O
132	.	O
132	[SEP]	O
133	[CLS]	O
133	a	O
133	simple	O
133	liquid	O
133	ch	O
133	##roma	O
133	##tography	O
133	tandem	O
133	mass	O
133	s	O
133	##pect	O
133	##rome	O
133	##try	O
133	method	O
133	was	O
133	developed	O
133	and	O
133	valid	O
133	##ated	O
133	according	O
133	to	O
133	the	O
133	guidelines	O
133	of	O
133	the	O
133	us	O
133	food	O
133	and	O
133	drug	O
133	administration	O
133	and	O
133	the	O
133	euro	O
133	##pe	O
133	##an	O
133	medicines	O
133	agency	O
133	for	O
133	a	O
133	simultaneous	O
133	q	O
133	##uant	O
133	##ification	O
133	of	O
133	le	O
133	##vet	O
133	##ira	O
133	##ce	O
133	##tam	O
133	(	O
133	le	O
133	##v	O
133	)	O
133	and	O
133	its	O
133	meta	O
133	##bol	O
133	##ite	O
133	,	O
133	u	O
133	##c	O
133	##b	O
133	l	O
133	##0	O
133	##5	O
133	##7	O
133	in	O
133	the	O
133	plasma	O
133	of	O
133	patients	O
133	.	O
133	[SEP]	O
134	[CLS]	O
134	further	O
134	,	O
134	the	O
134	24	O
134	-	O
134	h	O
134	u	O
134	##ge	O
134	of	O
134	w	O
134	##t	O
134	mice	O
134	did	O
134	not	O
134	show	O
134	a	O
134	significant	O
134	response	O
134	to	O
134	the	O
134	1	O
134	mg	O
134	/	O
134	kg	O
134	dose	O
134	of	O
134	l	O
134	##p	O
134	-	O
134	92	O
134	##5	O
134	##21	O
134	##9	O
134	,	O
134	and	O
134	the	O
134	response	O
134	to	O
134	the	O
134	60	O
134	mg	O
134	/	O
134	kg	O
134	dose	O
134	,	O
134	which	O
134	was	O
134	68	O
134	±	O
134	15	O
134	%	O
134	of	O
134	ma	O
134	##ximal	O
134	,	O
134	was	O
134	significantly	O
134	greater	O
134	than	O
134	vehicle	O
134	-	O
134	treated	O
134	control	O
134	values	O
134	but	O
134	was	O
134	still	O
134	significantly	O
134	less	O
134	than	O
134	ma	O
134	##ximal	O
134	values	O
134	.	O
134	[SEP]	O
135	[CLS]	O
135	bio	B-PK
135	##ava	I-PK
135	##ila	I-PK
135	##bility	I-PK
135	of	O
135	ace	O
135	##ta	O
135	##zo	O
135	##lam	O
135	##ide	O
135	tablets	O
135	.	O
135	[SEP]	O
136	[CLS]	O
136	however	O
136	,	O
136	the	O
136	number	O
136	of	O
136	he	O
136	##pa	O
136	##to	O
136	##cy	O
136	##tes	O
136	isolated	O
136	per	O
136	gram	O
136	of	O
136	per	O
136	##fused	O
136	tissue	O
136	was	O
136	five	O
136	##fold	O
136	higher	O
136	than	O
136	that	O
136	reported	O
136	by	O
136	s	O
136	##te	O
136	##fan	O
136	##ski	O
136	et	O
136	al	O
136	.	O
136	(	O
136	2013	O
136	)	O
136	(	O
136	n	O
136	=	O
136	9	O
136	)	O
136	but	O
136	five	O
136	##fold	O
136	lower	O
136	than	O
136	in	O
136	the	O
136	study	O
136	by	O
136	b	O
136	##aka	O
136	##la	O
136	et	O
136	al	O
136	.	O
136	(	O
136	2003	O
136	)	O
136	.	O
136	[SEP]	O
137	[CLS]	O
137	the	O
137	duration	O
137	of	O
137	therapy	O
137	was	O
137	also	O
137	assessed	O
137	.	O
137	[SEP]	O
138	[CLS]	O
138	no	O
138	me	O
138	##as	O
138	##urable	O
138	plasma	O
138	concentrations	O
138	of	O
138	the	O
138	n	O
138	##1	O
138	-	O
138	g	O
138	##lu	O
138	##cu	O
138	##ron	O
138	##ides	O
138	from	O
138	su	O
138	##lf	O
138	##adi	O
138	##met	O
138	##ho	O
138	##xin	O
138	##e	O
138	are	O
138	found	O
138	in	O
138	plasma	O
138	.	O
138	[SEP]	O
139	[CLS]	O
139	since	O
139	m	O
139	##3	O
139	##g	O
139	has	O
139	been	O
139	shown	O
139	to	O
139	be	O
139	anti	O
139	##ana	O
139	##lge	O
139	##si	O
139	##c	O
139	and	O
139	is	O
139	the	O
139	only	O
139	meta	O
139	##bol	O
139	##ite	O
139	of	O
139	m	O
139	##or	O
139	##phine	O
139	in	O
139	the	O
139	rat	O
139	,	O
139	it	O
139	is	O
139	concluded	O
139	that	O
139	the	O
139	levels	O
139	of	O
139	this	O
139	meta	O
139	##bol	O
139	##ite	O
139	may	O
139	regulate	O
139	the	O
139	anal	O
139	##ges	O
139	##ic	O
139	effect	O
139	of	O
139	m	O
139	##or	O
139	##phine	O
139	in	O
139	the	O
139	rat	O
139	.	O
139	[SEP]	O
140	[CLS]	O
140	four	O
140	patients	O
140	had	O
140	grade	O
140	3	O
140	toxic	O
140	##ities	O
140	at	O
140	longer	O
140	in	O
140	##fusion	O
140	schedules	O
140	.	O
140	[SEP]	O
141	[CLS]	O
141	the	O
141	compound	O
141	-	O
141	dependent	O
141	m	O
141	##s	O
141	/	O
141	m	O
141	##s	O
141	parameters	O
141	for	O
141	anal	O
141	##yte	O
141	##s	O
141	in	O
141	the	O
141	m	O
141	##rm	O
141	mode	O
141	are	O
141	summarized	O
141	in	O
141	table	O
141	1	O
141	.	O
141	[SEP]	O
142	[CLS]	O
142	the	O
142	mean	O
142	(	O
142	±	O
142	s	O
142	##d	O
142	)	O
142	c	B-PK
142	<	I-PK
142	sub	I-PK
142	>	I-PK
142	ma	I-PK
142	##x	I-PK
142	<	I-PK
142	/	I-PK
142	sub	I-PK
142	>	I-PK
142	of	O
142	the	O
142	test	O
142	and	O
142	the	O
142	reference	O
142	formulation	O
142	were	O
142	141	O
142	.	O
142	401	O
142	±	O
142	29	O
142	.	O
142	44	O
142	##7	O
142	ng	O
142	/	O
142	m	O
142	##l	O
142	and	O
142	138	O
142	.	O
142	83	O
142	##7	O
142	±	O
142	31	O
142	.	O
142	39	O
142	##2	O
142	ng	O
142	/	O
142	m	O
142	##l	O
142	,	O
142	respectively	O
142	.	O
142	[SEP]	O
143	[CLS]	O
143	the	O
143	data	O
143	of	O
143	each	O
143	patient	O
143	are	O
143	stored	O
143	on	O
143	the	O
143	hospital	O
143	server	O
143	and	O
143	protected	O
143	by	O
143	a	O
143	fire	O
143	##wall	O
143	system	O
143	with	O
143	password	O
143	access	O
143	.	O
143	[SEP]	O
144	[CLS]	O
144	the	O
144	aim	O
144	of	O
144	the	O
144	study	O
144	was	O
144	to	O
144	investigate	O
144	the	O
144	p	O
144	##har	O
144	##ma	O
144	##co	O
144	##kin	O
144	##etics	O
144	of	O
144	si	O
144	##m	O
144	##vas	O
144	##tat	O
144	##in	O
144	and	O
144	its	O
144	h	O
144	##ydro	O
144	##ly	O
144	##sat	O
144	##e	O
144	si	O
144	##m	O
144	##vas	O
144	##tat	O
144	##in	O
144	acid	O
144	in	O
144	a	O
144	rat	O
144	model	O
144	of	O
144	type	O
144	2	O
144	diabetes	O
144	.	O
144	[SEP]	O
145	[CLS]	O
145	the	O
145	c	O
145	##s	O
145	##f	O
145	level	O
145	was	O
145	below	O
145	the	O
145	limit	O
145	of	O
145	detection	O
145	except	O
145	in	O
145	the	O
145	high	O
145	dose	O
145	group	O
145	.	O
145	[SEP]	O
146	[CLS]	O
146	the	O
146	detection	O
146	of	O
146	anal	O
146	##yte	O
146	##s	O
146	was	O
146	achieved	O
146	by	O
146	electro	O
146	##sp	O
146	##ray	O
146	ion	O
146	##ization	O
146	(	O
146	es	O
146	##i	O
146	)	O
146	in	O
146	the	O
146	positive	O
146	mode	O
146	with	O
146	the	O
146	appropriate	O
146	m	O
146	##s	O
146	/	O
146	m	O
146	##s	O
146	transitions	O
146	,	O
146	if	O
146	necessary	O
146	.	O
146	[SEP]	O
147	[CLS]	O
147	time	O
147	-	O
147	dependent	O
147	se	O
147	##ns	O
147	##iti	O
147	##zation	O
147	to	O
147	t	O
147	##ria	O
147	##zo	O
147	##lam	O
147	?	O
147	[SEP]	O
148	[CLS]	O
148	it	O
148	increased	O
148	significantly	O
148	(	O
148	p	O
148	less	O
148	than	O
148	0	O
148	.	O
148	05	O
148	)	O
148	to	O
148	258	O
148	.	O
148	7	O
148	+	O
148	-	O
148	54	O
148	.	O
148	2	O
148	mm	O
148	##ol	O
148	for	O
148	the	O
148	2	O
148	days	O
148	of	O
148	dos	O
148	##age	O
148	and	O
148	the	O
148	following	O
148	day	O
148	.	O
148	[SEP]	O
149	[CLS]	O
149	to	O
149	reflect	O
149	the	O
149	actual	O
149	meal	O
149	time	O
149	,	O
149	eh	O
149	##c	O
149	models	O
149	with	O
149	two	O
149	or	O
149	more	O
149	meal	O
149	times	O
149	were	O
149	tested	O
149	.	O
149	[SEP]	O
150	[CLS]	O
150	the	O
150	in	O
150	##hibition	O
150	of	O
150	ad	O
150	##p	O
150	-	O
150	induced	O
150	plate	O
150	##let	O
150	a	O
150	##gg	O
150	##regation	O
150	of	O
150	plate	O
150	##let	O
150	-	O
150	rich	O
150	plasma	O
150	(	O
150	p	O
150	##rp	O
150	)	O
150	was	O
150	measured	O
150	in	O
150	response	O
150	to	O
150	5	O
150	μ	O
150	##m	O
150	ad	O
150	##p	O
150	as	O
150	described	O
150	elsewhere	O
150	(	O
150	m	O
150	##ull	O
150	##er	O
150	et	O
150	al	O
150	.	O
150	,	O
150	2003	O
150	;	O
150	g	O
150	##ei	O
150	##ger	O
150	et	O
150	al	O
150	.	O
150	,	O
150	2005	O
150	)	O
150	.	O
150	[SEP]	O
151	[CLS]	O
151	maximum	O
151	changes	O
151	in	O
151	b	O
151	##p	O
151	were	O
151	observed	O
151	on	O
151	average	O
151	6	O
151	hours	O
151	after	O
151	dos	O
151	##ing	O
151	with	O
151	a	O
151	com	O
151	##pen	O
151	##sat	O
151	##ory	O
151	p	O
151	##r	O
151	increase	O
151	.	O
151	[SEP]	O
152	[CLS]	O
152	each	O
152	blank	O
152	sample	O
152	was	O
152	tested	O
152	for	O
152	any	O
152	interference	O
152	,	O
152	also	O
152	the	O
152	ones	O
152	associated	O
152	with	O
152	th	O
152	##io	O
152	##pent	O
152	##al	O
152	,	O
152	using	O
152	the	O
152	proposed	O
152	extraction	O
152	procedure	O
152	and	O
152	ch	O
152	##roma	O
152	##to	O
152	##graphic	O
152	/	O
152	mass	O
152	s	O
152	##pect	O
152	##rome	O
152	##tric	O
152	conditions	O
152	and	O
152	compared	O
152	with	O
152	those	O
152	obtained	O
152	with	O
152	an	O
152	a	O
152	##que	O
152	##ous	O
152	solution	O
152	of	O
152	the	O
152	anal	O
152	##yte	O
152	at	O
152	a	O
152	concentration	O
152	near	O
152	the	O
152	lower	O
152	limit	O
152	of	O
152	q	O
152	##uant	O
152	##ification	O
152	(	O
152	ll	O
152	##o	O
152	##q	O
152	)	O
152	.	O
152	[SEP]	O
153	[CLS]	O
153	the	O
153	hp	O
153	##l	O
153	##c	O
153	method	O
153	was	O
153	cross	O
153	-	O
153	valid	O
153	##ated	O
153	with	O
153	a	O
153	previously	O
153	reported	O
153	g	O
153	##c	O
153	method	O
153	by	O
153	the	O
153	analysis	O
153	of	O
153	73	O
153	plasma	O
153	samples	O
153	spike	O
153	##d	O
153	with	O
153	various	O
153	concentrations	O
153	of	O
153	s	O
153	##ch	O
153	39	O
153	##16	O
153	##6	O
153	and	O
153	s	O
153	##ch	O
153	40	O
153	##8	O
153	##53	O
153	.	O
153	[SEP]	O
154	[CLS]	O
154	the	O
154	kinetic	O
154	##s	O
154	of	O
154	binding	O
154	of	O
154	111	O
154	##in	O
154	-	O
154	not	O
154	##a	O
154	-	O
154	p	O
154	##eg	O
154	##n	O
154	-	O
154	r	O
154	##m	O
154	##26	O
154	to	O
154	the	O
154	p	O
154	##c	O
154	-	O
154	3	O
154	cells	O
154	was	O
154	measured	O
154	in	O
154	real	O
154	-	O
154	time	O
154	at	O
154	r	O
154	##t	O
154	using	O
154	l	O
154	##igan	O
154	##dt	O
154	##race	O
154	##r	O
154	instruments	O
154	(	O
154	ridge	O
154	##view	O
154	instruments	O
154	a	O
154	##b	O
154	,	O
154	up	O
154	##ps	O
154	##ala	O
154	,	O
154	s	O
154	##wed	O
154	##en	O
154	)	O
154	,	O
154	as	O
154	described	O
154	previously	O
154	[	O
154	42	O
154	]	O
154	.	O
154	[SEP]	O
155	[CLS]	O
155	the	O
155	disappearance	B-PK
155	rate	I-PK
155	of	O
155	p	O
155	##hen	O
155	##ace	O
155	##tin	O
155	tended	O
155	to	O
155	be	O
155	lower	O
155	in	O
155	the	O
155	presence	O
155	of	O
155	ho	O
155	##no	O
155	##ki	O
155	##ol	O
155	and	O
155	ma	O
155	##gno	O
155	##lo	O
155	##l	O
155	of	O
155	≥	O
155	##2	O
155	μ	O
155	##m	O
155	than	O
155	in	O
155	their	O
155	absence	O
155	.	O
155	[SEP]	O
156	[CLS]	O
156	mon	O
156	##oc	O
156	##lon	O
156	##al	O
156	antibodies	O
156	(	O
156	ma	O
156	##bs	O
156	)	O
156	against	O
156	high	O
156	-	O
156	molecular	O
156	-	O
156	weight	O
156	me	O
156	##lan	O
156	##oma	O
156	-	O
156	associated	O
156	anti	O
156	##gen	O
156	(	O
156	h	O
156	##m	O
156	##w	O
156	-	O
156	ma	O
156	##a	O
156	)	O
156	have	O
156	been	O
156	used	O
156	in	O
156	v	O
156	##ivo	O
156	to	O
156	target	O
156	me	O
156	##lan	O
156	##oma	O
156	.	O
156	[SEP]	O
157	[CLS]	O
157	p	O
157	##har	O
157	##ma	O
157	##co	O
157	##kin	O
157	##etics	O
157	and	O
157	electro	O
157	##phy	O
157	##sio	O
157	##logical	O
157	effects	O
157	of	O
157	so	O
157	##tal	O
157	##ol	O
157	h	O
157	##ydro	O
157	##ch	O
157	##lor	O
157	##ide	O
157	in	O
157	horses	O
157	.	O
157	[SEP]	O
158	[CLS]	O
158	static	O
158	fuzzy	O
158	locally	O
158	adaptive	O
158	bay	O
158	##esi	O
158	##an	O
158	(	O
158	fl	O
158	##ab	O
158	)	O
158	volumes	O
158	correspond	O
158	##ed	O
158	best	O
158	with	O
158	path	O
158	##ology	O
158	volumes	O
158	(	O
158	in	O
158	##tra	O
158	##c	O
158	##lass	O
158	correlation	O
158	coefficient	O
158	,	O
158	0	O
158	.	O
158	72	O
158	;	O
158	p	O
158	<	O
158	.	O
158	00	O
158	##1	O
158	)	O
158	.	O
158	[SEP]	O
159	[CLS]	O
159	min	O
159	/	O
159	m	O
159	##l	O
159	)	O
159	by	O
159	g	O
159	##g	O
159	##9	O
159	##18	O
159	(	O
159	1	O
159	,	O
159	73	O
159	##0	O
159	+	O
159	-	O
159	270	O
159	ng	O
159	.	O
159	[SEP]	O
160	[CLS]	O
160	in	O
160	three	O
160	open	O
160	,	O
160	random	O
160	##ized	O
160	,	O
160	cross	O
160	-	O
160	over	O
160	sessions	O
160	with	O
160	>	O
160	or	O
160	=	O
160	14	O
160	days	O
160	wash	O
160	##out	O
160	,	O
160	l	O
160	##t	O
160	##g	O
160	100	O
160	mg	O
160	and	O
160	o	O
160	##x	O
160	##c	O
160	600	O
160	mg	O
160	were	O
160	given	O
160	oral	O
160	##ly	O
160	,	O
160	each	O
160	to	O
160	6	O
160	subjects	O
160	.	O
160	[SEP]	O
161	[CLS]	O
161	the	O
161	objective	O
161	of	O
161	this	O
161	phase	O
161	i	O
161	,	O
161	open	O
161	-	O
161	label	O
161	single	O
161	-	O
161	dose	O
161	study	O
161	was	O
161	to	O
161	determine	O
161	if	O
161	mild	O
161	or	O
161	moderate	O
161	he	O
161	##pa	O
161	##tic	O
161	imp	O
161	##air	O
161	##ment	O
161	alter	O
161	##s	O
161	the	O
161	p	O
161	##har	O
161	##ma	O
161	##co	O
161	##kin	O
161	##etics	O
161	of	O
161	mi	O
161	##rog	O
161	##aba	O
161	##lin	O
161	.	O
161	[SEP]	O
162	[CLS]	O
162	no	O
162	correlation	O
162	was	O
162	found	O
162	between	O
162	m	O
162	##dr	O
162	##1	O
162	m	O
162	##rna	O
162	expression	O
162	and	O
162	re	B-PK
162	##nal	I-PK
162	clearance	I-PK
162	of	O
162	di	O
162	##c	O
162	##lo	O
162	##xa	O
162	##ci	O
162	##llin	O
162	.	O
162	[SEP]	O
163	[CLS]	O
163	for	O
163	trim	O
163	##eth	O
163	##op	O
163	##rim	O
163	concentrations	O
163	,	O
163	p	O
163	##ks	O
163	were	O
163	also	O
163	found	O
163	to	O
163	be	O
163	best	O
163	described	O
163	by	O
163	a	O
163	one	O
163	‐	O
163	compartment	O
163	model	O
163	(	O
163	table	O
163	##2	O
163	)	O
163	.	O
163	[SEP]	O
164	[CLS]	O
164	c	O
164	##es	O
164	##1	O
164	gene	O
164	variation	O
164	only	O
164	partially	O
164	explains	O
164	p	O
164	##har	O
164	##ma	O
164	##co	O
164	##kin	O
164	##etic	O
164	(	O
164	p	O
164	##k	O
164	)	O
164	var	O
164	##iability	O
164	.	O
164	[SEP]	O
165	[CLS]	O
165	according	O
165	to	O
165	the	O
165	da	O
165	##rp	O
165	##a	O
165	standard	O
165	,	O
165	a	O
165	highly	O
165	effective	O
165	re	O
165	##age	O
165	##nt	O
165	retains	O
165	>	O
165	85	O
165	%	O
165	activity	O
165	after	O
165	heating	O
165	at	O
165	70	O
165	##°	O
165	##c	O
165	for	O
165	1	O
165	h	O
165	.	O
165	5	O
165	as	O
165	an	O
165	initial	O
165	test	O
165	of	O
165	the	O
165	thermal	O
165	effect	O
165	on	O
165	the	O
165	activity	O
165	of	O
165	bi	O
165	‐	O
165	l	O
165	##pa	O
165	,	O
165	we	O
165	performed	O
165	an	O
165	el	O
165	##isa	O
165	before	O
165	and	O
165	after	O
165	heating	O
165	at	O
165	70	O
165	##°	O
165	##c	O
165	for	O
165	1	O
165	h	O
165	.	O
165	as	O
165	shown	O
165	in	O
165	figure	O
165	6	O
165	##b	O
165	,	O
165	the	O
165	k	O
165	##d	O
165	for	O
165	un	O
165	##heat	O
165	##ed	O
165	bi	O
165	‐	O
165	l	O
165	##pa	O
165	is	O
165	216	O
165	±	O
165	7	O
165	nm	O
165	,	O
165	whereas	O
165	the	O
165	k	O
165	##d	O
165	after	O
165	an	O
165	hour	O
165	is	O
165	28	O
165	##3	O
165	nm	O
165	±	O
165	27	O
165	nm	O
165	,	O
165	suggesting	O
165	ins	O
165	##ign	O
165	##ificant	O
165	reduction	O
165	in	O
165	k	O
165	##d	O
165	after	O
165	the	O
165	re	O
165	##age	O
165	##nt	O
165	is	O
165	heated	O
165	,	O
165	sur	O
165	##passing	O
165	the	O
165	70	O
165	##°	O
165	##c	O
165	for	O
165	1	O
165	h	O
165	precedence	O
165	.	O
165	[SEP]	O
166	[CLS]	O
166	p	O
166	##k	O
166	assessment	O
166	was	O
166	conducted	O
166	on	O
166	day	O
166	1	O
166	at	O
166	0	O
166	,	O
166	1	O
166	,	O
166	2	O
166	,	O
166	3	O
166	,	O
166	4	O
166	,	O
166	6	O
166	,	O
166	9	O
166	,	O
166	12	O
166	and	O
166	24	O
166	hours	O
166	post	O
166	-	O
166	dose	O
166	and	O
166	on	O
166	day	O
166	11	O
166	at	O
166	0	O
166	,	O
166	1	O
166	,	O
166	2	O
166	,	O
166	3	O
166	,	O
166	4	O
166	,	O
166	6	O
166	,	O
166	9	O
166	,	O
166	12	O
166	and	O
166	24	O
166	hours	O
166	post	O
166	-	O
166	dose	O
166	.	O
166	[SEP]	O
167	[CLS]	O
167	this	O
167	hp	O
167	##l	O
167	##c	O
167	method	O
167	is	O
167	useful	O
167	for	O
167	the	O
167	analysis	O
167	and	O
167	evaluation	O
167	of	O
167	the	O
167	p	O
167	##har	O
167	##ma	O
167	##co	O
167	##kin	O
167	##etics	O
167	of	O
167	v	O
167	##n	O
167	/	O
167	14	O
167	-	O
167	1	O
167	##ra	O
167	in	O
167	rats	O
167	.	O
167	[SEP]	O
168	[CLS]	O
168	do	O
168	##ce	O
168	##ta	O
168	##xe	O
168	##l	O
168	and	O
168	v	O
168	##ino	O
168	##rel	O
168	##bine	O
168	were	O
168	given	O
168	at	O
168	80	O
168	mg	O
168	/	O
168	m	O
168	##2	O
168	and	O
168	20	O
168	mg	O
168	/	O
168	m	O
168	##2	O
168	i	O
168	.	O
168	v	O
168	.	O
168	,	O
168	respectively	O
168	,	O
168	on	O
168	day	O
168	1	O
168	every	O
168	3	O
168	weeks	O
168	.	O
168	[SEP]	O
169	[CLS]	O
169	there	O
169	were	O
169	no	O
169	further	O
169	differences	O
169	(	O
169	p	O
169	>	O
169	0	O
169	.	O
169	1	O
169	)	O
169	.	O
169	[SEP]	O
170	[CLS]	O
170	b	O
170	##g	O
170	##9	O
170	##9	O
170	##28	O
170	was	O
170	well	O
170	tolerate	O
170	##d	O
170	.	O
170	[SEP]	O
171	[CLS]	O
171	consequently	O
171	,	O
171	the	O
171	m	O
171	##pe	O
171	##g	O
171	##2	O
171	##k	O
171	-	O
171	b	O
171	-	O
171	t	O
171	##ria	O
171	polymer	O
171	##s	O
171	would	O
171	be	O
171	another	O
171	promising	O
171	carrier	O
171	for	O
171	h	O
171	##ydro	O
171	##phobic	O
171	anti	O
171	-	O
171	cancer	O
171	drugs	O
171	delivery	O
171	.	O
171	[SEP]	O
172	[CLS]	O
172	unlike	O
172	car	O
172	##ba	O
172	##ma	O
172	##ze	O
172	##pine	O
172	,	O
172	la	O
172	##mot	O
172	##rig	O
172	##ine	O
172	is	O
172	ads	O
172	##or	O
172	##bed	O
172	to	O
172	the	O
172	root	O
172	and	O
172	undergo	O
172	##es	O
172	ion	O
172	trapping	O
172	in	O
172	root	O
172	cells	O
172	thus	O
172	its	O
172	trans	O
172	##location	O
172	to	O
172	the	O
172	shoots	O
172	is	O
172	limited	O
172	.	O
172	[SEP]	O
173	[CLS]	O
173	in	O
173	##c	O
173	.	O
173	s	O
173	##t	O
173	.	O
173	lo	O
173	##ui	O
173	##s	O
173	.	O
173	[SEP]	O
174	[CLS]	O
174	no	O
174	d	O
174	##lts	O
174	occurred	O
174	during	O
174	the	O
174	21	O
174	-	O
174	day	O
174	d	O
174	##lt	O
174	assessment	O
174	period	O
174	,	O
174	so	O
174	the	O
174	m	O
174	##t	O
174	##d	O
174	was	O
174	not	O
174	reached	O
174	.	O
174	[SEP]	O
175	[CLS]	O
175	elimination	O
175	was	O
175	reduced	O
175	in	O
175	comparison	O
175	with	O
175	healthy	O
175	volunteers	O
175	:	O
175	t	B-PK
175	##1	I-PK
175	/	I-PK
175	2	I-PK
175	beta	I-PK
175	510	O
175	+	O
175	-	O
175	158	O
175	min	O
175	with	O
175	a	O
175	total	B-PK
175	area	I-PK
175	under	I-PK
175	the	I-PK
175	curve	I-PK
175	of	O
175	18	O
175	.	O
175	2	O
175	+	O
175	-	O
175	10	O
175	.	O
175	3	O
175	mg	O
175	x	O
175	h	O
175	/	O
175	l	O
175	.	O
175	[SEP]	O
176	[CLS]	O
176	p	O
176	##har	O
176	##ma	O
176	##co	O
176	##kin	O
176	##etics	O
176	of	O
176	controlled	O
176	-	O
176	release	O
176	polymer	O
176	##s	O
176	in	O
176	the	O
176	sub	O
176	##ara	O
176	##ch	O
176	##no	O
176	##id	O
176	space	O
176	after	O
176	sub	O
176	##ara	O
176	##ch	O
176	##no	O
176	##id	O
176	hem	O
176	##or	O
176	##r	O
176	##hage	O
176	in	O
176	rabbits	O
176	.	O
176	[SEP]	O
177	[CLS]	O
177	the	O
177	model	O
177	predicted	O
177	an	O
177	approximate	O
177	60	O
177	%	O
177	decrease	O
177	for	O
177	the	O
177	mean	O
177	estimates	O
177	of	O
177	e	O
177	##f	O
177	##v	O
177	apparent	B-PK
177	oral	I-PK
177	clearance	I-PK
177	(	I-PK
177	c	I-PK
177	##l	I-PK
177	)	I-PK
177	in	O
177	p	O
177	##ediatric	O
177	subjects	O
177	who	O
177	were	O
177	ho	O
177	##mo	O
177	##zy	O
177	##go	O
177	##us	O
177	for	O
177	the	O
177	156	O
177	##31	O
177	##gt	O
177	substitution	O
177	(	O
177	156	O
177	##31	O
177	##tt	O
177	)	O
177	relative	O
177	to	O
177	that	O
177	in	O
177	p	O
177	##ediatric	O
177	subjects	O
177	who	O
177	did	O
177	not	O
177	carry	O
177	the	O
177	substitution	O
177	on	O
177	either	O
177	all	O
177	##ele	O
177	(	O
177	156	O
177	##31	O
177	##gg	O
177	)	O
177	and	O
177	an	O
177	approximate	O
177	25	O
177	%	O
177	decrease	O
177	in	O
177	p	O
177	##ediatric	O
177	subjects	O
177	who	O
177	carried	O
177	the	O
177	substitution	O
177	on	O
177	one	O
177	all	O
177	##ele	O
177	(	O
177	156	O
177	##31	O
177	##gt	O
177	)	O
177	relative	O
177	to	O
177	that	O
177	in	O
177	subjects	O
177	who	O
177	carried	O
177	the	O
177	wild	O
177	type	O
177	.	O
177	[SEP]	O
178	[CLS]	O
178	mean	O
178	ca	O
178	##sp	O
178	##of	O
178	##ung	O
178	##in	O
178	t	B-PK
178	##rough	I-PK
178	and	O
178	peak	B-PK
178	levels	I-PK
178	were	O
178	3	O
178	.	O
178	73	O
178	and	O
178	11	O
178	.	O
178	95	O
178	micro	O
178	##g	O
178	/	O
178	m	O
178	##l	O
178	.	O
178	these	O
178	are	O
178	comparable	O
178	to	O
178	previously	O
178	reported	O
178	ones	O
178	.	O
178	[SEP]	O
179	[CLS]	O
179	the	O
179	exact	O
179	role	O
179	of	O
179	the	O
179	s	O
179	##v	O
179	##2	O
179	##a	O
179	protein	O
179	is	O
179	not	O
179	fully	O
179	understood	O
179	;	O
179	it	O
179	is	O
179	thought	O
179	to	O
179	participate	O
179	in	O
179	the	O
179	p	O
179	##hy	O
179	##sio	O
179	##log	O
179	##ic	O
179	functioning	O
179	of	O
179	the	O
179	s	O
179	##yna	O
179	##ptic	O
179	ve	O
179	##si	O
179	##cle	O
179	.	O
179	19	O
179	its	O
179	role	O
179	in	O
179	e	O
179	##pile	O
179	##psy	O
179	is	O
179	supported	O
179	by	O
179	the	O
179	fact	O
179	that	O
179	s	O
179	##v	O
179	##2	O
179	##a	O
179	knock	O
179	-	O
179	out	O
179	mice	O
179	develop	O
179	seizure	O
179	##s	O
179	soon	O
179	after	O
179	birth	O
179	and	O
179	usually	O
179	die	O
179	within	O
179	3	O
179	weeks	O
179	.	O
179	21	O
179	further	O
179	##more	O
179	,	O
179	the	O
179	affinity	O
179	of	O
179	various	O
179	compounds	O
179	to	O
179	the	O
179	s	O
179	##v	O
179	##2	O
179	##a	O
179	binding	O
179	site	O
179	co	O
179	##rrel	O
179	##ates	O
179	strongly	O
179	with	O
179	their	O
179	anti	O
179	-	O
179	seizure	O
179	pot	O
179	##ency	O
179	in	O
179	the	O
179	audio	O
179	##genic	O
179	e	O
179	##pile	O
179	##psy	O
179	mouse	O
179	model	O
179	.	O
179	19	O
179	[SEP]	O
180	[CLS]	O
180	the	O
180	mean	O
180	absolute	O
180	recover	O
180	##ies	O
180	of	O
180	two	O
180	anal	O
180	##yte	O
180	##s	O
180	were	O
180	>	O
180	90	O
180	%	O
180	.	O
180	[SEP]	O
181	[CLS]	O
181	r	O
181	##ito	O
181	##na	O
181	##vir	O
181	powder	O
181	formulation	O
181	administered	O
181	in	O
181	chocolate	O
181	milk	O
181	,	O
181	pu	O
181	##dding	O
181	,	O
181	infant	O
181	formula	O
181	or	O
181	apple	O
181	sauce	O
181	was	O
181	bio	O
181	##e	O
181	##qui	O
181	##valent	O
181	to	O
181	the	O
181	powder	O
181	formulation	O
181	administered	O
181	in	O
181	water	O
181	.	O
181	[SEP]	O
182	[CLS]	O
182	the	O
182	sample	O
182	preparation	O
182	for	O
182	ca	O
182	##li	O
182	##bra	O
182	##tion	O
182	curves	O
182	was	O
182	obtained	O
182	by	O
182	freshly	O
182	spike	O
182	##d	O
182	plasma	O
182	samples	O
182	with	O
182	stock	O
182	solution	O
182	of	O
182	r	O
182	##hein	O
182	at	O
182	concentration	O
182	ranges	O
182	of	O
182	0	O
182	.	O
182	05	O
182	–	O
182	2	O
182	.	O
182	5	O
182	µ	O
182	##g	O
182	/	O
182	m	O
182	##l	O
182	.	O
182	a	O
182	blank	O
182	plasma	O
182	sample	O
182	was	O
182	also	O
182	analyzed	O
182	to	O
182	confirm	O
182	absence	O
182	of	O
182	interference	O
182	##s	O
182	.	O
182	[SEP]	O
183	[CLS]	O
183	this	O
183	is	O
183	the	O
183	most	O
183	comprehensive	O
183	p	O
183	##k	O
183	study	O
183	to	O
183	date	O
183	in	O
183	subjects	O
183	with	O
183	hereditary	O
183	f	O
183	##x	O
183	deficiency	O
183	.	O
183	[SEP]	O
184	[CLS]	O
184	multiple	O
184	linear	O
184	re	O
184	##gression	O
184	models	O
184	showed	O
184	significant	O
184	correlation	O
184	##s	O
184	between	O
184	parameters	O
184	of	O
184	met	O
184	##hot	O
184	##re	O
184	##xa	O
184	##te	O
184	clearance	B-PK
184	and	O
184	certain	O
184	re	O
184	##nal	O
184	function	O
184	tests	O
184	.	O
184	[SEP]	O
185	[CLS]	O
185	however	O
185	,	O
185	be	O
185	##rber	O
185	##ine	O
185	release	O
185	took	O
185	several	O
185	hours	O
185	,	O
185	indicating	O
185	that	O
185	certain	O
185	resistance	O
185	was	O
185	provided	O
185	by	O
185	the	O
185	dial	O
185	##ys	O
185	##is	O
185	bag	O
185	.	O
185	[SEP]	O
186	[CLS]	O
186	parameters	O
186	such	O
186	as	O
186	recovery	O
186	,	O
186	linear	O
186	##ity	O
186	,	O
186	accuracy	O
186	,	O
186	precision	O
186	,	O
186	select	O
186	##ivity	O
186	,	O
186	matrix	O
186	effect	O
186	and	O
186	stability	O
186	of	O
186	samples	O
186	were	O
186	investigated	O
186	.	O
186	[SEP]	O
187	[CLS]	O
187	the	O
187	self	O
187	‐	O
187	mediated	O
187	,	O
187	time	O
187	‐	O
187	dependent	O
187	c	O
187	##y	O
187	##p	O
187	##2	O
187	##c	O
187	##19	O
187	in	O
187	##hibition	O
187	by	O
187	o	O
187	##me	O
187	##pra	O
187	##zo	O
187	##le	O
187	suggests	O
187	that	O
187	multiple	O
187	doses	O
187	of	O
187	this	O
187	agent	O
187	are	O
187	not	O
187	recommended	O
187	in	O
187	drug	O
187	–	O
187	drug	O
187	interaction	O
187	studies	O
187	,	O
187	unless	O
187	there	O
187	is	O
187	sufficient	O
187	wash	O
187	##out	O
187	time	O
187	.	O
187	[SEP]	O
188	[CLS]	O
188	as	O
188	a	O
188	consequence	O
188	,	O
188	the	O
188	ni	O
188	##r	O
188	spat	O
188	##iot	O
188	##em	O
188	##por	O
188	##al	O
188	bio	O
188	##ima	O
188	##ging	O
188	in	O
188	v	O
188	##ivo	O
188	with	O
188	dual	O
188	flu	O
188	##ores	O
188	##cence	O
188	channels	O
188	allows	O
188	the	O
188	pro	O
188	##dr	O
188	##ug	O
188	release	O
188	profile	O
188	to	O
188	be	O
188	extracted	O
188	precisely	O
188	,	O
188	particularly	O
188	in	O
188	visual	O
188	##izing	O
188	drug	O
188	-	O
188	released	O
188	information	O
188	from	O
188	complex	O
188	biological	O
188	systems	O
188	such	O
188	as	O
188	mice	O
188	,	O
188	thereby	O
188	providing	O
188	a	O
188	unique	O
188	opportunity	O
188	to	O
188	take	O
188	insight	O
188	into	O
188	the	O
188	relationship	O
188	between	O
188	the	O
188	##rano	O
188	##sis	O
188	and	O
188	p	O
188	##har	O
188	##ma	O
188	##co	O
188	##kin	O
188	##etics	O
188	.	O
188	[SEP]	O
189	[CLS]	O
189	administration	O
189	of	O
189	et	O
189	##ra	O
189	##vir	O
189	##ine	O
189	in	O
189	a	O
189	fast	O
189	##ed	O
189	state	O
189	resulted	O
189	in	O
189	51	O
189	%	O
189	lower	O
189	mean	O
189	exposure	O
189	compared	O
189	with	O
189	dos	O
189	##ing	O
189	after	O
189	a	O
189	standard	O
189	breakfast	O
189	.	O
189	[SEP]	O
190	[CLS]	O
190	a	O
190	summary	O
190	of	O
190	the	O
190	i	O
190	##pa	O
190	data	O
190	obtained	O
190	from	O
190	study	O
190	i	O
190	and	O
190	study	O
190	ii	O
190	is	O
190	presented	O
190	in	O
190	table	O
190	3	O
190	.	O
190	[SEP]	O
191	[CLS]	O
191	m	O
191	##rz	O
191	2	O
191	/	O
191	57	O
191	##9	O
191	blocked	O
191	steady	O
191	-	O
191	state	O
191	inward	O
191	current	O
191	responses	O
191	of	O
191	culture	O
191	##d	O
191	hip	O
191	##po	O
191	##cam	O
191	##pal	O
191	ne	O
191	##uron	O
191	##es	O
191	to	O
191	nm	O
191	##da	O
191	with	O
191	an	O
191	i	B-PK
191	##c	I-PK
191	##50	I-PK
191	of	O
191	1	O
191	.	O
191	11	O
191	micro	O
191	##m	O
191	at	O
191	-	O
191	70	O
191	m	O
191	##v	O
191	.	O
191	much	O
191	higher	O
191	concentrations	O
191	of	O
191	m	O
191	##rz	O
191	2	O
191	/	O
191	57	O
191	##9	O
191	blocked	O
191	voltage	O
191	-	O
191	activated	O
191	ca	O
191	##2	O
191	+	O
191	channels	O
191	with	O
191	an	O
191	i	B-PK
191	##c	I-PK
191	##50	I-PK
191	of	O
191	340	O
191	micro	O
191	##m	O
191	.	O
191	m	O
191	##rz	O
191	2	O
191	/	O
191	57	O
191	##9	O
191	(	O
191	10	O
191	micro	O
191	##m	O
191	)	O
191	reduced	O
191	peak	O
191	inward	O
191	current	O
191	responses	O
191	of	O
191	ne	O
191	##uron	O
191	##al	O
191	ni	O
191	##cot	O
191	##ini	O
191	##c	O
191	receptors	O
191	only	O
191	to	O
191	72	O
191	.	O
191	3	O
191	%	O
191	of	O
191	control	O
191	.	O
191	[SEP]	O
192	[CLS]	O
192	the	O
192	absorption	O
192	and	O
192	ex	O
192	##cre	O
192	##tion	O
192	of	O
192	n	O
192	##s	O
192	-	O
192	49	O
192	(	O
192	(	O
192	r	O
192	)	O
192	-	O
192	(	O
192	-	O
192	)	O
192	-	O
192	3	O
192	'	O
192	-	O
192	(	O
192	2	O
192	-	O
192	amino	O
192	-	O
192	1	O
192	-	O
192	h	O
192	##ydro	O
192	##xy	O
192	##eth	O
192	##yl	O
192	)	O
192	-	O
192	4	O
192	'	O
192	-	O
192	flu	O
192	##oro	O
192	##met	O
192	##hane	O
192	##sul	O
192	##fo	O
192	##nan	O
192	##ili	O
192	##de	O
192	h	O
192	##ydro	O
192	##ch	O
192	##lor	O
192	##ide	O
192	,	O
192	ca	O
192	##s	O
192	137	O
192	##43	O
192	##1	O
192	-	O
192	04	O
192	-	O
192	0	O
192	)	O
192	,	O
192	a	O
192	p	O
192	##hen	O
192	##eth	O
192	##yla	O
192	##mine	O
192	class	O
192	alpha	O
192	1	O
192	##a	O
192	-	O
192	ad	O
192	##ren	O
192	##oc	O
192	##ept	O
192	##or	O
192	ago	O
192	##nist	O
192	,	O
192	were	O
192	studied	O
192	in	O
192	rats	O
192	after	O
192	a	O
192	single	O
192	administration	O
192	of	O
192	14	O
192	##c	O
192	-	O
192	n	O
192	##s	O
192	-	O
192	49	O
192	.	O
192	[SEP]	O
193	[CLS]	O
193	statistical	O
193	analysis	O
193	of	O
193	quantitative	O
193	a	O
193	##ero	O
193	##bic	O
193	and	O
193	an	O
193	##ae	O
193	##ro	O
193	##bic	O
193	cultures	O
193	of	O
193	f	O
193	##ec	O
193	##es	O
193	was	O
193	performed	O
193	,	O
193	and	O
193	beta	O
193	-	O
193	la	O
193	##ct	O
193	##ama	O
193	##se	O
193	activity	O
193	was	O
193	determined	O
193	.	O
193	[SEP]	O
194	[CLS]	O
194	the	O
194	study	O
194	drugs	O
194	were	O
194	administered	O
194	after	O
194	a	O
194	>	O
194	or	O
194	=	O
194	12	O
194	-	O
194	hour	O
194	(	O
194	overnight	O
194	)	O
194	fast	O
194	.	O
194	[SEP]	O
195	[CLS]	O
195	last	O
195	##ly	O
195	,	O
195	a	O
195	combination	O
195	therapy	O
195	experiment	O
195	with	O
195	two	O
195	drugs	O
195	showing	O
195	different	O
195	half	B-PK
195	-	I-PK
195	lives	I-PK
195	was	O
195	conducted	O
195	using	O
195	is	O
195	##onia	O
195	##zi	O
195	##d	O
195	at	O
195	cm	B-PK
195	##ax	I-PK
195	=	O
195	1	O
195	,	O
195	200	O
195	ng	O
195	/	O
195	m	O
195	##l	O
195	,	O
195	t	B-PK
195	##max	I-PK
195	=	O
195	2	O
195	.	O
195	2	O
195	hour	O
195	and	O
195	t	B-PK
195	##1	I-PK
195	/	I-PK
195	2	I-PK
195	=	O
195	4	O
195	.	O
195	7	O
195	hour	O
195	and	O
195	p	O
195	##yra	O
195	##zin	O
195	##ami	O
195	##de	O
195	at	O
195	cm	B-PK
195	##ax	I-PK
195	=	O
195	28	O
195	,	O
195	900	O
195	ng	O
195	/	O
195	m	O
195	##l	O
195	,	O
195	t	B-PK
195	##max	I-PK
195	=	O
195	2	O
195	.	O
195	2	O
195	hour	O
195	and	O
195	t	B-PK
195	##1	I-PK
195	/	I-PK
195	2	I-PK
195	=	O
195	8	O
195	.	O
195	7	O
195	hour	O
195	.	O
195	[SEP]	O
196	[CLS]	O
196	p	O
196	##har	O
196	##ma	O
196	##co	O
196	##kin	O
196	##etics	O
196	and	O
196	efficacy	O
196	of	O
196	high	O
196	-	O
196	dose	O
196	met	O
196	##oc	O
196	##lop	O
196	##ram	O
196	##ide	O
196	given	O
196	by	O
196	continuous	O
196	in	O
196	##fusion	O
196	for	O
196	the	O
196	control	O
196	of	O
196	c	O
196	##yt	O
196	##oto	O
196	##xi	O
196	##c	O
196	drug	O
196	-	O
196	induced	O
196	vomit	O
196	##ing	O
196	.	O
196	[SEP]	O
197	[CLS]	O
197	an	O
197	##ae	O
197	##mia	O
197	led	O
197	to	O
197	rib	O
197	##avi	O
197	##rin	O
197	dose	O
197	reduction	O
197	in	O
197	five	O
197	patients	O
197	.	O
197	[SEP]	O
198	[CLS]	O
198	the	O
198	mat	O
198	##la	O
198	##b	O
198	code	O
198	for	O
198	the	O
198	simulation	O
198	is	O
198	provided	O
198	in	O
198	the	O
198	supplement	O
198	##ary	O
198	material	O
198	online	O
198	.	O
198	[SEP]	O
199	[CLS]	O
199	this	O
199	resulted	O
199	in	O
199	excellent	O
199	predictions	O
199	of	O
199	the	O
199	in	O
199	v	O
199	##ivo	O
199	oral	O
199	plasma	O
199	concentration	O
199	-	O
199	time	O
199	profiles	O
199	,	O
199	as	O
199	compared	O
199	to	O
199	using	O
199	the	O
199	traditional	O
199	inputs	O
199	of	O
199	the	O
199	##rm	O
199	##ody	O
199	##nam	O
199	##ic	O
199	p	O
199	##h	O
199	-	O
199	so	O
199	##lub	O
199	##ility	O
199	profiles	O
199	.	O
199	[SEP]	O
200	[CLS]	O
200	camp	O
200	##to	O
200	##the	O
200	##cin	O
200	showed	O
200	strong	O
200	c	O
200	##yt	O
200	##oto	O
200	##xi	O
200	##city	O
200	against	O
200	a	O
200	variety	O
200	of	O
200	t	O
200	##umour	O
200	types	O
200	in	O
200	v	O
200	##it	O
200	##ro	O
200	and	O
200	in	O
200	v	O
200	##ivo	O
200	(	O
200	wall	O
200	and	O
200	wa	O
200	##ni	O
200	,	O
200	1996	O
200	;	O
200	ch	O
200	##ab	O
200	##ot	O
200	,	O
200	1997	O
200	)	O
200	.	O
200	[SEP]	O
201	[CLS]	O
201	less	O
201	potent	O
201	but	O
201	more	O
201	water	O
201	soluble	O
201	compounds	O
201	such	O
201	as	O
201	13	O
201	##h	O
201	(	O
201	i	B-PK
201	##c	I-PK
201	##50	I-PK
201	=	O
201	60	O
201	nm	O
201	)	O
201	and	O
201	13	O
201	##n	O
201	(	O
201	i	B-PK
201	##c	I-PK
201	##50	I-PK
201	=	O
201	70	O
201	nm	O
201	)	O
201	are	O
201	absorbed	O
201	following	O
201	oral	O
201	dos	O
201	##ing	O
201	and	O
201	achieve	O
201	plasma	O
201	levels	O
201	significantly	O
201	in	O
201	excess	O
201	of	O
201	their	O
201	i	B-PK
201	##c	I-PK
201	##50	I-PK
201	for	O
201	a	O
201	##cat	O
201	in	O
201	##hibition	O
201	.	O
201	[SEP]	O
202	[CLS]	O
202	bitch	O
202	##es	O
202	were	O
202	dose	O
202	##d	O
202	again	O
202	once	O
202	on	O
202	day	O
202	28	O
202	before	O
202	the	O
202	pu	O
202	##ps	O
202	were	O
202	suck	O
202	##ling	O
202	.	O
202	[SEP]	O
203	[CLS]	O
203	the	O
203	mean	O
203	re	O
203	##gression	O
203	coefficient	O
203	was	O
203	more	O
203	than	O
203	0	O
203	.	O
203	99	O
203	.	O
203	[SEP]	O
204	[CLS]	O
204	in	O
204	general	O
204	,	O
204	h	O
204	##dl	O
204	‐	O
204	c	O
204	levels	O
204	increased	O
204	in	O
204	a	O
204	dose	O
204	‐	O
204	dependent	O
204	manner	O
204	for	O
204	both	O
204	r	O
204	##n	O
204	##31	O
204	##7	O
204	and	O
204	b	O
204	##oc	O
204	##oc	O
204	##iz	O
204	##uma	O
204	##b	O
204	.	O
204	[SEP]	O
205	[CLS]	O
205	these	O
205	studies	O
205	indicated	O
205	in	O
205	particular	O
205	that	O
205	:	O
205	(	O
205	1	O
205	)	O
205	the	O
205	injection	O
205	of	O
205	a	O
205	minimal	O
205	neutral	O
205	##izing	O
205	anti	O
205	##ven	O
205	##om	O
205	dose	O
205	is	O
205	required	O
205	for	O
205	a	O
205	complete	O
205	and	O
205	permanent	O
205	neutral	O
205	##ization	O
205	of	O
205	circulating	O
205	venom	O
205	anti	O
205	##gens	O
205	;	O
205	this	O
205	dose	O
205	is	O
205	named	O
205	minimal	O
205	(	O
205	threshold	O
205	)	O
205	e	O
205	##ff	O
205	##ica	O
205	##cious	O
205	anti	O
205	##ven	O
205	##om	O
205	dose	O
205	;	O
205	(	O
205	2	O
205	)	O
205	the	O
205	in	O
205	##tra	O
205	##mus	O
205	##cular	O
205	route	O
205	is	O
205	not	O
205	the	O
205	most	O
205	appropriate	O
205	way	O
205	for	O
205	anti	O
205	##ven	O
205	##om	O
205	injection	O
205	;	O
205	and	O
205	(	O
205	3	O
205	)	O
205	a	O
205	delayed	O
205	anti	O
205	##ven	O
205	##om	O
205	im	O
205	##mu	O
205	##not	O
205	##her	O
205	##ap	O
205	##y	O
205	remains	O
205	e	O
205	##ff	O
205	##ica	O
205	##cious	O
205	especially	O
205	on	O
205	the	O
205	neutral	O
205	##ization	O
205	of	O
205	the	O
205	remaining	O
205	circulating	O
205	venom	O
205	.	O
205	[SEP]	O
206	[CLS]	O
206	for	O
206	the	O
206	p	O
206	##k	O
206	-	O
206	p	O
206	##d	O
206	analysis	O
206	,	O
206	patients	O
206	were	O
206	included	O
206	if	O
206	they	O
206	fulfilled	O
206	all	O
206	of	O
206	the	O
206	criteria	O
206	for	O
206	the	O
206	p	O
206	##k	O
206	analysis	O
206	,	O
206	as	O
206	well	O
206	as	O
206	the	O
206	following	O
206	conditions	O
206	:	O
206	a	O
206	history	O
206	of	O
206	treatment	O
206	with	O
206	v	O
206	##pa	O
206	for	O
206	one	O
206	year	O
206	or	O
206	longer	O
206	;	O
206	not	O
206	taking	O
206	any	O
206	drugs	O
206	that	O
206	may	O
206	affect	O
206	the	O
206	liver	O
206	function	O
206	,	O
206	except	O
206	for	O
206	anti	O
206	##ep	O
206	##ile	O
206	##ptic	O
206	agents	O
206	;	O
206	and	O
206	no	O
206	history	O
206	of	O
206	either	O
206	viral	O
206	or	O
206	alcoholic	O
206	liver	O
206	disease	O
206	.	O
206	[SEP]	O
207	[CLS]	O
207	figure	O
207	3	O
207	##b	O
207	,	O
207	c	O
207	demonstrated	O
207	that	O
207	be	O
207	##va	O
207	##ci	O
207	##zu	O
207	##ma	O
207	##b	O
207	clearance	B-PK
207	was	O
207	significantly	O
207	faster	O
207	(	O
207	p	O
207	=	O
207	0	O
207	.	O
207	00	O
207	##14	O
207	)	O
207	in	O
207	patients	O
207	without	O
207	prior	O
207	gas	O
207	##tre	O
207	##ct	O
207	##omy	O
207	(	O
207	median	O
207	=	O
207	4	O
207	.	O
207	72	O
207	m	O
207	##l	O
207	/	O
207	day	O
207	/	O
207	kg	O
207	,	O
207	n	O
207	=	O
207	120	O
207	)	O
207	than	O
207	those	O
207	with	O
207	gas	O
207	##tre	O
207	##ct	O
207	##omy	O
207	(	O
207	median	O
207	=	O
207	3	O
207	.	O
207	75	O
207	m	O
207	##l	O
207	/	O
207	day	O
207	/	O
207	kg	O
207	,	O
207	n	O
207	=	O
207	42	O
207	)	O
207	with	O
207	a	O
207	ratio	O
207	of	O
207	geometric	O
207	means	O
207	of	O
207	1	O
207	.	O
207	19	O
207	(	O
207	95	O
207	%	O
207	c	O
207	##i	O
207	=	O
207	1	O
207	.	O
207	07	O
207	to	O
207	1	O
207	.	O
207	32	O
207	)	O
207	.	O
207	[SEP]	O
208	[CLS]	O
208	after	O
208	an	O
208	overnight	O
208	fast	O
208	,	O
208	g	O
208	##lu	O
208	##cos	O
208	##amine	O
208	h	O
208	##c	O
208	##l	O
208	(	O
208	20	O
208	mg	O
208	/	O
208	kg	O
208	of	O
208	body	O
208	weight	O
208	)	O
208	was	O
208	administered	O
208	by	O
208	either	O
208	na	O
208	##so	O
208	##gas	O
208	##tric	O
208	(	O
208	ng	O
208	)	O
208	in	O
208	##tub	O
208	##ation	O
208	or	O
208	in	O
208	##tra	O
208	##ven	O
208	##ous	O
208	(	O
208	i	O
208	##v	O
208	)	O
208	injection	O
208	.	O
208	[SEP]	O
209	[CLS]	O
209	the	O
209	authors	O
209	confirm	O
209	that	O
209	all	O
209	ongoing	O
209	and	O
209	related	O
209	trials	O
209	for	O
209	this	O
209	drug	O
209	/	O
209	intervention	O
209	are	O
209	registered	O
209	.	O
209	[SEP]	O
210	[CLS]	O
210	second	O
210	,	O
210	heat	O
210	may	O
210	increase	O
210	the	O
210	mi	O
210	##so	O
210	-	O
210	al	O
210	##ky	O
210	##lating	O
210	agent	O
210	interactions	O
210	,	O
210	which	O
210	are	O
210	independent	O
210	of	O
210	pre	O
210	-	O
210	in	O
210	##cu	O
210	##bation	O
210	time	O
210	.	O
210	[SEP]	O
211	[CLS]	O
211	in	O
211	conclusion	O
211	,	O
211	trans	O
211	##bu	O
211	##cca	O
211	##l	O
211	t	O
211	therapy	O
211	was	O
211	sufficient	O
211	to	O
211	maintain	O
211	normal	O
211	sexual	O
211	function	O
211	while	O
211	mini	O
211	##mizing	O
211	the	O
211	total	O
211	time	O
211	of	O
211	exposure	O
211	to	O
211	elevated	O
211	circulating	O
211	serum	O
211	t	O
211	levels	O
211	.	O
211	[SEP]	O
212	[CLS]	O
212	p	O
212	##x	O
212	-	O
212	86	O
212	##6	O
212	exhibited	O
212	in	O
212	v	O
212	##ivo	O
212	anti	O
212	##tum	O
212	##or	O
212	activity	O
212	against	O
212	s	O
212	.	O
212	c	O
212	.	O
212	o	O
212	##v	O
212	##car	O
212	-	O
212	3	O
212	human	O
212	o	O
212	##var	O
212	##ian	O
212	cancer	O
212	and	O
212	a	O
212	-	O
212	54	O
212	##9	O
212	human	O
212	lung	O
212	cancer	O
212	x	O
212	##eno	O
212	##gra	O
212	##fts	O
212	in	O
212	im	O
212	##mu	O
212	##no	O
212	##de	O
212	##ficient	O
212	mice	O
212	with	O
212	log	O
212	cell	O
212	kills	O
212	up	O
212	to	O
212	1	O
212	.	O
212	2	O
212	.	O
212	[SEP]	O
213	[CLS]	O
213	put	O
213	##ative	O
213	therapeutic	O
213	me	O
213	##lat	O
213	##oni	O
213	##n	O
213	levels	O
213	were	O
213	reached	O
213	8	O
213	h	O
213	after	O
213	hi	O
213	(	O
213	104	O
213	increase	O
213	from	O
213	base	O
213	##line	O
213	;	O
213	~	O
213	15	O
213	-	O
213	30	O
213	mg	O
213	/	O
213	l	O
213	)	O
213	.	O
213	[SEP]	O
214	[CLS]	O
214	the	O
214	micro	O
214	##dos	O
214	##e	O
214	and	O
214	regular	O
214	dose	O
214	of	O
214	o	O
214	##me	O
214	##pra	O
214	##zo	O
214	##le	O
214	were	O
214	again	O
214	administered	O
214	on	O
214	days	O
214	8	O
214	and	O
214	9	O
214	(	O
214	figure	O
214	1	O
214	)	O
214	.	O
214	[SEP]	O
215	[CLS]	O
215	the	O
215	lower	O
215	limit	O
215	of	O
215	q	O
215	##uant	O
215	##itation	O
215	(	O
215	ll	O
215	##o	O
215	##q	O
215	)	O
215	was	O
215	calculated	O
215	(	O
215	n	O
215	=	O
215	12	O
215	)	O
215	as	O
215	the	O
215	lowest	O
215	drug	O
215	concentration	O
215	on	O
215	the	O
215	standard	O
215	curve	O
215	that	O
215	could	O
215	be	O
215	q	O
215	##uant	O
215	##itated	O
215	with	O
215	c	O
215	##v	O
215	and	O
215	relative	O
215	error	O
215	not	O
215	exceeding	O
215	20	O
215	%	O
215	,	O
215	and	O
215	recovery	O
215	between	O
215	20	O
215	and	O
215	80	O
215	%	O
215	of	O
215	nominal	O
215	value	O
215	(	O
215	11	O
215	,	O
215	12	O
215	)	O
215	.	O
215	[SEP]	O
216	[CLS]	O
216	the	O
216	average	O
216	values	O
216	of	O
216	the	O
216	estimated	O
216	parameters	O
216	by	O
216	the	O
216	boots	O
216	##tra	O
216	##p	O
216	method	O
216	resembled	O
216	the	O
216	final	O
216	estimates	O
216	of	O
216	the	O
216	population	O
216	p	O
216	##k	O
216	parameters	O
216	(	O
216	table	O
216	4	O
216	)	O
216	.	O
216	[SEP]	O
217	[CLS]	O
217	subjects	O
217	were	O
217	recreational	O
217	drug	O
217	users	O
217	who	O
217	reported	O
217	having	O
217	used	O
217	2	O
217	##c	O
217	-	O
217	b	O
217	at	O
217	least	O
217	once	O
217	in	O
217	their	O
217	lives	O
217	.	O
217	[SEP]	O
218	[CLS]	O
218	mon	O
218	##oc	O
218	##lon	O
218	##al	O
218	anti	O
218	##body	O
218	216	O
218	targeting	O
218	was	O
218	determined	O
218	with	O
218	an	O
218	anti	O
218	-	O
218	idiot	O
218	##y	O
218	##pic	O
218	anti	O
218	##body	O
218	to	O
218	mon	O
218	##oc	O
218	##lon	O
218	##al	O
218	anti	O
218	##body	O
218	216	O
218	and	O
218	preliminary	O
218	efficacy	O
218	was	O
218	analyzed	O
218	by	O
218	changes	O
218	in	O
218	peripheral	O
218	blood	O
218	blast	O
218	##s	O
218	.	O
218	[SEP]	O
219	[CLS]	O
219	the	O
219	concentration	O
219	of	O
219	bi	O
219	##le	O
219	salts	O
219	in	O
219	plasma	O
219	was	O
219	increased	O
219	by	O
219	2	O
219	.	O
219	1	O
219	fold	O
219	in	O
219	ch	O
219	##ole	O
219	##static	O
219	rats	O
219	.	O
219	[SEP]	O
220	[CLS]	O
220	single	O
220	-	O
220	dose	O
220	administration	O
220	of	O
220	can	O
220	##na	O
220	##bid	O
220	##iol	O
220	oral	O
220	solution	O
220	showed	O
220	inter	O
220	-	O
220	individual	O
220	var	O
220	##iability	O
220	with	O
220	differences	O
220	in	O
220	systemic	O
220	exposure	O
220	between	O
220	co	O
220	##hor	O
220	##ts	O
220	(	O
220	table	O
220	3	O
220	)	O
220	.	O
220	[SEP]	O
221	[CLS]	O
221	the	O
221	study	O
221	noted	O
221	that	O
221	p	O
221	##hen	O
221	##ob	O
221	##ar	O
221	##bit	O
221	##al	O
221	dos	O
221	##ing	O
221	should	O
221	take	O
221	into	O
221	account	O
221	the	O
221	patient	O
221	’	O
221	s	O
221	fat	O
221	-	O
221	free	O
221	mass	O
221	,	O
221	post	O
221	##men	O
221	##st	O
221	##ru	O
221	##al	O
221	age	O
221	,	O
221	serum	O
221	c	O
221	##rea	O
221	##tin	O
221	##ine	O
221	,	O
221	and	O
221	age	O
221	in	O
221	years	O
221	.	O
221	[SEP]	O
222	[CLS]	O
222	during	O
222	continuous	O
222	war	O
222	##fari	O
222	##n	O
222	treatment	O
222	(	O
222	mean	O
222	daily	O
222	dose	O
222	5	O
222	.	O
222	3	O
222	mg	O
222	,	O
222	range	O
222	2	O
222	.	O
222	5	O
222	-	O
222	9	O
222	.	O
222	4	O
222	mg	O
222	)	O
222	,	O
222	te	O
222	##rod	O
222	##ili	O
222	##ne	O
222	or	O
222	place	O
222	##bo	O
222	was	O
222	given	O
222	for	O
222	two	O
222	weeks	O
222	in	O
222	a	O
222	random	O
222	##ized	O
222	and	O
222	double	O
222	-	O
222	blind	O
222	fashion	O
222	,	O
222	and	O
222	then	O
222	the	O
222	drugs	O
222	were	O
222	crossed	O
222	over	O
222	and	O
222	given	O
222	for	O
222	another	O
222	two	O
222	weeks	O
222	.	O
222	[SEP]	O
223	[CLS]	O
223	safety	O
223	evaluation	O
223	##s	O
223	included	O
223	physical	O
223	examinations	O
223	,	O
223	physician	O
223	ratings	O
223	of	O
223	a	O
223	##es	O
223	,	O
223	safety	O
223	laboratory	O
223	tests	O
223	,	O
223	vital	O
223	signs	O
223	,	O
223	12	O
223	-	O
223	lead	O
223	e	O
223	##c	O
223	##g	O
223	and	O
223	e	O
223	##c	O
223	##g	O
223	te	O
223	##lem	O
223	##et	O
223	##ry	O
223	from	O
223	-	O
223	1	O
223	h	O
223	to	O
223	24	O
223	h	O
223	.	O
223	whole	O
223	blood	O
223	concentrations	O
223	of	O
223	i	O
223	##bo	O
223	##gai	O
223	##ne	O
223	and	O
223	nor	O
223	##ib	O
223	##oga	O
223	##ine	O
223	were	O
223	measured	O
223	using	O
223	a	O
223	valid	O
223	##ated	O
223	g	O
223	##c	O
223	/	O
223	m	O
223	##s	O
223	method	O
223	with	O
223	de	O
223	##uter	O
223	##ated	O
223	internal	O
223	standards	O
223	(	O
223	hear	O
223	##n	O
223	et	O
223	al	O
223	.	O
223	,	O
223	1995	O
223	)	O
223	.	O
223	[SEP]	O
224	[CLS]	O
224	there	O
224	were	O
224	,	O
224	however	O
224	,	O
224	a	O
224	few	O
224	individuals	O
224	with	O
224	a	O
224	prolonged	O
224	elimination	O
224	phase	O
224	.	O
224	[SEP]	O
225	[CLS]	O
225	as	O
225	expected	O
225	,	O
225	no	O
225	b	O
225	##l	O
225	##q	O
225	data	O
225	were	O
225	found	O
225	at	O
225	2	O
225	##hr	O
225	and	O
225	24	O
225	##hr	O
225	.	O
225	[SEP]	O
226	[CLS]	O
226	a	O
226	total	O
226	of	O
226	0	O
226	.	O
226	05	O
226	m	O
226	##l	O
226	of	O
226	s	O
226	##r	O
226	-	O
226	03	O
226	##7	O
226	##9	O
226	solution	O
226	was	O
226	administered	O
226	per	O
226	spray	O
226	using	O
226	this	O
226	container	O
226	.	O
226	[SEP]	O
227	[CLS]	O
227	several	O
227	minor	O
227	meta	O
227	##bol	O
227	##ites	O
227	were	O
227	seen	O
227	that	O
227	ch	O
227	##roma	O
227	##to	O
227	##graph	O
227	##ed	O
227	in	O
227	the	O
227	di	O
227	##hy	O
227	##dr	O
227	##ox	O
227	##y	O
227	acid	O
227	region	O
227	as	O
227	judged	O
227	by	O
227	hp	O
227	##l	O
227	##c	O
227	and	O
227	t	O
227	##l	O
227	##c	O
227	.	O
227	[SEP]	O
228	[CLS]	O
228	third	O
228	,	O
228	b	O
228	##f	O
228	(	O
228	50	O
228	mg	O
228	/	O
228	kg	O
228	)	O
228	was	O
228	administered	O
228	to	O
228	rats	O
228	on	O
228	day	O
228	15	O
228	of	O
228	pregnancy	O
228	to	O
228	determine	O
228	whether	O
228	d	O
228	##b	O
228	##f	O
228	could	O
228	cross	O
228	the	O
228	place	O
228	##nta	O
228	.	O
228	[SEP]	O
229	[CLS]	O
229	during	O
229	a	O
229	cross	O
229	-	O
229	over	O
229	study	O
229	,	O
229	the	O
229	p	O
229	##har	O
229	##ma	O
229	##co	O
229	##kin	O
229	##etics	O
229	of	O
229	et	O
229	##hin	O
229	##yle	O
229	##stra	O
229	##dio	O
229	##l	O
229	(	O
229	e	O
229	##e	O
229	)	O
229	and	O
229	3	O
229	-	O
229	k	O
229	##eto	O
229	-	O
229	des	O
229	##og	O
229	##est	O
229	##rel	O
229	(	O
229	k	O
229	##d	O
229	##g	O
229	)	O
229	were	O
229	investigated	O
229	on	O
229	days	O
229	7	O
229	and	O
229	22	O
229	of	O
229	one	O
229	cycle	O
229	of	O
229	treatment	O
229	with	O
229	two	O
229	bi	O
229	##pha	O
229	##si	O
229	##c	O
229	formulation	O
229	##s	O
229	containing	O
229	50	O
229	micro	O
229	##gram	O
229	##s	O
229	e	O
229	##e	O
229	(	O
229	7	O
229	tablets	O
229	)	O
229	and	O
229	50	O
229	micro	O
229	##gram	O
229	##s	O
229	e	O
229	##e	O
229	+	O
229	125	O
229	micro	O
229	##gram	O
229	##s	O
229	des	O
229	##og	O
229	##est	O
229	##rel	O
229	(	O
229	d	O
229	##g	O
229	)	O
229	(	O
229	15	O
229	tablets	O
229	)	O
229	(	O
229	50	O
229	/	O
229	50	O
229	e	O
229	##e	O
229	)	O
229	or	O
229	40	O
229	micro	O
229	##gram	O
229	##s	O
229	e	O
229	##e	O
229	+	O
229	25	O
229	micro	O
229	##gram	O
229	##s	O
229	d	O
229	##g	O
229	(	O
229	7	O
229	tablets	O
229	)	O
229	and	O
229	30	O
229	micro	O
229	##gram	O
229	##s	O
229	e	O
229	##e	O
229	+	O
229	125	O
229	micro	O
229	##gram	O
229	##s	O
229	d	O
229	##g	O
229	(	O
229	15	O
229	tablets	O
229	)	O
229	(	O
229	40	O
229	/	O
229	30	O
229	e	O
229	##e	O
229	)	O
229	.	O
229	[SEP]	O
230	[CLS]	O
230	the	O
230	m	O
230	##dr	O
230	##1	O
230	g	O
230	##eno	O
230	##type	O
230	at	O
230	ex	O
230	##on	O
230	26	O
230	was	O
230	determined	O
230	in	O
230	114	O
230	healthy	O
230	volunteers	O
230	by	O
230	polymer	O
230	##ase	O
230	chain	O
230	reaction	O
230	-	O
230	restriction	O
230	fragment	O
230	length	O
230	p	O
230	##oly	O
230	##mor	O
230	##phism	O
230	.	O
230	[SEP]	O
231	[CLS]	O
231	the	O
231	black	O
231	circles	O
231	represent	O
231	the	O
231	values	O
231	of	O
231	the	O
231	individual	O
231	patients	O
231	.	O
231	[SEP]	O
232	[CLS]	O
232	study	O
232	highlights	O
232	##w	O
232	##hat	O
232	is	O
232	the	O
232	current	O
232	knowledge	O
232	on	O
232	the	O
232	topic	O
232	?	O
232	[SEP]	O
233	[CLS]	O
233	re	O
233	##tino	O
233	##ic	O
233	acid	O
233	regulate	O
233	##s	O
233	growth	O
233	and	O
233	differentiation	O
233	of	O
233	ne	O
233	##uro	O
233	##blast	O
233	##oma	O
233	cells	O
233	in	O
233	v	O
233	##it	O
233	##ro	O
233	,	O
233	and	O
233	has	O
233	shown	O
233	activity	O
233	against	O
233	human	O
233	ne	O
233	##uro	O
233	##blast	O
233	##oma	O
233	##s	O
233	in	O
233	v	O
233	##ivo	O
233	.	O
233	[SEP]	O
234	[CLS]	O
234	subjects	O
234	who	O
234	received	O
234	≥	O
234	##7	O
234	doses	O
234	of	O
234	the	O
234	study	O
234	drug	O
234	were	O
234	considered	O
234	e	O
234	##val	O
234	##ua	O
234	##ble	O
234	.	O
234	[SEP]	O
235	[CLS]	O
235	more	O
235	##over	O
235	,	O
235	excluded	O
235	were	O
235	patients	O
235	with	O
235	a	O
235	history	O
235	of	O
235	p	O
235	##el	O
235	##vic	O
235	ma	O
235	##li	O
235	##gna	O
235	##ncy	O
235	,	O
235	h	O
235	##ydro	O
235	##ne	O
235	##ph	O
235	##rosis	O
235	,	O
235	or	O
235	clinical	O
235	##ly	O
235	significant	O
235	abnormal	O
235	##ities	O
235	of	O
235	the	O
235	upper	O
235	u	O
235	##rina	O
235	##ry	O
235	tract	O
235	and	O
235	those	O
235	who	O
235	had	O
235	undergone	O
235	b	O
235	##c	O
235	##g	O
235	therapy	O
235	within	O
235	6	O
235	weeks	O
235	prior	O
235	to	O
235	the	O
235	start	O
235	of	O
235	v	O
235	##b	O
235	##4	O
235	-	O
235	84	O
235	##5	O
235	dos	O
235	##ing	O
235	.	O
235	[SEP]	O
236	[CLS]	O
236	these	O
236	results	O
236	indicated	O
236	that	O
236	the	O
236	micro	O
236	##so	O
236	##mal	O
236	mon	O
236	##oo	O
236	##xy	O
236	##gen	O
236	##ase	O
236	system	O
236	might	O
236	be	O
236	mainly	O
236	responsible	O
236	for	O
236	the	O
236	an	O
236	##s	O
236	metabolism	O
236	.	O
236	[SEP]	O
237	[CLS]	O
237	con	O
237	##com	O
237	##ita	O
237	##ntly	O
237	,	O
237	l	O
237	##dl	O
237	ch	O
237	##ole	O
237	##ster	O
237	##ol	O
237	levels	O
237	decreased	O
237	by	O
237	16	O
237	%	O
237	.	O
237	[SEP]	O
238	[CLS]	O
238	the	O
238	median	O
238	m	O
238	##pa	O
238	-	O
238	au	B-PK
238	##c	I-PK
238	##0	I-PK
238	-	I-PK
238	12	I-PK
238	values	O
238	increased	O
238	2	O
238	-	O
238	fold	O
238	from	O
238	32	O
238	.	O
238	4	O
238	(	O
238	range	O
238	,	O
238	13	O
238	.	O
238	9	O
238	to	O
238	57	O
238	.	O
238	0	O
238	)	O
238	mg	O
238	x	O
238	h	O
238	/	O
238	l	O
238	at	O
238	3	O
238	weeks	O
238	to	O
238	65	O
238	.	O
238	1	O
238	(	O
238	range	O
238	,	O
238	32	O
238	.	O
238	6	O
238	to	O
238	114	O
238	)	O
238	mg	O
238	x	O
238	h	O
238	/	O
238	l	O
238	at	O
238	3	O
238	months	O
238	after	O
238	transplant	O
238	##ation	O
238	,	O
238	whereas	O
238	the	O
238	median	O
238	au	B-PK
238	##c	I-PK
238	##0	I-PK
238	-	I-PK
238	12	I-PK
238	values	O
238	of	O
238	free	O
238	m	O
238	##pa	O
238	did	O
238	not	O
238	significantly	O
238	change	O
238	over	O
238	time	O
238	.	O
238	[SEP]	O
239	[CLS]	O
239	the	O
239	anti	O
239	##hy	O
239	##pert	O
239	##ens	O
239	##ive	O
239	effect	O
239	of	O
239	oral	O
239	##ly	O
239	administered	O
239	ni	O
239	##fe	O
239	##di	O
239	##pine	O
239	-	O
239	loaded	O
239	na	O
239	##no	O
239	##par	O
239	##tic	O
239	##les	O
239	in	O
239	spontaneous	O
239	##ly	O
239	h	O
239	##yper	O
239	##tensive	O
239	rats	O
239	.	O
239	[SEP]	O
240	[CLS]	O
240	a	O
240	two	O
240	##fold	O
240	reduction	O
240	in	O
240	g	O
240	##i	O
240	c	O
240	##y	O
240	##p	O
240	##3	O
240	##a	O
240	gave	O
240	a	O
240	post	O
240	/	O
240	pre	O
240	##su	O
240	##rg	O
240	##ical	O
240	au	B-PK
240	##c	I-PK
240	ratio	I-PK
240	of	O
240	1	O
240	.	O
240	99	O
240	(	O
240	0	O
240	.	O
240	83	O
240	–	O
240	6	O
240	.	O
240	76	O
240	)	O
240	,	O
240	whereas	O
240	cm	B-PK
240	##ax	I-PK
240	increased	O
240	to	O
240	a	O
240	minor	O
240	extent	O
240	,	O
240	displaying	O
240	an	O
240	au	B-PK
240	##c	I-PK
240	ratio	I-PK
240	of	O
240	1	O
240	.	O
240	80	O
240	(	O
240	0	O
240	.	O
240	79	O
240	–	O
240	4	O
240	.	O
240	00	O
240	)	O
240	.	O
240	[SEP]	O
241	[CLS]	O
241	(	O
241	4	O
241	)	O
241	all	O
241	##og	O
241	##raft	O
241	survival	O
241	was	O
241	similar	O
241	for	O
241	r	O
241	##34	O
241	##8	O
241	20	O
241	and	O
241	40	O
241	mg	O
241	/	O
241	kg	O
241	,	O
241	which	O
241	was	O
241	comparable	O
241	with	O
241	therapeutic	O
241	##ally	O
241	dose	O
241	##d	O
241	ta	O
241	##c	O
241	##rol	O
241	##imus	O
241	or	O
241	rap	O
241	##am	O
241	##y	O
241	##cin	O
241	.	O
241	[SEP]	O
242	[CLS]	O
242	patients	O
242	with	O
242	c	O
242	##ea	O
242	-	O
242	producing	O
242	meta	O
242	##static	O
242	ma	O
242	##li	O
242	##gna	O
242	##ncies	O
242	were	O
242	administered	O
242	a	O
242	single	O
242	in	O
242	##tra	O
242	##ven	O
242	##ous	O
242	dose	O
242	of	O
242	5	O
242	m	O
242	##ci	O
242	111	O
242	##in	O
242	-	O
242	diet	O
242	##hyl	O
242	##ene	O
242	##tri	O
242	##amine	O
242	##pent	O
242	##aa	O
242	##ce	O
242	##tic	O
242	acid	O
242	-	O
242	c	O
242	##t	O
242	##8	O
242	##4	O
242	.	O
242	66	O
242	.	O
242	[SEP]	O
243	[CLS]	O
243	thus	O
243	,	O
243	bi	O
243	##lia	O
243	##ry	O
243	ex	O
243	##cre	O
243	##tion	O
243	plays	O
243	a	O
243	considerable	O
243	part	O
243	in	O
243	the	O
243	p	O
243	##har	O
243	##ma	O
243	##co	O
243	##kin	O
243	##etics	O
243	of	O
243	to	O
243	##lf	O
243	##ena	O
243	##mic	O
243	acid	O
243	.	O
243	[SEP]	O
244	[CLS]	O
244	further	O
244	studies	O
244	are	O
244	needed	O
244	to	O
244	improve	O
244	the	O
244	reliability	O
244	of	O
244	p	O
244	##har	O
244	##ma	O
244	##co	O
244	##kin	O
244	##etic	O
244	models	O
244	in	O
244	est	O
244	##imating	O
244	serum	O
244	dig	O
244	##ox	O
244	##in	O
244	concentrations	O
244	in	O
244	the	O
244	elderly	O
244	.	O
244	[SEP]	O
245	[CLS]	O
245	the	O
245	31	O
245	##p	O
245	{	O
245	1	O
245	##h	O
245	}	O
245	nm	O
245	##r	O
245	spectrum	O
245	in	O
245	d	O
245	##2	O
245	##o	O
245	for	O
245	3	O
245	(	O
245	δ	O
245	=	O
245	37	O
245	.	O
245	73	O
245	pp	O
245	##m	O
245	)	O
245	shows	O
245	an	O
245	additional	O
245	##sign	O
245	##al	O
245	(	O
245	δ	O
245	=	O
245	38	O
245	.	O
245	34	O
245	pp	O
245	##m	O
245	)	O
245	that	O
245	may	O
245	be	O
245	assigned	O
245	to	O
245	a	O
245	h	O
245	##ydro	O
245	##ly	O
245	##zed	O
245	##sp	O
245	##ec	O
245	##ies	O
245	of	O
245	the	O
245	type	O
245	[	O
245	(	O
245	η	O
245	##6	O
245	-	O
245	p	O
245	-	O
245	c	O
245	##yme	O
245	##ne	O
245	)	O
245	r	O
245	##u	O
245	(	O
245	p	O
245	##h	O
245	##3	O
245	##p	O
245	=	O
245	n	O
245	-	O
245	8	O
245	-	O
245	c	O
245	##9	O
245	##h	O
245	##6	O
245	##n	O
245	)	O
245	(	O
245	oh	O
245	##2	O
245	)	O
245	]	O
245	2	O
245	+	O
245	.	O
245	[SEP]	O
246	[CLS]	O
246	the	O
246	area	B-PK
246	under	I-PK
246	the	I-PK
246	concentration	I-PK
246	-	I-PK
246	time	I-PK
246	curve	I-PK
246	(	I-PK
246	au	I-PK
246	##c	I-PK
246	)	I-PK
246	was	O
246	calculated	O
246	using	O
246	the	O
246	log	O
246	-	O
246	linear	O
246	trap	O
246	##ez	O
246	##oid	O
246	##al	O
246	rule	O
246	,	O
246	either	O
246	from	O
246	the	O
246	time	O
246	of	O
246	administration	O
246	to	O
246	a	O
246	specified	O
246	time	O
246	point	O
246	thereafter	O
246	,	O
246	or	O
246	to	O
246	the	O
246	last	O
246	q	O
246	##uant	O
246	##ifiable	O
246	time	O
246	point	O
246	(	O
246	au	B-PK
246	##c	I-PK
246	##0	I-PK
246	-	I-PK
246	last	I-PK
246	)	O
246	.	O
246	[SEP]	O
247	[CLS]	O
247	ma	O
247	##ri	O
247	##ba	O
247	##vir	O
247	p	O
247	##har	O
247	##ma	O
247	##co	O
247	##kin	O
247	##etics	O
247	and	O
247	the	O
247	effects	O
247	of	O
247	multiple	O
247	-	O
247	dose	O
247	ma	O
247	##ri	O
247	##ba	O
247	##vir	O
247	on	O
247	c	O
247	##yt	O
247	##och	O
247	##rome	O
247	p	O
247	##45	O
247	##0	O
247	(	O
247	c	O
247	##y	O
247	##p	O
247	)	O
247	1	O
247	##a	O
247	##2	O
247	,	O
247	c	O
247	##y	O
247	##p	O
247	2	O
247	##c	O
247	##9	O
247	,	O
247	c	O
247	##y	O
247	##p	O
247	2	O
247	##c	O
247	##19	O
247	,	O
247	c	O
247	##y	O
247	##p	O
247	2d	O
247	##6	O
247	,	O
247	c	O
247	##y	O
247	##p	O
247	3	O
247	##a	O
247	,	O
247	n	O
247	-	O
247	ace	O
247	##ty	O
247	##lt	O
247	##ran	O
247	##s	O
247	##fer	O
247	##ase	O
247	-	O
247	2	O
247	,	O
247	and	O
247	x	O
247	##ant	O
247	##hine	O
247	o	O
247	##xi	O
247	##das	O
247	##e	O
247	activities	O
247	in	O
247	healthy	O
247	adults	O
247	.	O
247	[SEP]	O
248	[CLS]	O
248	the	O
248	base	O
248	model	O
248	was	O
248	first	O
248	developed	O
248	using	O
248	dense	O
248	data	O
248	.	O
248	[SEP]	O
249	[CLS]	O
249	a	O
249	ratio	O
249	of	O
249	ta	O
249	##z	O
249	to	O
249	p	O
249	##ip	O
249	##c	O
249	was	O
249	about	O
249	1	O
249	to	O
249	4	O
249	in	O
249	plasma	O
249	levels	O
249	.	O
249	[SEP]	O
250	[CLS]	O
250	rate	O
250	-	O
250	limiting	O
250	steps	O
250	in	O
250	oral	O
250	absorption	O
250	of	O
250	a	O
250	le	O
250	##uc	O
250	##ot	O
250	##rien	O
250	##e	O
250	d	O
250	##4	O
250	antagonist	O
250	in	O
250	the	O
250	be	O
250	##ag	O
250	##le	O
250	dog	O
250	.	O
250	[SEP]	O
251	[CLS]	O
251	the	O
251	dose	O
251	of	O
251	t	O
251	##rane	O
251	##xa	O
251	##mic	O
251	acid	O
251	used	O
251	in	O
251	our	O
251	patient	O
251	was	O
251	employed	O
251	from	O
251	previous	O
251	experience	O
251	in	O
251	trauma	O
251	patients	O
251	.	O
251	[SEP]	O
252	[CLS]	O
252	16	O
252	%	O
252	of	O
252	the	O
252	control	O
252	,	O
252	and	O
252	in	O
252	those	O
252	diet	O
252	##ary	O
252	groups	O
252	severe	O
252	hem	O
252	##or	O
252	##r	O
252	##hage	O
252	##s	O
252	in	O
252	e	O
252	##pid	O
252	##idy	O
252	##mis	O
252	and	O
252	other	O
252	organs	O
252	were	O
252	also	O
252	observed	O
252	.	O
252	[SEP]	O
253	[CLS]	O
253	ha	O
253	##lop	O
253	##eri	O
253	##do	O
253	##l	O
253	and	O
253	reduced	O
253	ha	O
253	##lop	O
253	##eri	O
253	##do	O
253	##l	O
253	plasma	O
253	concentrations	O
253	were	O
253	ass	O
253	##ay	O
253	##ed	O
253	by	O
253	hp	O
253	##l	O
253	##c	O
253	.	O
253	[SEP]	O
254	[CLS]	O
254	in	O
254	v	O
254	##ivo	O
254	,	O
254	p	O
254	##har	O
254	##ma	O
254	##co	O
254	##kin	O
254	##etics	O
254	of	O
254	ta	O
254	-	O
254	s	O
254	##s	O
254	##ln	O
254	##s	O
254	and	O
254	ta	O
254	-	O
254	n	O
254	##s	O
254	##ln	O
254	##s	O
254	after	O
254	a	O
254	single	O
254	dose	O
254	in	O
254	##tra	O
254	##ven	O
254	##ous	O
254	injection	O
254	to	O
254	rat	O
254	has	O
254	been	O
254	studied	O
254	.	O
254	[SEP]	O
255	[CLS]	O
255	the	O
255	study	O
255	was	O
255	conducted	O
255	on	O
255	new	O
255	z	O
255	##eal	O
255	##and	O
255	white	O
255	rabbits	O
255	with	O
255	three	O
255	groups	O
255	having	O
255	two	O
255	subgroup	O
255	##s	O
255	each	O
255	(	O
255	n	O
255	=	O
255	12	O
255	)	O
255	.	O
255	[SEP]	O
256	[CLS]	O
256	samples	O
256	were	O
256	drawn	O
256	just	O
256	prior	O
256	to	O
256	,	O
256	and	O
256	at	O
256	1	O
256	,	O
256	4	O
256	,	O
256	and	O
256	10	O
256	hours	O
256	after	O
256	,	O
256	the	O
256	observed	O
256	dose	O
256	.	O
256	[SEP]	O
257	[CLS]	O
257	the	O
257	au	B-PK
257	##c	I-PK
257	values	O
257	(	O
257	mean	O
257	+	O
257	-	O
257	s	O
257	.	O
257	d	O
257	.	O
257	of	O
257	4	O
257	rats	O
257	)	O
257	for	O
257	f	O
257	##ad	O
257	,	O
257	f	O
257	##m	O
257	##n	O
257	and	O
257	r	O
257	##f	O
257	were	O
257	70	O
257	##7	O
257	+	O
257	-	O
257	37	O
257	##8	O
257	,	O
257	36	O
257	##43	O
257	+	O
257	-	O
257	95	O
257	##8	O
257	and	O
257	300	O
257	##9	O
257	##5	O
257	+	O
257	-	O
257	35	O
257	##44	O
257	nm	O
257	##ol	O
257	x	O
257	min	O
257	/	O
257	l	O
257	,	O
257	respectively	O
257	.	O
257	[SEP]	O
258	[CLS]	O
258	protection	O
258	of	O
258	g	O
258	##em	O
258	##ci	O
258	##ta	O
258	##bine	O
258	with	O
258	t	O
258	##b	O
258	##d	O
258	##ms	O
258	:	O
258	under	O
258	nitrogen	O
258	,	O
258	g	O
258	##em	O
258	##ci	O
258	##ta	O
258	##bine	O
258	h	O
258	##ydro	O
258	##ch	O
258	##lor	O
258	##ide	O
258	(	O
258	6	O
258	,	O
258	0	O
258	.	O
258	50	O
258	g	O
258	,	O
258	1	O
258	.	O
258	7	O
258	mm	O
258	##ol	O
258	)	O
258	and	O
258	im	O
258	##ida	O
258	##zo	O
258	##le	O
258	(	O
258	1	O
258	.	O
258	16	O
258	g	O
258	,	O
258	17	O
258	.	O
258	0	O
258	mm	O
258	##ol	O
258	)	O
258	were	O
258	dissolved	O
258	in	O
258	an	O
258	##hy	O
258	##dr	O
258	##ous	O
258	dim	O
258	##eth	O
258	##yl	O
258	##form	O
258	##ami	O
258	##de	O
258	and	O
258	te	O
258	##rt	O
258	-	O
258	but	O
258	##yl	O
258	##di	O
258	##met	O
258	##hyl	O
258	##si	O
258	##ly	O
258	##l	O
258	chloride	O
258	(	O
258	t	O
258	##b	O
258	##d	O
258	##ms	O
258	-	O
258	c	O
258	##l	O
258	,	O
258	2	O
258	.	O
258	65	O
258	g	O
258	,	O
258	10	O
258	.	O
258	0	O
258	mm	O
258	##ol	O
258	)	O
258	was	O
258	added	O
258	.	O
258	[SEP]	O
259	[CLS]	O
259	insulin	O
259	l	O
259	##is	O
259	##p	O
259	##ro	O
259	was	O
259	provided	O
259	in	O
259	a	O
259	di	O
259	##sp	O
259	##osa	O
259	##ble	O
259	pen	O
259	for	O
259	meal	O
259	##time	O
259	administration	O
259	and	O
259	correction	O
259	of	O
259	h	O
259	##yper	O
259	##gly	O
259	##ca	O
259	##emia	O
259	.	O
259	[SEP]	O
260	[CLS]	O
260	the	O
260	cm	B-PK
260	##ax	I-PK
260	in	O
260	the	O
260	br	O
260	##oms	O
260	##ite	O
260	##®	O
260	bid	O
260	group	O
260	was	O
260	statistical	O
260	##ly	O
260	significantly	O
260	higher	O
260	(	O
260	p	O
260	<	O
260	0	O
260	.	O
260	05	O
260	)	O
260	than	O
260	that	O
260	of	O
260	il	O
260	##ev	O
260	##ro	O
260	##®	O
260	.	O
260	[SEP]	O
261	[CLS]	O
261	ch	O
261	##roma	O
261	##to	O
261	##graphic	O
261	separation	O
261	was	O
261	performed	O
261	on	O
261	a	O
261	l	O
261	##ich	O
261	##ros	O
261	##pher	O
261	c	O
261	##n	O
261	column	O
261	with	O
261	a	O
261	mobile	O
261	phase	O
261	of	O
261	met	O
261	##han	O
261	##ol	O
261	and	O
261	water	O
261	(	O
261	containing	O
261	0	O
261	.	O
261	1	O
261	%	O
261	form	O
261	##ic	O
261	acid	O
261	)	O
261	(	O
261	70	O
261	:	O
261	30	O
261	,	O
261	v	O
261	/	O
261	v	O
261	)	O
261	.	O
261	[SEP]	O
262	[CLS]	O
262	valid	O
262	##ated	O
262	high	O
262	performance	O
262	liquid	O
262	ch	O
262	##roma	O
262	##tography	O
262	-	O
262	u	O
262	##v	O
262	detection	O
262	method	O
262	for	O
262	the	O
262	determination	O
262	of	O
262	da	O
262	##pt	O
262	##omy	O
262	##cin	O
262	in	O
262	human	O
262	plasma	O
262	.	O
262	[SEP]	O
263	[CLS]	O
263	for	O
263	in	O
263	v	O
263	##it	O
263	##ro	O
263	experiments	O
263	,	O
263	extract	O
263	from	O
263	mouse	O
263	ma	O
263	##mma	O
263	##ry	O
263	t	O
263	##umour	O
263	##s	O
263	were	O
263	prepared	O
263	and	O
263	in	O
263	##cu	O
263	##bate	O
263	##d	O
263	with	O
263	radio	O
263	##io	O
263	##dina	O
263	##ted	O
263	p	O
263	##14	O
263	##9	O
263	-	O
263	q	O
263	##y	O
263	p	O
263	##eptide	O
263	in	O
263	the	O
263	presence	O
263	of	O
263	a	O
263	cross	O
263	-	O
263	linking	O
263	re	O
263	##age	O
263	##nt	O
263	.	O
263	[SEP]	O
264	[CLS]	O
264	forty	O
264	patients	O
264	with	O
264	active	O
264	p	O
264	##ept	O
264	##ic	O
264	ul	O
264	##cer	O
264	were	O
264	randomly	O
264	assigned	O
264	to	O
264	receive	O
264	a	O
264	single	O
264	oral	O
264	dose	O
264	of	O
264	r	O
264	##abe	O
264	##pra	O
264	##zo	O
264	##le	O
264	10	O
264	mg	O
264	,	O
264	o	O
264	##me	O
264	##pra	O
264	##zo	O
264	##le	O
264	20	O
264	mg	O
264	,	O
264	or	O
264	pan	O
264	##top	O
264	##raz	O
264	##ole	O
264	40	O
264	mg	O
264	;	O
264	the	O
264	in	O
264	##tra	O
264	##gas	O
264	##tric	O
264	p	O
264	##h	O
264	was	O
264	monitored	O
264	1	O
264	hour	O
264	before	O
264	and	O
264	24	O
264	hours	O
264	after	O
264	the	O
264	dose	O
264	was	O
264	given	O
264	.	O
264	[SEP]	O
265	[CLS]	O
265	assessment	O
265	of	O
265	re	O
265	##nal	O
265	function	O
265	by	O
265	means	O
265	of	O
265	plasma	B-PK
265	clearance	I-PK
265	of	O
265	a	O
265	suitable	O
265	marker	O
265	has	O
265	become	O
265	standard	O
265	procedure	O
265	for	O
265	est	O
265	##imation	O
265	of	O
265	g	O
265	##lo	O
265	##mer	O
265	##ular	O
265	fi	O
265	##ltration	O
265	rate	O
265	(	O
265	g	O
265	##f	O
265	##r	O
265	)	O
265	.	O
265	[SEP]	O
266	[CLS]	O
266	within	O
266	each	O
266	organ	O
266	compartment	O
266	,	O
266	there	O
266	are	O
266	three	O
266	sub	O
266	-	O
266	compartment	O
266	##s	O
266	representing	O
266	cap	O
266	##illa	O
266	##ry	O
266	blood	O
266	,	O
266	tissue	O
266	,	O
266	and	O
266	p	O
266	##ha	O
266	##go	O
266	##cy	O
266	##ti	O
266	##zing	O
266	cells	O
266	(	O
266	p	O
266	##cs	O
266	)	O
266	.	O
266	[SEP]	O
267	[CLS]	O
267	no	O
267	changes	O
267	in	O
267	electro	O
267	##card	O
267	##io	O
267	##gram	O
267	or	O
267	vital	O
267	signs	O
267	were	O
267	observed	O
267	.	O
267	[SEP]	O
268	[CLS]	O
268	the	O
268	student	O
268	’	O
268	s	O
268	t	O
268	test	O
268	was	O
268	used	O
268	to	O
268	compare	O
268	in	O
268	##f	O
268	##lix	O
268	##ima	O
268	##b	O
268	concentrations	O
268	,	O
268	h	O
268	##s	O
268	-	O
268	c	O
268	##rp	O
268	and	O
268	f	O
268	##c	O
268	levels	O
268	in	O
268	study	O
268	subjects	O
268	and	O
268	controls	O
268	with	O
268	the	O
268	significance	O
268	level	O
268	set	O
268	at	O
268	5	O
268	%	O
268	.	O
268	[SEP]	O
269	[CLS]	O
269	the	O
269	lo	O
269	##q	O
269	was	O
269	also	O
269	the	O
269	lowest	O
269	point	O
269	of	O
269	the	O
269	ca	O
269	##li	O
269	##bra	O
269	##tion	O
269	curve	O
269	and	O
269	was	O
269	set	O
269	at	O
269	200	O
269	ng	O
269	·	O
269	m	O
269	##l	O
269	##−	O
269	##1	O
269	(	O
269	n	O
269	=	O
269	6	O
269	,	O
269	mean	O
269	result	O
269	:	O
269	190	O
269	.	O
269	2	O
269	±	O
269	3	O
269	.	O
269	44	O
269	ng	O
269	·	O
269	m	O
269	##l	O
269	##−	O
269	##1	O
269	)	O
269	.	O
269	[SEP]	O
270	[CLS]	O
270	this	O
270	study	O
270	was	O
270	approved	O
270	by	O
270	the	O
270	animal	O
270	et	O
270	##hic	O
270	committee	O
270	of	O
270	university	O
270	of	O
270	ad	O
270	##nan	O
270	men	O
270	##der	O
270	##es	O
270	.	O
270	[SEP]	O
271	[CLS]	O
271	however	O
271	,	O
271	600	O
271	mg	O
271	e	O
271	##f	O
271	##v	O
271	has	O
271	been	O
271	associated	O
271	with	O
271	ne	O
271	##uro	O
271	##to	O
271	##xi	O
271	##city	O
271	(	O
271	r	O
271	##ak	O
271	##hman	O
271	##ina	O
271	and	O
271	van	O
271	den	O
271	an	O
271	##ker	O
271	,	O
271	2010	O
271	;	O
271	a	O
271	##post	O
271	##olo	O
271	##va	O
271	et	O
271	al	O
271	.	O
271	,	O
271	2015	O
271	)	O
271	.	O
271	[SEP]	O
272	[CLS]	O
272	as	O
272	shown	O
272	in	O
272	table	O
272	2	O
272	,	O
272	peak	B-PK
272	concentration	I-PK
272	was	O
272	found	O
272	to	O
272	be	O
272	significantly	O
272	higher	O
272	for	O
272	d	O
272	-	O
272	p	O
272	##n	O
272	##ps	O
272	(	O
272	1	O
272	.	O
272	92	O
272	±	O
272	0	O
272	.	O
272	69	O
272	μ	O
272	##g	O
272	/	O
272	m	O
272	##l	O
272	)	O
272	and	O
272	d	O
272	-	O
272	c	O
272	##n	O
272	##ps	O
272	(	O
272	2	O
272	.	O
272	44	O
272	±	O
272	0	O
272	.	O
272	74	O
272	μ	O
272	##g	O
272	/	O
272	m	O
272	##l	O
272	)	O
272	than	O
272	for	O
272	da	O
272	##id	O
272	##ze	O
272	##in	O
272	suspension	O
272	group	O
272	(	O
272	1	O
272	.	O
272	35	O
272	±	O
272	0	O
272	.	O
272	47	O
272	μ	O
272	##g	O
272	/	O
272	m	O
272	##l	O
272	)	O
272	.	O
272	[SEP]	O
273	[CLS]	O
273	m	O
273	##cc	O
273	##s	O
273	(	O
273	c	O
273	##eo	O
273	##lus	O
273	r	O
273	##c	O
273	-	O
273	a	O
273	##5	O
273	##9	O
273	##1	O
273	n	O
273	##f	O
273	;	O
273	as	O
273	##ahi	O
273	ka	O
273	##sei	O
273	,	O
273	to	O
273	##ky	O
273	##o	O
273	,	O
273	j	O
273	##apa	O
273	##n	O
273	)	O
273	was	O
273	commercially	O
273	obtained	O
273	.	O
273	[SEP]	O
274	[CLS]	O
274	p	O
274	##har	O
274	##ma	O
274	##co	O
274	##dynamic	O
274	assessment	O
274	confirmed	O
274	par	O
274	##p	O
274	in	O
274	##hibition	O
274	although	O
274	no	O
274	dose	O
274	response	O
274	was	O
274	apparent	O
274	.	O
274	[SEP]	O
275	[CLS]	O
275	be	O
275	##rber	O
275	##ine	O
275	(	O
275	be	O
275	##r	O
275	)	O
275	,	O
275	possessing	O
275	a	O
275	variety	O
275	of	O
275	p	O
275	##har	O
275	##ma	O
275	##cological	O
275	functions	O
275	,	O
275	has	O
275	caused	O
275	a	O
275	growing	O
275	interest	O
275	in	O
275	recent	O
275	years	O
275	.	O
275	[SEP]	O
276	[CLS]	O
276	the	O
276	drug	O
276	is	O
276	highly	O
276	(	O
276	greater	O
276	than	O
276	99	O
276	%	O
276	)	O
276	bound	O
276	to	O
276	plasma	O
276	album	O
276	##ins	O
276	and	O
276	penetrate	O
276	##s	O
276	easily	O
276	into	O
276	the	O
276	s	O
276	##yn	O
276	##ov	O
276	##ial	O
276	fluid	O
276	.	O
276	[SEP]	O
277	[CLS]	O
277	m	O
277	##dh	O
277	##p	O
277	was	O
277	found	O
277	to	O
277	be	O
277	the	O
277	major	O
277	u	O
277	##rina	O
277	##ry	O
277	meta	O
277	##bol	O
277	##ite	O
277	.	O
277	[SEP]	O
278	[CLS]	O
278	p	O
278	##har	O
278	##ma	O
278	##co	O
278	##kin	O
278	##etic	O
278	parameters	O
278	,	O
278	such	O
278	as	O
278	half	B-PK
278	‐	I-PK
278	life	I-PK
278	and	O
278	clearance	B-PK
278	,	O
278	were	O
278	then	O
278	calculated	O
278	using	O
278	non	O
278	‐	O
278	compartment	O
278	##al	O
278	analysis	O
278	of	O
278	the	O
278	data	O
278	from	O
278	the	O
278	p	O
278	##har	O
278	##ma	O
278	##co	O
278	##kin	O
278	##etic	O
278	study	O
278	.	O
278	[SEP]	O
279	[CLS]	O
279	compared	O
279	with	O
279	the	O
279	reference	O
279	treatment	O
279	,	O
279	the	O
279	au	B-PK
279	##cs	I-PK
279	(	I-PK
279	0	I-PK
279	–	I-PK
279	∞	I-PK
279	)	I-PK
279	for	O
279	do	O
279	##lut	O
279	##eg	O
279	##ra	O
279	##vir	O
279	after	O
279	a	O
279	##ba	O
279	##ca	O
279	##vir	O
279	/	O
279	do	O
279	##lut	O
279	##eg	O
279	##ra	O
279	##vir	O
279	/	O
279	la	O
279	##mi	O
279	##vu	O
279	##dine	O
279	–	O
279	high	O
279	mineral	O
279	—	O
279	immediate	O
279	,	O
279	a	O
279	##ba	O
279	##ca	O
279	##vir	O
279	/	O
279	do	O
279	##lut	O
279	##eg	O
279	##ra	O
279	##vir	O
279	/	O
279	la	O
279	##mi	O
279	##vu	O
279	##dine	O
279	–	O
279	high	O
279	mineral	O
279	—	O
279	delayed	O
279	,	O
279	a	O
279	##ba	O
279	##ca	O
279	##vir	O
279	/	O
279	do	O
279	##lut	O
279	##eg	O
279	##ra	O
279	##vir	O
279	/	O
279	la	O
279	##mi	O
279	##vu	O
279	##dine	O
279	–	O
279	zero	O
279	mineral	O
279	—	O
279	immediate	O
279	,	O
279	and	O
279	a	O
279	##ba	O
279	##ca	O
279	##vir	O
279	/	O
279	do	O
279	##lut	O
279	##eg	O
279	##ra	O
279	##vir	O
279	/	O
279	la	O
279	##mi	O
279	##vu	O
279	##dine	O
279	–	O
279	zero	O
279	mineral	O
279	—	O
279	delayed	O
279	were	O
279	56	O
279	%	O
279	,	O
279	53	O
279	%	O
279	,	O
279	58	O
279	%	O
279	,	O
279	and	O
279	54	O
279	%	O
279	higher	O
279	,	O
279	respectively	O
279	(	O
279	table	O
279	3	O
279	)	O
279	.	O
279	[SEP]	O
280	[CLS]	O
280	is	O
280	##onia	O
280	##zi	O
280	##d	O
280	p	O
280	##har	O
280	##ma	O
280	##co	O
280	##kin	O
280	##etics	O
280	were	O
280	best	O
280	explained	O
280	by	O
280	a	O
280	2	O
280	-	O
280	compartment	O
280	model	O
280	,	O
280	whereas	O
280	r	O
280	##if	O
280	##amp	O
280	##in	O
280	and	O
280	p	O
280	##yra	O
280	##zin	O
280	##ami	O
280	##de	O
280	concentrations	O
280	were	O
280	best	O
280	explained	O
280	by	O
280	a	O
280	1	O
280	-	O
280	compartment	O
280	model	O
280	.	O
280	[SEP]	O
281	[CLS]	O
281	extraction	O
281	recover	O
281	##ies	O
281	ranged	O
281	from	O
281	64	O
281	%	O
281	to	O
281	115	O
281	%	O
281	,	O
281	l	O
281	##c	O
281	-	O
281	m	O
281	##s	O
281	/	O
281	m	O
281	##s	O
281	matrix	O
281	effects	O
281	were	O
281	≤	O
281	##21	O
281	%	O
281	,	O
281	and	O
281	overall	O
281	process	O
281	efficiency	O
281	ranged	O
281	from	O
281	57	O
281	%	O
281	to	O
281	93	O
281	%	O
281	at	O
281	low	O
281	and	O
281	high	O
281	quality	O
281	control	O
281	concentrations	O
281	.	O
281	[SEP]	O
282	[CLS]	O
282	of	O
282	the	O
282	cocaine	O
282	groups	O
282	,	O
282	18	O
282	of	O
282	23	O
282	e	O
282	##ac	O
282	##d	O
282	subjects	O
282	and	O
282	3	O
282	of	O
282	7	O
282	d	O
282	##ff	O
282	##c	O
282	##d	O
282	subjects	O
282	were	O
282	cigarette	O
282	smoke	O
282	##rs	O
282	.	O
282	[SEP]	O
283	[CLS]	O
283	the	O
283	rats	O
283	were	O
283	then	O
283	switched	O
283	to	O
283	the	O
283	iron	O
283	-	O
283	def	O
283	##icient	O
283	diet	O
283	(	O
283	ain	O
283	-	O
283	93	O
283	##g	O
283	pu	O
283	##rified	O
283	rode	O
283	##nt	O
283	diet	O
283	;	O
283	dye	O
283	##ts	O
283	in	O
283	##c	O
283	.	O
283	,	O
283	bet	O
283	##hl	O
283	##eh	O
283	##em	O
283	,	O
283	p	O
283	##a	O
283	,	O
283	u	O
283	.	O
283	s	O
283	.	O
283	a	O
283	.	O
283	)	O
283	which	O
283	was	O
283	administered	O
283	to	O
283	all	O
283	animals	O
283	from	O
283	day	O
283	0	O
283	to	O
283	day	O
283	24	O
283	of	O
283	the	O
283	study	O
283	(	O
283	for	O
283	the	O
283	complete	O
283	diet	O
283	composition	O
283	see	O
283	table	O
283	s	O
283	##1	O
283	)	O
283	.	O
283	[SEP]	O
284	[CLS]	O
284	is	O
284	##onia	O
284	##zi	O
284	##d	O
284	in	O
284	##hibit	O
284	##ed	O
284	the	O
284	clearance	B-PK
284	of	O
284	ch	O
284	##lor	O
284	##zo	O
284	##xa	O
284	##zone	O
284	by	O
284	58	O
284	%	O
284	,	O
284	as	O
284	assessed	O
284	from	O
284	plasma	O
284	data	O
284	,	O
284	and	O
284	in	O
284	##hibit	O
284	##ed	O
284	the	O
284	formation	O
284	of	O
284	ace	O
284	##tam	O
284	##ino	O
284	##phe	O
284	##n	O
284	th	O
284	##io	O
284	##eth	O
284	##er	O
284	meta	O
284	##bol	O
284	##ites	O
284	(	O
284	a	O
284	measure	O
284	of	O
284	the	O
284	formation	O
284	of	O
284	the	O
284	he	O
284	##pa	O
284	##to	O
284	##to	O
284	##xin	O
284	n	O
284	-	O
284	ace	O
284	##ty	O
284	##l	O
284	-	O
284	p	O
284	-	O
284	ben	O
284	##zo	O
284	##quin	O
284	##one	O
284	im	O
284	##ine	O
284	and	O
284	cat	O
284	##ech	O
284	##ol	O
284	o	O
284	##xi	O
284	##da	O
284	##tive	O
284	meta	O
284	##bol	O
284	##ites	O
284	of	O
284	ace	O
284	##tam	O
284	##ino	O
284	##phe	O
284	##n	O
284	,	O
284	as	O
284	determined	O
284	from	O
284	their	O
284	recovery	O
284	in	O
284	urine	O
284	,	O
284	by	O
284	63	O
284	%	O
284	and	O
284	49	O
284	%	O
284	,	O
284	respectively	O
284	.	O
284	[SEP]	O
285	[CLS]	O
285	both	O
285	d	O
285	##tic	O
285	and	O
285	a	O
285	##ic	O
285	have	O
285	re	O
285	##p	O
285	##rod	O
285	##uc	O
285	##ible	O
285	retention	O
285	times	O
285	on	O
285	the	O
285	amid	O
285	##e	O
285	-	O
285	80	O
285	hp	O
285	##l	O
285	##c	O
285	column	O
285	.	O
285	[SEP]	O
286	[CLS]	O
286	after	O
286	an	O
286	oral	O
286	administration	O
286	of	O
286	be	O
286	##rga	O
286	##pt	O
286	##en	O
286	at	O
286	a	O
286	dose	O
286	of	O
286	15	O
286	mg	O
286	kg	O
286	##−	O
286	##1	O
286	to	O
286	the	O
286	rats	O
286	,	O
286	be	O
286	##rga	O
286	##pt	O
286	##en	O
286	could	O
286	be	O
286	detected	O
286	in	O
286	rat	O
286	urine	O
286	until	O
286	72	O
286	h	O
286	.	O
286	be	O
286	##rga	O
286	##pt	O
286	##en	O
286	increased	O
286	rapidly	O
286	in	O
286	urine	O
286	during	O
286	a	O
286	time	O
286	period	O
286	of	O
286	4	O
286	–	O
286	8	O
286	h	O
286	.	O
286	after	O
286	8	O
286	h	O
286	however	O
286	,	O
286	there	O
286	was	O
286	a	O
286	gradual	O
286	increase	O
286	of	O
286	be	O
286	##rga	O
286	##pt	O
286	##en	O
286	in	O
286	urine	O
286	.	O
286	[SEP]	O
287	[CLS]	O
287	the	O
287	efficacy	O
287	of	O
287	most	O
287	anti	O
287	##can	O
287	##cer	O
287	drugs	O
287	is	O
287	highly	O
287	limited	O
287	in	O
287	v	O
287	##ivo	O
287	due	O
287	mainly	O
287	to	O
287	poor	O
287	p	O
287	##har	O
287	##ma	O
287	##co	O
287	##kin	O
287	##etics	O
287	behavior	O
287	including	O
287	poor	O
287	bio	B-PK
287	##ava	I-PK
287	##ila	I-PK
287	##bility	I-PK
287	after	O
287	extra	O
287	##vas	O
287	##cular	O
287	administration	O
287	.	O
287	[SEP]	O
288	[CLS]	O
288	the	O
288	p	O
288	##har	O
288	##ma	O
288	##co	O
288	##kin	O
288	##etics	O
288	of	O
288	el	O
288	##trom	O
288	##bo	O
288	##pa	O
288	##g	O
288	were	O
288	dose	O
288	dependent	O
288	and	O
288	linear	O
288	,	O
288	and	O
288	el	O
288	##trom	O
288	##bo	O
288	##pa	O
288	##g	O
288	increased	O
288	plate	O
288	##let	O
288	counts	O
288	in	O
288	a	O
288	dose	O
288	-	O
288	dependent	O
288	manner	O
288	.	O
288	[SEP]	O
289	[CLS]	O
289	these	O
289	valid	O
289	##ation	O
289	data	O
289	indicated	O
289	that	O
289	the	O
289	present	O
289	l	O
289	##c	O
289	-	O
289	m	O
289	##s	O
289	method	O
289	,	O
289	including	O
289	the	O
289	pre	O
289	##tre	O
289	##at	O
289	##ment	O
289	procedure	O
289	,	O
289	was	O
289	sufficient	O
289	for	O
289	the	O
289	determination	O
289	of	O
289	plasma	O
289	m	O
289	##p	O
289	##c	O
289	concentration	O
289	.	O
289	[SEP]	O
290	[CLS]	O
290	comparison	O
290	of	O
290	meta	O
290	##bol	O
290	##ite	O
290	recover	O
290	##ies	O
290	in	O
290	urine	O
290	indicated	O
290	a	O
290	positive	O
290	correlation	O
290	between	O
290	activation	O
290	and	O
290	in	O
290	##act	O
290	##ivation	O
290	routes	O
290	of	O
290	metabolism	O
290	.	O
290	[SEP]	O
291	[CLS]	O
291	alternate	O
291	anti	O
291	##biotics	O
291	may	O
291	be	O
291	equally	O
291	effective	O
291	and	O
291	allow	O
291	similar	O
291	dos	O
291	##ing	O
291	in	O
291	the	O
291	chronic	O
291	hem	O
291	##od	O
291	##ial	O
291	##ys	O
291	##is	O
291	population	O
291	.	O
291	[SEP]	O
292	[CLS]	O
292	these	O
292	results	O
292	indicate	O
292	that	O
292	differences	O
292	in	O
292	these	O
292	p	O
292	##har	O
292	##ma	O
292	##co	O
292	##kin	O
292	##etic	O
292	parameters	O
292	do	O
292	not	O
292	account	O
292	for	O
292	the	O
292	well	O
292	-	O
292	established	O
292	clinical	O
292	observation	O
292	that	O
292	some	O
292	patients	O
292	require	O
292	daily	O
292	pre	O
292	##dn	O
292	##ison	O
292	##e	O
292	doses	O
292	and	O
292	that	O
292	their	O
292	disease	O
292	cannot	O
292	be	O
292	managed	O
292	with	O
292	alternate	O
292	-	O
292	day	O
292	s	O
292	##tero	O
292	##id	O
292	therapy	O
292	.	O
292	[SEP]	O
293	[CLS]	O
293	shifts	O
293	of	O
293	d	O
293	##lm	O
293	##o	O
293	,	O
293	so	O
293	,	O
293	and	O
293	so	O
293	##l	O
293	in	O
293	the	O
293	three	O
293	groups	O
293	with	O
293	me	O
293	##lat	O
293	##oni	O
293	##n	O
293	were	O
293	plot	O
293	##ted	O
293	as	O
293	function	O
293	of	O
293	clock	O
293	to	O
293	##a	O
293	(	O
293	fi	O
293	##g	O
293	.	O
293	3	O
293	##a	O
293	)	O
293	and	O
293	as	O
293	function	O
293	of	O
293	circa	O
293	##dian	O
293	to	O
293	##a	O
293	(	O
293	fi	O
293	##g	O
293	.	O
293	3	O
293	##b	O
293	)	O
293	.	O
293	[SEP]	O
294	[CLS]	O
294	the	O
294	cumulative	O
294	percentage	O
294	of	O
294	pro	O
294	##ges	O
294	##tero	O
294	##ne	O
294	released	O
294	from	O
294	the	O
294	na	O
294	##no	O
294	##par	O
294	##tic	O
294	##les	O
294	formed	O
294	by	O
294	the	O
294	addition	O
294	of	O
294	20	O
294	%	O
294	,	O
294	10	O
294	%	O
294	,	O
294	and	O
294	5	O
294	%	O
294	of	O
294	s	O
294	##te	O
294	##ari	O
294	##c	O
294	acid	O
294	at	O
294	the	O
294	end	O
294	of	O
294	10	O
294	h	O
294	was	O
294	88	O
294	±	O
294	5	O
294	.	O
294	4	O
294	,	O
294	76	O
294	±	O
294	8	O
294	.	O
294	2	O
294	,	O
294	and	O
294	60	O
294	%	O
294	±	O
294	5	O
294	.	O
294	3	O
294	%	O
294	,	O
294	respectively	O
294	.	O
294	[SEP]	O
295	[CLS]	O
295	the	O
295	antibodies	O
295	(	O
295	14	O
295	##c	O
295	##10	O
295	h	O
295	##g	O
295	##1	O
295	and	O
295	d	O
295	##29	O
295	h	O
295	##g	O
295	##1	O
295	)	O
295	were	O
295	used	O
295	at	O
295	a	O
295	fixed	O
295	concentration	O
295	of	O
295	6	O
295	##μ	O
295	##g	O
295	/	O
295	m	O
295	##l	O
295	and	O
295	pre	O
295	-	O
295	in	O
295	##cu	O
295	##bate	O
295	##d	O
295	with	O
295	e	O
295	##1	O
295	f	O
295	##ab	O
295	or	O
295	anti	O
295	-	O
295	den	O
295	##v	O
295	-	O
295	2	O
295	f	O
295	##ab	O
295	for	O
295	one	O
295	hour	O
295	at	O
295	room	O
295	temperature	O
295	,	O
295	at	O
295	a	O
295	starting	O
295	concentration	O
295	of	O
295	50	O
295	##μ	O
295	##g	O
295	/	O
295	m	O
295	##l	O
295	and	O
295	serial	O
295	##ly	O
295	di	O
295	##lut	O
295	##ed	O
295	by	O
295	half	O
295	a	O
295	log	O
295	in	O
295	blocking	O
295	buffer	O
295	(	O
295	4	O
295	%	O
295	m	O
295	##p	O
295	##bs	O
295	)	O
295	,	O
295	at	O
295	room	O
295	temperature	O
295	,	O
295	before	O
295	the	O
295	addition	O
295	to	O
295	den	O
295	##v	O
295	-	O
295	1	O
295	.	O
295	[SEP]	O
296	[CLS]	O
296	considering	O
296	there	O
296	are	O
296	many	O
296	components	O
296	of	O
296	originated	O
296	from	O
296	r	O
296	##hi	O
296	##zo	O
296	##ma	O
296	z	O
296	##ing	O
296	##iber	O
296	##is	O
296	re	O
296	##cens	O
296	,	O
296	the	O
296	probable	O
296	reason	O
296	was	O
296	that	O
296	the	O
296	main	O
296	components	O
296	of	O
296	r	O
296	##hi	O
296	##zo	O
296	##ma	O
296	z	O
296	##ing	O
296	##iber	O
296	##is	O
296	re	O
296	##cens	O
296	were	O
296	hard	O
296	to	O
296	meta	O
296	##bol	O
296	##ize	O
296	.	O
296	[SEP]	O
297	[CLS]	O
297	these	O
297	results	O
297	describe	O
297	an	O
297	effective	O
297	strategy	O
297	for	O
297	oral	O
297	delivery	O
297	of	O
297	da	O
297	##id	O
297	##ze	O
297	##in	O
297	-	O
297	loaded	O
297	p	O
297	##l	O
297	##ga	O
297	na	O
297	##no	O
297	##par	O
297	##tic	O
297	##les	O
297	and	O
297	might	O
297	provide	O
297	a	O
297	fresh	O
297	approach	O
297	to	O
297	enhancing	O
297	the	O
297	bio	B-PK
297	##ava	I-PK
297	##ila	I-PK
297	##bility	I-PK
297	of	O
297	drugs	O
297	with	O
297	poor	O
297	lip	O
297	##op	O
297	##hil	O
297	##ic	O
297	and	O
297	poor	O
297	h	O
297	##ydro	O
297	##phi	O
297	##lic	O
297	properties	O
297	.	O
297	[SEP]	O
298	[CLS]	O
298	further	O
298	##more	O
298	,	O
298	no	O
298	information	O
298	is	O
298	available	O
298	defining	O
298	the	O
298	relationship	O
298	between	O
298	drug	O
298	exposure	O
298	and	O
298	clinical	O
298	response	O
298	.	O
298	[SEP]	O
299	[CLS]	O
299	these	O
299	results	O
299	suggest	O
299	that	O
299	no	O
299	s	O
299	##ynth	O
299	##ase	O
299	in	O
299	##hibition	O
299	by	O
299	l	O
299	-	O
299	name	O
299	enhance	O
299	##s	O
299	the	O
299	cardiac	O
299	toxicity	O
299	of	O
299	b	O
299	##up	O
299	##iva	O
299	##ca	O
299	##ine	O
299	,	O
299	probably	O
299	by	O
299	a	O
299	p	O
299	##har	O
299	##ma	O
299	##co	O
299	##kin	O
299	##etic	O
299	action	O
299	,	O
299	and	O
299	reduces	O
299	its	O
299	central	O
299	nervous	O
299	system	O
299	toxicity	O
299	,	O
299	probably	O
299	by	O
299	a	O
299	p	O
299	##har	O
299	##ma	O
299	##co	O
299	##dynamic	O
299	action	O
299	.	O
299	[SEP]	O
300	[CLS]	O
300	to	O
300	determine	O
300	the	O
300	milk	B-PK
300	-	I-PK
300	to	I-PK
300	-	I-PK
300	plasma	I-PK
300	(	I-PK
300	m	I-PK
300	/	I-PK
300	p	I-PK
300	)	I-PK
300	concentration	I-PK
300	ratio	I-PK
300	of	O
300	c	O
300	##ele	O
300	##co	O
300	##xi	O
300	##b	O
300	,	O
300	and	O
300	estimate	O
300	likely	O
300	infant	O
300	exposure	O
300	.	O
300	[SEP]	O
301	[CLS]	O
301	the	O
301	plasma	O
301	concentrations	O
301	were	O
301	expressed	O
301	as	O
301	arithmetic	O
301	mean	O
301	±	O
301	standard	O
301	de	O
301	##viation	O
301	(	O
301	s	O
301	##d	O
301	)	O
301	.	O
301	[SEP]	O
302	[CLS]	O
302	in	O
302	the	O
302	group	O
302	,	O
302	peak	B-PK
302	serum	I-PK
302	concentration	I-PK
302	of	O
302	mm	O
302	##c	O
302	was	O
302	0	O
302	.	O
302	29	O
302	micro	O
302	##gram	O
302	##s	O
302	/	O
302	m	O
302	##l	O
302	.	O
302	[SEP]	O
303	[CLS]	O
303	the	O
303	long	O
303	-	O
303	chain	O
303	h	O
303	##ydro	O
303	##phobic	O
303	m	O
303	##oi	O
303	##ety	O
303	of	O
303	surf	O
303	##act	O
303	##ants	O
303	showed	O
303	a	O
303	greater	O
303	stab	O
303	##ilization	O
303	effect	O
303	than	O
303	polo	O
303	##xa	O
303	##mers	O
303	and	O
303	gel	O
303	##uc	O
303	##ires	O
303	.	O
303	[SEP]	O
304	[CLS]	O
304	the	O
304	objective	O
304	of	O
304	the	O
304	study	O
304	was	O
304	to	O
304	prepare	O
304	and	O
304	evaluate	O
304	a	O
304	18	O
304	##f	O
304	-	O
304	radio	O
304	##la	O
304	##bled	O
304	trace	O
304	##r	O
304	(	O
304	al	O
304	##18	O
304	##f	O
304	-	O
304	5	O
304	)	O
304	,	O
304	der	O
304	##ivated	O
304	from	O
304	the	O
304	anti	O
304	##tum	O
304	##or	O
304	agent	O
304	2	O
304	-	O
304	(	O
304	4	O
304	-	O
304	amino	O
304	##phe	O
304	##ny	O
304	##l	O
304	)	O
304	ben	O
304	##zo	O
304	##thi	O
304	##az	O
304	##ole	O
304	,	O
304	as	O
304	a	O
304	pet	O
304	probe	O
304	for	O
304	tumor	O
304	imaging	O
304	.	O
304	[SEP]	O
305	[CLS]	O
305	the	O
305	influence	O
305	of	O
305	different	O
305	dos	O
305	##ing	O
305	intervals	O
305	on	O
305	the	O
305	p	O
305	##har	O
305	##ma	O
305	##co	O
305	##kin	O
305	##etics	O
305	,	O
305	changes	O
305	in	O
305	bone	O
305	turnover	O
305	markers	O
305	,	O
305	and	O
305	safety	O
305	profiles	O
305	of	O
305	twice	O
305	‐	O
305	weekly	O
305	28	O
305	.	O
305	2	O
305	‐	O
305	μ	O
305	##g	O
305	te	O
305	##rip	O
305	##ara	O
305	##tide	O
305	injection	O
305	##s	O
305	over	O
305	6	O
305	weeks	O
305	.	O
305	[SEP]	O
306	[CLS]	O
306	the	O
306	apparent	B-PK
306	clearance	I-PK
306	was	O
306	1	O
306	.	O
306	46	O
306	+	O
306	-	O
306	0	O
306	.	O
306	45	O
306	l	O
306	/	O
306	h	O
306	##r	O
306	with	O
306	an	O
306	apparent	B-PK
306	volume	I-PK
306	of	I-PK
306	distribution	I-PK
306	in	I-PK
306	the	I-PK
306	terminal	I-PK
306	phase	I-PK
306	of	O
306	40	O
306	##7	O
306	+	O
306	-	O
306	111	O
306	l	O
306	(	O
306	data	O
306	for	O
306	both	O
306	s	O
306	##ten	O
306	##t	O
306	doses	O
306	pool	O
306	##ed	O
306	)	O
306	.	O
306	[SEP]	O
307	[CLS]	O
307	in	O
307	order	O
307	to	O
307	c	O
307	##lar	O
307	##ify	O
307	whether	O
307	re	O
307	##pi	O
307	##rina	O
307	##st	O
307	,	O
307	an	O
307	inhibitor	O
307	of	O
307	chemical	O
307	media	O
307	##tor	O
307	release	O
307	,	O
307	could	O
307	influence	O
307	the	O
307	p	O
307	##har	O
307	##ma	O
307	##co	O
307	##kin	O
307	##etics	O
307	of	O
307	the	O
307	##op	O
307	##hyl	O
307	##line	O
307	,	O
307	a	O
307	loading	O
307	test	O
307	using	O
307	in	O
307	##tra	O
307	##ven	O
307	##ous	O
307	injection	O
307	of	O
307	amino	O
307	##phy	O
307	##llin	O
307	##e	O
307	was	O
307	performed	O
307	in	O
307	10	O
307	subjects	O
307	with	O
307	br	O
307	##on	O
307	##chia	O
307	##l	O
307	as	O
307	##th	O
307	##ma	O
307	before	O
307	and	O
307	after	O
307	treatment	O
307	with	O
307	300	O
307	mg	O
307	/	O
307	day	O
307	of	O
307	re	O
307	##pi	O
307	##rina	O
307	##st	O
307	.	O
307	[SEP]	O
308	[CLS]	O
308	su	O
308	##l	O
308	##pha	O
308	##met	O
308	##ho	O
308	##xa	O
308	##zo	O
308	##le	O
308	,	O
308	su	O
308	##l	O
308	##pha	O
308	##di	O
308	##met	O
308	##hyl	O
308	##ox	O
308	##az	O
308	##ole	O
308	and	O
308	su	O
308	##l	O
308	##pha	O
308	##di	O
308	##met	O
308	##ho	O
308	##xin	O
308	##e	O
308	were	O
308	once	O
308	administered	O
308	in	O
308	goats	O
308	via	O
308	oral	O
308	and	O
308	i	O
308	.	O
308	v	O
308	.	O
308	route	O
308	(	O
308	100	O
308	mg	O
308	/	O
308	kg	O
308	b	O
308	.	O
308	w	O
308	##t	O
308	.	O
308	)	O
308	for	O
308	determination	O
308	of	O
308	plasma	O
308	and	O
308	urine	O
308	concentrations	O
308	of	O
308	the	O
308	unchanged	O
308	su	O
308	##l	O
308	##phon	O
308	##ami	O
308	##des	O
308	and	O
308	their	O
308	ace	O
308	##ty	O
308	##lated	O
308	derivatives	O
308	,	O
308	kinetic	O
308	behavior	O
308	,	O
308	systemic	B-PK
308	bio	I-PK
308	##ava	I-PK
308	##ila	I-PK
308	##bility	I-PK
308	,	O
308	tissue	O
308	levels	O
308	and	O
308	ace	O
308	##ty	O
308	##lation	O
308	.	O
308	[SEP]	O
309	[CLS]	O
309	other	O
309	exclusion	O
309	criteria	O
309	included	O
309	known	O
309	brain	O
309	or	O
309	le	O
309	##pt	O
309	##ome	O
309	##ning	O
309	##eal	O
309	meta	O
309	##sta	O
309	##ses	O
309	,	O
309	no	O
309	prior	O
309	e	O
309	##g	O
309	##f	O
309	##r	O
309	inhibitor	O
309	therapy	O
309	,	O
309	no	O
309	known	O
309	ne	O
309	##uro	O
309	##mus	O
309	##cular	O
309	disorders	O
309	as	O
309	well	O
309	as	O
309	known	O
309	h	O
309	##yper	O
309	##sen	O
309	##si	O
309	##ti	O
309	##vity	O
309	or	O
309	all	O
309	##er	O
309	##gy	O
309	to	O
309	h	O
309	##m	O
309	##g	O
309	-	O
309	co	O
309	##a	O
309	red	O
309	##uc	O
309	##tase	O
309	inhibitor	O
309	##s	O
309	including	O
309	r	O
309	##os	O
309	##u	O
309	##vas	O
309	##tat	O
309	##in	O
309	in	O
309	as	O
309	##ian	O
309	populations	O
309	which	O
309	were	O
309	also	O
309	excluded	O
309	[	O
309	33	O
309	]	O
309	,	O
309	(	O
309	us	O
309	f	O
309	##da	O
309	public	O
309	health	O
309	advisory	O
309	,	O
309	2	O
309	march	O
309	2005	O
309	,	O
309	www	O
309	.	O
309	f	O
309	##da	O
309	.	O
309	go	O
309	##v	O
309	)	O
309	.	O
309	[SEP]	O
310	[CLS]	O
310	bench	O
310	top	O
310	stability	O
310	was	O
310	assessed	O
310	by	O
310	using	O
310	six	O
310	replica	O
310	##tes	O
310	of	O
310	l	O
310	##q	O
310	##c	O
310	and	O
310	h	O
310	##q	O
310	##c	O
310	stored	O
310	at	O
310	room	O
310	temperature	O
310	for	O
310	18	O
310	h	O
310	.	O
310	[SEP]	O
311	[CLS]	O
311	the	O
311	effect	O
311	of	O
311	inter	O
311	##ind	O
311	##iv	O
311	##id	O
311	##ual	O
311	var	O
311	##iability	O
311	on	O
311	study	O
311	power	O
311	was	O
311	assessed	O
311	by	O
311	first	O
311	setting	O
311	the	O
311	coefficient	O
311	of	O
311	variation	O
311	(	O
311	c	O
311	##v	O
311	)	O
311	of	O
311	o	O
311	##at	O
311	##p	O
311	##1	O
311	##b	O
311	##1	O
311	and	O
311	o	O
311	##at	O
311	##p	O
311	##1	O
311	##b	O
311	##3	O
311	abundance	O
311	to	O
311	0	O
311	and	O
311	carrying	O
311	out	O
311	the	O
311	same	O
311	power	O
311	analysis	O
311	as	O
311	above	O
311	.	O
311	[SEP]	O
312	[CLS]	O
312	these	O
312	results	O
312	indicate	O
312	that	O
312	protein	O
312	binding	O
312	can	O
312	be	O
312	successfully	O
312	included	O
312	in	O
312	a	O
312	p	O
312	##har	O
312	##ma	O
312	##co	O
312	##kin	O
312	##etic	O
312	model	O
312	.	O
312	[SEP]	O
313	[CLS]	O
313	the	O
313	se	O
313	##ma	O
313	##g	O
313	##lut	O
313	##ide	O
313	plasma	O
313	concentrations	O
313	were	O
313	measured	O
313	following	O
313	protein	O
313	precipitation	O
313	using	O
313	a	O
313	valid	O
313	##ated	O
313	liquid	O
313	ch	O
313	##roma	O
313	##tography	O
313	ass	O
313	##ay	O
313	followed	O
313	by	O
313	a	O
313	tandem	O
313	mass	O
313	s	O
313	##pect	O
313	##rome	O
313	##try	O
313	ass	O
313	##ay	O
313	(	O
313	c	O
313	##ele	O
313	##rion	O
313	in	O
313	##c	O
313	.	O
313	f	O
313	##eh	O
313	##ral	O
313	##tor	O
313	##f	O
313	,	O
313	s	O
313	##witz	O
313	##erland	O
313	)	O
313	;	O
313	see	O
313	[	O
313	24	O
313	]	O
313	for	O
313	more	O
313	details	O
313	.	O
313	[SEP]	O
314	[CLS]	O
314	using	O
314	commercial	O
314	g	O
314	##erman	O
314	capsule	O
314	##s	O
314	as	O
314	the	O
314	reference	O
314	(	O
314	r	O
314	)	O
314	,	O
314	two	O
314	coating	O
314	formulation	O
314	##s	O
314	were	O
314	selected	O
314	for	O
314	tests	O
314	after	O
314	optimization	O
314	:	O
314	p	O
314	##h	O
314	-	O
314	dependent	O
314	p	O
314	##elle	O
314	##ts	O
314	with	O
314	a	O
314	ratio	O
314	of	O
314	e	O
314	##ud	O
314	##rag	O
314	##it	O
314	(	O
314	®	O
314	)	O
314	ne	O
314	##30	O
314	##d	O
314	/	O
314	l	O
314	##30	O
314	##d	O
314	##55	O
314	of	O
314	10	O
314	:	O
314	1	O
314	,	O
314	a	O
314	3	O
314	%	O
314	coating	O
314	level	O
314	(	O
314	t	O
314	(	O
314	1	O
314	)	O
314	)	O
314	,	O
314	and	O
314	p	O
314	##h	O
314	-	O
314	independent	O
314	p	O
314	##elle	O
314	##ts	O
314	with	O
314	a	O
314	e	O
314	##ud	O
314	##rag	O
314	##it	O
314	(	O
314	®	O
314	)	O
314	ne	O
314	##30	O
314	##d	O
314	coating	O
314	level	O
314	(	O
314	t	O
314	(	O
314	2	O
314	)	O
314	)	O
314	of	O
314	3	O
314	.	O
314	5	O
314	%	O
314	.	O
314	[SEP]	O
315	[CLS]	O
315	the	O
315	ll	O
315	##o	O
315	##q	O
315	was	O
315	expressed	O
315	for	O
315	the	O
315	anal	O
315	##yte	O
315	concentration	O
315	having	O
315	response	O
315	at	O
315	least	O
315	5	O
315	times	O
315	more	O
315	compared	O
315	to	O
315	blank	O
315	response	O
315	.	O
315	[SEP]	O
316	[CLS]	O
316	subsequently	O
316	,	O
316	t	O
316	##f	O
316	##v	O
316	undergo	O
316	##es	O
316	two	O
316	p	O
316	##hos	O
316	##ph	O
316	##ory	O
316	##lation	O
316	steps	O
316	forming	O
316	ten	O
316	##of	O
316	##ov	O
316	##ir	O
316	dip	O
316	##hos	O
316	##phate	O
316	(	O
316	t	O
316	##f	O
316	##v	O
316	-	O
316	d	O
316	##p	O
316	)	O
316	,	O
316	which	O
316	is	O
316	an	O
316	analog	O
316	of	O
316	end	O
316	##ogen	O
316	##ous	O
316	de	O
316	##ox	O
316	##ya	O
316	##den	O
316	##os	O
316	##ine	O
316	trip	O
316	##hos	O
316	##phate	O
316	.	O
316	[SEP]	O
317	[CLS]	O
317	no	O
317	single	O
317	sat	O
317	##urable	O
317	elimination	O
317	pathway	O
317	was	O
317	identified	O
317	.	O
317	[SEP]	O
318	[CLS]	O
318	at	O
318	the	O
318	1400	O
318	mg	O
318	bid	O
318	dose	O
318	level	O
318	,	O
318	in	O
318	an	O
318	expanded	O
318	co	O
318	##hor	O
318	##t	O
318	during	O
318	dose	O
318	de	O
318	-	O
318	es	O
318	##cal	O
318	##ation	O
318	one	O
318	patient	O
318	experienced	O
318	a	O
318	grade	O
318	4	O
318	h	O
318	##y	O
318	##pot	O
318	##ens	O
318	##ion	O
318	and	O
318	a	O
318	rising	O
318	grade	O
318	2	O
318	c	O
318	##rea	O
318	##tin	O
318	##ine	O
318	that	O
318	were	O
318	dose	O
318	limiting	O
318	,	O
318	and	O
318	a	O
318	second	O
318	patient	O
318	had	O
318	a	O
318	rising	O
318	grade	O
318	2	O
318	c	O
318	##rea	O
318	##tin	O
318	##ine	O
318	in	O
318	cycle	O
318	1	O
318	,	O
318	where	O
318	treatment	O
318	was	O
318	terminated	O
318	before	O
318	it	O
318	reached	O
318	a	O
318	grade	O
318	3	O
318	and	O
318	was	O
318	therefore	O
318	considered	O
318	dose	O
318	limiting	O
318	.	O
318	[SEP]	O
319	[CLS]	O
319	based	O
319	on	O
319	coefficient	O
319	of	O
319	drug	O
319	interaction	O
319	(	O
319	c	O
319	##di	O
319	)	O
319	values	O
319	,	O
319	the	O
319	combination	O
319	of	O
319	try	O
319	##ps	O
319	##ino	O
319	##gen	O
319	plus	O
319	ch	O
319	##ym	O
319	##ot	O
319	##ry	O
319	##ps	O
319	##ino	O
319	##gen	O
319	a	O
319	demonstrated	O
319	greater	O
319	growth	O
319	in	O
319	##hibition	O
319	at	O
319	ratios	O
319	of	O
319	1	O
319	:	O
319	4	O
319	,	O
319	1	O
319	:	O
319	6	O
319	and	O
319	1	O
319	:	O
319	8	O
319	compared	O
319	to	O
319	the	O
319	1	O
319	:	O
319	1	O
319	ratio	O
319	in	O
319	all	O
319	cell	O
319	lines	O
319	tested	O
319	except	O
319	for	O
319	78	O
319	##6	O
319	-	O
319	o	O
319	,	O
319	g	O
319	-	O
319	36	O
319	##1	O
319	,	O
319	b	O
319	##t	O
319	-	O
319	47	O
319	##4	O
319	and	O
319	h	O
319	##l	O
319	-	O
319	60	O
319	t	O
319	##umour	O
319	cells	O
319	(	O
319	fi	O
319	##g	O
319	.	O
319	1	O
319	;	O
319	supplement	O
319	##ary	O
319	table	O
319	s	O
319	##4	O
319	)	O
319	.	O
319	[SEP]	O
320	[CLS]	O
320	in	O
320	study	O
320	1	O
320	,	O
320	44	O
320	subjects	O
320	were	O
320	random	O
320	##ized	O
320	and	O
320	included	O
320	in	O
320	the	O
320	“	O
320	all	O
320	subjects	O
320	”	O
320	population	O
320	:	O
320	93	O
320	%	O
320	(	O
320	n	O
320	=	O
320	41	O
320	)	O
320	completed	O
320	the	O
320	study	O
320	and	O
320	received	O
320	all	O
320	planned	O
320	treatments	O
320	;	O
320	three	O
320	subjects	O
320	discontinued	O
320	study	O
320	medication	O
320	due	O
320	to	O
320	an	O
320	sa	O
320	##e	O
320	(	O
320	n	O
320	=	O
320	1	O
320	)	O
320	or	O
320	investigator	O
320	discretion	O
320	(	O
320	n	O
320	=	O
320	2	O
320	)	O
320	.	O
320	[SEP]	O
321	[CLS]	O
321	the	O
321	fully	O
321	human	O
321	anti	O
321	-	O
321	lip	O
321	##op	O
321	##oly	O
321	##sa	O
321	##cc	O
321	##hari	O
321	##de	O
321	(	O
321	l	O
321	##ps	O
321	)	O
321	im	O
321	##mu	O
321	##no	O
321	##g	O
321	##lo	O
321	##bul	O
321	##in	O
321	m	O
321	(	O
321	i	O
321	##g	O
321	##m	O
321	)	O
321	mon	O
321	##oc	O
321	##lon	O
321	##al	O
321	anti	O
321	##body	O
321	pan	O
321	##ob	O
321	##ac	O
321	##uma	O
321	##b	O
321	was	O
321	developed	O
321	as	O
321	an	O
321	ad	O
321	##junct	O
321	##ive	O
321	im	O
321	##mu	O
321	##not	O
321	##her	O
321	##ap	O
321	##y	O
321	for	O
321	the	O
321	treatment	O
321	of	O
321	o	O
321	##11	O
321	se	O
321	##rot	O
321	##ype	O
321	pseudo	O
321	##mona	O
321	##s	O
321	a	O
321	##er	O
321	##ug	O
321	##ino	O
321	##sa	O
321	infections	O
321	.	O
321	[SEP]	O
322	[CLS]	O
322	h	O
322	##ts	O
322	advancement	O
322	##sha	O
322	##ve	O
322	accelerated	O
322	the	O
322	preparation	O
322	of	O
322	drug	O
322	##like	O
322	molecules	O
322	.	O
322	24	O
322	,	O
322	25	O
322	comparatively	O
322	,	O
322	examples	O
322	of	O
322	creating	O
322	larger	O
322	,	O
322	well	O
322	-	O
322	defined	O
322	systems	O
322	##using	O
322	high	O
322	-	O
322	through	O
322	##put	O
322	machinery	O
322	are	O
322	emerging	O
322	,	O
322	such	O
322	as	O
322	un	O
322	##imo	O
322	##le	O
322	##cular	O
322	##ma	O
322	##c	O
322	##rom	O
322	##ole	O
322	##cule	O
322	##s	O
322	##26	O
322	and	O
322	re	O
322	##versible	O
322	addition	O
322	–	O
322	fragment	O
322	##ation	O
322	##cha	O
322	##in	O
322	transfer	O
322	(	O
322	r	O
322	##aft	O
322	)	O
322	polymer	O
322	##s	O
322	.	O
322	27	O
322	we	O
322	conducted	O
322	##raft	O
322	chemistry	O
322	on	O
322	a	O
322	lab	O
322	scale	O
322	first	O
322	(	O
322	figure	O
322	s	O
322	-	O
322	1	O
322	)	O
322	.	O
322	[SEP]	O
323	[CLS]	O
323	p	O
323	##har	O
323	##ma	O
323	##co	O
323	##kin	O
323	##etic	O
323	studies	O
323	of	O
323	bi	O
323	##lia	O
323	##ry	O
323	ex	O
323	##cre	O
323	##tion	O
323	.	O
323	[SEP]	O
324	[CLS]	O
324	the	O
324	following	O
324	settings	O
324	were	O
324	used	O
324	:	O
324	ion	O
324	spray	O
324	voltage	O
324	350	O
324	##0	O
324	v	O
324	,	O
324	collision	O
324	energy	O
324	10	O
324	e	O
324	##v	O
324	,	O
324	vapor	O
324	##izer	O
324	temperature	O
324	300	O
324	°	O
324	##c	O
324	,	O
324	tube	O
324	lens	O
324	voltage	O
324	at	O
324	60	O
324	v	O
324	,	O
324	sheath	O
324	and	O
324	auxiliary	O
324	gas	O
324	pressure	O
324	40	O
324	and	O
324	35	O
324	ps	O
324	##i	O
324	,	O
324	respectively	O
324	.	O
324	[SEP]	O
325	[CLS]	O
325	during	O
325	in	O
325	##fusion	O
325	of	O
325	s	O
325	##t	O
325	##gs	O
325	the	O
325	medium	O
325	-	O
325	chain	O
325	fatty	O
325	acids	O
325	o	O
325	##ct	O
325	##ano	O
325	##ic	O
325	(	O
325	c	O
325	:	O
325	8	O
325	)	O
325	and	O
325	de	O
325	##cano	O
325	##ic	O
325	acid	O
325	(	O
325	c	O
325	:	O
325	10	O
325	)	O
325	constituted	O
325	approximately	O
325	half	O
325	of	O
325	circulating	O
325	fatty	O
325	acids	O
325	that	O
325	correspond	O
325	to	O
325	the	O
325	composition	O
325	##al	O
325	ratio	O
325	of	O
325	the	O
325	em	O
325	##ul	O
325	##sion	O
325	.	O
325	[SEP]	O
326	[CLS]	O
326	figure	O
326	2	O
326	shows	O
326	the	O
326	percentage	O
326	of	O
326	mit	O
326	##omy	O
326	##cin	O
326	c	O
326	absorbed	O
326	from	O
326	the	O
326	per	O
326	##ito	O
326	##nea	O
326	##l	O
326	space	O
326	as	O
326	compared	O
326	to	O
326	the	O
326	p	O
326	##le	O
326	##ural	O
326	space	O
326	.	O
326	[SEP]	O
327	[CLS]	O
327	the	O
327	median	O
327	v	O
327	##agi	O
327	##nal	O
327	p	O
327	##h	O
327	prior	O
327	to	O
327	i	O
327	##v	O
327	##r	O
327	placement	O
327	(	O
327	visits	O
327	0	O
327	and	O
327	1	O
327	)	O
327	was	O
327	4	O
327	.	O
327	0	O
327	(	O
327	i	O
327	##q	O
327	##r	O
327	,	O
327	4	O
327	.	O
327	0	O
327	–	O
327	4	O
327	.	O
327	5	O
327	)	O
327	,	O
327	and	O
327	with	O
327	the	O
327	t	O
327	##d	O
327	##f	O
327	and	O
327	t	O
327	##d	O
327	##f	O
327	-	O
327	ft	O
327	##c	O
327	pod	O
327	-	O
327	i	O
327	##v	O
327	##rs	O
327	in	O
327	place	O
327	was	O
327	4	O
327	.	O
327	5	O
327	(	O
327	i	O
327	##q	O
327	##r	O
327	,	O
327	4	O
327	.	O
327	1	O
327	–	O
327	4	O
327	.	O
327	5	O
327	)	O
327	and	O
327	4	O
327	.	O
327	0	O
327	(	O
327	i	O
327	##q	O
327	##r	O
327	,	O
327	4	O
327	.	O
327	0	O
327	–	O
327	4	O
327	.	O
327	5	O
327	)	O
327	,	O
327	respectively	O
327	.	O
327	[SEP]	O
328	[CLS]	O
328	the	O
328	au	B-PK
328	##c	I-PK
328	##0	I-PK
328	–	I-PK
328	24	I-PK
328	/	I-PK
328	mi	I-PK
328	##c	I-PK
328	ratio	I-PK
328	was	O
328	calculated	O
328	by	O
328	dividing	O
328	the	O
328	au	B-PK
328	##c	I-PK
328	##0	I-PK
328	–	I-PK
328	24	I-PK
328	by	O
328	mi	O
328	##cs	O
328	0	O
328	.	O
328	5	O
328	,	O
328	1	O
328	and	O
328	2	O
328	mg	O
328	/	O
328	l	O
328	.	O
328	[SEP]	O
329	[CLS]	O
329	in	O
329	v	O
329	##it	O
329	##ro	O
329	release	O
329	studies	O
329	at	O
329	p	O
329	##h	O
329	6	O
329	.	O
329	8	O
329	phosphate	O
329	buffer	O
329	(	O
329	p	O
329	##bs	O
329	)	O
329	and	O
329	at	O
329	p	O
329	##h	O
329	1	O
329	.	O
329	2	O
329	h	O
329	##c	O
329	##l	O
329	0	O
329	.	O
329	1	O
329	##n	O
329	showed	O
329	a	O
329	slow	O
329	release	O
329	in	O
329	both	O
329	media	O
329	.	O
329	[SEP]	O
330	[CLS]	O
330	steady	O
330	-	O
330	state	O
330	plasma	O
330	v	O
330	##pa	O
330	concentration	O
330	-	O
330	time	O
330	profiles	O
330	from	O
330	5	O
330	published	O
330	di	O
330	##val	O
330	##p	O
330	##ro	O
330	##ex	O
330	-	O
330	er	O
330	studies	O
330	(	O
330	healthy	O
330	subjects	O
330	and	O
330	e	O
330	##pile	O
330	##psy	O
330	patients	O
330	)	O
330	were	O
330	analyzed	O
330	.	O
330	[SEP]	O
331	[CLS]	O
331	the	O
331	label	O
331	##ing	O
331	yield	O
331	,	O
331	in	O
331	v	O
331	##it	O
331	##ro	O
331	stability	O
331	and	O
331	in	O
331	v	O
331	##ivo	O
331	bio	O
331	##dis	O
331	##tribution	O
331	profile	O
331	of	O
331	(	O
331	90	O
331	)	O
331	y	O
331	-	O
331	m	O
331	##n	O
331	##ps	O
331	were	O
331	compared	O
331	.	O
331	[SEP]	O
332	[CLS]	O
332	the	O
332	flow	O
332	rate	O
332	was	O
332	set	O
332	at	O
332	500	O
332	µ	O
332	##l	O
332	/	O
332	min	O
332	and	O
332	the	O
332	temperature	O
332	of	O
332	the	O
332	column	O
332	was	O
332	maintained	O
332	at	O
332	40	O
332	°	O
332	##c	O
332	.	O
332	[SEP]	O
333	[CLS]	O
333	p	O
333	##osa	O
333	##cona	O
333	##zo	O
333	##le	O
333	is	O
333	a	O
333	lip	O
333	##op	O
333	##hil	O
333	##ic	O
333	t	O
333	##ria	O
333	##zo	O
333	##le	O
333	anti	O
333	##fu	O
333	##nga	O
333	##l	O
333	that	O
333	exhibits	O
333	variable	O
333	absorption	O
333	when	O
333	administered	O
333	oral	O
333	##ly	O
333	.	O
333	[SEP]	O
334	[CLS]	O
334	the	O
334	c	O
334	##y	O
334	##c	O
334	##lin	O
334	-	O
334	dependent	O
334	kinase	O
334	inhibitor	O
334	u	O
334	##c	O
334	##n	O
334	-	O
334	01	O
334	plus	O
334	c	O
334	##is	O
334	##p	O
334	##lat	O
334	##in	O
334	in	O
334	advanced	O
334	solid	O
334	tumors	O
334	:	O
334	a	O
334	ca	O
334	##li	O
334	##fo	O
334	##rn	O
334	##ia	O
334	cancer	O
334	consortium	O
334	phase	O
334	i	O
334	p	O
334	##har	O
334	##ma	O
334	##co	O
334	##kin	O
334	##etic	O
334	and	O
334	molecular	O
334	co	O
334	##rrel	O
334	##ative	O
334	trial	O
334	.	O
334	[SEP]	O
335	[CLS]	O
335	however	O
335	,	O
335	no	O
335	association	O
335	was	O
335	observed	O
335	.	O
335	[SEP]	O
336	[CLS]	O
336	the	O
336	mobile	O
336	phase	O
336	was	O
336	prepared	O
336	by	O
336	mixing	O
336	met	O
336	##han	O
336	##ol	O
336	,	O
336	ace	O
336	##ton	O
336	##it	O
336	##ril	O
336	##e	O
336	and	O
336	10	O
336	mm	O
336	am	O
336	##mon	O
336	##ium	O
336	ace	O
336	##tate	O
336	buffer	O
336	(	O
336	p	O
336	##h	O
336	4	O
336	.	O
336	0	O
336	)	O
336	(	O
336	filtered	O
336	through	O
336	0	O
336	.	O
336	22	O
336	μ	O
336	##m	O
336	mill	O
336	##ip	O
336	##ore	O
336	filter	O
336	)	O
336	(	O
336	29	O
336	:	O
336	1	O
336	:	O
336	70	O
336	,	O
336	v	O
336	/	O
336	v	O
336	/	O
336	v	O
336	)	O
336	.	O
336	[SEP]	O
337	[CLS]	O
337	this	O
337	increased	O
337	up	O
337	##take	O
337	could	O
337	be	O
337	attributed	O
337	to	O
337	the	O
337	re	O
337	##tic	O
337	##ulo	O
337	##end	O
337	##oth	O
337	##eli	O
337	##al	O
337	system	O
337	leading	O
337	to	O
337	an	O
337	increase	O
337	in	O
337	re	O
337	##s	O
337	##ver	O
337	##at	O
337	##rol	O
337	concentration	O
337	in	O
337	the	O
337	liver	O
337	.	O
337	[SEP]	O
338	[CLS]	O
338	the	O
338	results	O
338	properly	O
338	indicated	O
338	that	O
338	moderate	O
338	clearance	B-PK
338	and	O
338	high	O
338	extra	O
338	##vas	O
338	##cular	O
338	distribution	O
338	would	O
338	be	O
338	exhibited	O
338	by	O
338	1	O
338	d	O
338	in	O
338	v	O
338	##ivo	O
338	.	O
338	[SEP]	O
339	[CLS]	O
339	the	O
339	findings	O
339	indicate	O
339	that	O
339	the	O
339	weight	O
339	for	O
339	age	O
339	are	O
339	not	O
339	con	O
339	##cor	O
339	##dant	O
339	for	O
339	the	O
339	two	O
339	middle	O
339	weight	O
339	groups	O
339	(	O
339	15	O
339	-	O
339	25	O
339	kg	O
339	and	O
339	>	O
339	25	O
339	-	O
339	35	O
339	kg	O
339	)	O
339	.	O
339	[SEP]	O
340	[CLS]	O
340	after	O
340	dose	O
340	normal	O
340	##ization	O
340	the	O
340	mean	O
340	peak	B-PK
340	plasma	I-PK
340	concentration	I-PK
340	was	O
340	0	O
340	.	O
340	68	O
340	micro	O
340	##m	O
340	(	O
340	range	O
340	0	O
340	.	O
340	12	O
340	-	O
340	1	O
340	.	O
340	38	O
340	)	O
340	and	O
340	the	O
340	area	B-PK
340	under	I-PK
340	the	I-PK
340	plasma	I-PK
340	concentration	I-PK
340	-	I-PK
340	time	I-PK
340	curve	I-PK
340	(	I-PK
340	au	I-PK
340	##c	I-PK
340	)	I-PK
340	was	O
340	1	O
340	.	O
340	37	O
340	micro	O
340	##m	O
340	.	O
340	h	O
340	(	O
340	range	O
340	0	O
340	.	O
340	12	O
340	-	O
340	3	O
340	.	O
340	04	O
340	)	O
340	.	O
340	[SEP]	O
341	[CLS]	O
341	this	O
341	equal	O
341	##ed	O
341	an	O
341	estimated	O
341	##b	O
341	##lo	O
341	##od	O
341	concentration	O
341	of	O
341	3	O
341	.	O
341	08	O
341	×	O
341	101	O
341	,	O
341	3	O
341	.	O
341	08	O
341	×	O
341	10	O
341	–	O
341	1	O
341	,	O
341	3	O
341	.	O
341	08	O
341	×	O
341	10	O
341	–	O
341	3	O
341	,	O
341	and	O
341	3	O
341	.	O
341	08	O
341	×	O
341	##10	O
341	–	O
341	4	O
341	ng	O
341	/	O
341	m	O
341	##l	O
341	,	O
341	respectively	O
341	.	O
341	[SEP]	O
342	[CLS]	O
342	sub	O
342	##ling	O
342	##ual	O
342	administration	O
342	of	O
342	de	O
342	##tom	O
342	##id	O
342	##ine	O
342	or	O
342	##om	O
342	##uc	O
342	##osa	O
342	##l	O
342	gel	O
342	at	O
342	40	O
342	μ	O
342	##g	O
342	/	O
342	kg	O
342	produces	O
342	safe	O
342	se	O
342	##dation	O
342	in	O
342	horses	O
342	.	O
342	[SEP]	O
343	[CLS]	O
343	in	O
343	the	O
343	present	O
343	study	O
343	,	O
343	the	O
343	au	B-PK
343	##ct	I-PK
343	##au	I-PK
343	and	O
343	cm	B-PK
343	##ax	I-PK
343	were	O
343	11	O
343	,	O
343	69	O
343	##0	O
343	.	O
343	71	O
343	hour	O
343	•	O
343	ng	O
343	/	O
343	m	O
343	##l	O
343	and	O
343	76	O
343	##4	O
343	.	O
343	3	O
343	ng	O
343	/	O
343	m	O
343	##l	O
343	,	O
343	respectively	O
343	.	O
343	[SEP]	O
344	[CLS]	O
344	when	O
344	combined	O
344	with	O
344	p	O
344	##az	O
344	##op	O
344	##ani	O
344	##b	O
344	,	O
344	800	O
344	mg	O
344	daily	O
344	,	O
344	the	O
344	recommended	O
344	doses	O
344	for	O
344	oral	O
344	top	O
344	##ote	O
344	##can	O
344	are	O
344	:	O
344	8	O
344	mg	O
344	weekly	O
344	and	O
344	2	O
344	.	O
344	5	O
344	mg	O
344	daily	O
344	-	O
344	times	O
344	-	O
344	five	O
344	.	O
344	[SEP]	O
345	[CLS]	O
345	all	O
345	regulated	O
345	procedures	O
345	on	O
345	living	O
345	animals	O
345	were	O
345	carried	O
345	out	O
345	under	O
345	##the	O
345	authority	O
345	of	O
345	a	O
345	license	O
345	issued	O
345	by	O
345	the	O
345	home	O
345	office	O
345	under	O
345	the	O
345	animals	O
345	(	O
345	scientific	O
345	procedures	O
345	)	O
345	[SEP]	O
346	[CLS]	O
346	o	O
346	##xy	O
346	##te	O
346	##tra	O
346	##cy	O
346	##cline	O
346	chloride	O
346	analytical	O
346	standard	O
346	(	O
346	97	O
346	%	O
346	purity	O
346	)	O
346	and	O
346	do	O
346	##xy	O
346	##cy	O
346	##cline	O
346	(	O
346	internal	O
346	standard	O
346	,	O
346	is	O
346	)	O
346	were	O
346	supplied	O
346	by	O
346	si	O
346	##gma	O
346	al	O
346	##dric	O
346	##h	O
346	,	O
346	m	O
346	##o	O
346	(	O
346	us	O
346	##a	O
346	)	O
346	.	O
346	[SEP]	O
347	[CLS]	O
347	in	O
347	rescue	O
347	experiments	O
347	,	O
347	an	O
347	##ae	O
347	##st	O
347	##he	O
347	##tized	O
347	rats	O
347	were	O
347	injected	O
347	s	O
347	.	O
347	c	O
347	.	O
347	with	O
347	multiple	O
347	m	O
347	##ld	O
347	of	O
347	venom	O
347	and	O
347	in	O
347	##fused	O
347	i	O
347	.	O
347	v	O
347	.	O
347	with	O
347	drugs	O
347	commonly	O
347	used	O
347	in	O
347	the	O
347	treatment	O
347	of	O
347	s	O
347	##cor	O
347	##pion	O
347	en	O
347	##ven	O
347	##oma	O
347	##tion	O
347	.	O
347	[SEP]	O
348	[CLS]	O
348	the	O
348	any	O
348	-	O
348	hit	O
348	model	O
348	was	O
348	consistent	O
348	with	O
348	poor	O
348	##er	O
348	survival	O
348	,	O
348	but	O
348	was	O
348	not	O
348	statistical	O
348	##ly	O
348	significant	O
348	.	O
348	[SEP]	O
349	[CLS]	O
349	the	O
349	concentrations	O
349	of	O
349	transfer	O
349	##rin	O
349	and	O
349	album	O
349	##in	O
349	were	O
349	determined	O
349	by	O
349	ne	O
349	##phe	O
349	##lo	O
349	##metry	O
349	.	O
349	[SEP]	O
350	[CLS]	O
350	[	O
350	14	O
350	##c	O
350	]	O
350	5	O
350	-	O
350	f	O
350	##u	O
350	was	O
350	purchased	O
350	from	O
350	m	O
350	##ora	O
350	##ve	O
350	##k	O
350	bio	O
350	##chemical	O
350	##s	O
350	(	O
350	br	O
350	##ea	O
350	,	O
350	ca	O
350	##li	O
350	##fo	O
350	##rn	O
350	##ia	O
350	,	O
350	us	O
350	)	O
350	.	O
350	[SEP]	O
351	[CLS]	O
351	the	O
351	potential	O
351	of	O
351	the	O
351	glass	O
351	##y	O
351	carbon	O
351	working	O
351	electro	O
351	##de	O
351	was	O
351	set	O
351	at	O
351	+	O
351	800	O
351	m	O
351	##v	O
351	.	O
351	the	O
351	limit	O
351	of	O
351	q	O
351	##uant	O
351	##itation	O
351	was	O
351	12	O
351	.	O
351	5	O
351	ng	O
351	m	O
351	##l	O
351	-	O
351	1	O
351	of	O
351	g	O
351	##p	O
351	##53	O
351	##1	O
351	using	O
351	100	O
351	micro	O
351	##lite	O
351	##rs	O
351	of	O
351	plasma	O
351	.	O
351	[SEP]	O
352	[CLS]	O
352	our	O
352	data	O
352	show	O
352	that	O
352	m	O
352	##od	O
352	##ulation	O
352	of	O
352	m	O
352	##4	O
352	and	O
352	mg	O
352	##lu	O
352	##2	O
352	receptors	O
352	may	O
352	potentially	O
352	be	O
352	beneficial	O
352	in	O
352	the	O
352	treatment	O
352	of	O
352	negative	O
352	and	O
352	cognitive	O
352	symptoms	O
352	of	O
352	s	O
352	##chi	O
352	##zophrenia	O
352	.	O
352	[SEP]	O
353	[CLS]	O
353	one	O
353	-	O
353	hundred	O
353	and	O
353	fifty	O
353	hi	O
353	##rs	O
353	##ute	O
353	women	O
353	(	O
353	68	O
353	with	O
353	type	O
353	i	O
353	or	O
353	ii	O
353	p	O
353	##oly	O
353	##cy	O
353	##stic	O
353	o	O
353	##vary	O
353	syndrome	O
353	and	O
353	82	O
353	with	O
353	id	O
353	##io	O
353	##pathic	O
353	hi	O
353	##rs	O
353	##uti	O
353	##sm	O
353	)	O
353	were	O
353	treated	O
353	for	O
353	periods	O
353	of	O
353	6	O
353	to	O
353	48	O
353	months	O
353	with	O
353	oral	O
353	c	O
353	##y	O
353	##p	O
353	##rote	O
353	##rone	O
353	(	O
353	c	O
353	##pa	O
353	)	O
353	,	O
353	a	O
353	drug	O
353	with	O
353	peripheral	O
353	anti	O
353	##and	O
353	##rogen	O
353	##ic	O
353	,	O
353	anti	O
353	##gon	O
353	##ado	O
353	##tro	O
353	##phic	O
353	and	O
353	pro	O
353	##ges	O
353	##tative	O
353	properties	O
353	,	O
353	and	O
353	17	O
353	beta	O
353	-	O
353	est	O
353	##rad	O
353	##iol	O
353	given	O
353	per	O
353	##cut	O
353	##aneous	O
353	##ly	O
353	to	O
353	ensure	O
353	est	O
353	##rogen	O
353	##ic	O
353	imp	O
353	##re	O
353	##gna	O
353	##tion	O
353	.	O
353	[SEP]	O
354	[CLS]	O
354	a	O
354	rapid	O
354	onset	O
354	of	O
354	drug	O
354	effect	O
354	was	O
354	observed	O
354	for	O
354	all	O
354	c	O
354	##lev	O
354	##id	O
354	##ip	O
354	##ine	O
354	co	O
354	##hor	O
354	##ts	O
354	,	O
354	with	O
354	no	O
354	evidence	O
354	of	O
354	a	O
354	dim	O
354	##ini	O
354	##shing	O
354	drug	O
354	effect	O
354	throughout	O
354	the	O
354	treatment	O
354	period	O
354	.	O
354	[SEP]	O
355	[CLS]	O
355	specific	O
355	features	O
355	of	O
355	drug	O
355	distribution	O
355	were	O
355	detected	O
355	;	O
355	for	O
355	example	O
355	,	O
355	s	O
355	##ple	O
355	##nic	O
355	tissue	O
355	selective	O
355	##ly	O
355	accumulated	O
355	th	O
355	##iet	O
355	##az	O
355	##ole	O
355	during	O
355	course	O
355	treatment	O
355	.	O
355	[SEP]	O
356	[CLS]	O
356	blood	O
356	samples	O
356	were	O
356	collected	O
356	from	O
356	all	O
356	patients	O
356	on	O
356	day	O
356	1	O
356	at	O
356	the	O
356	following	O
356	times	O
356	:	O
356	0	O
356	(	O
356	pre	O
356	##dos	O
356	##e	O
356	)	O
356	and	O
356	15	O
356	min	O
356	,	O
356	30	O
356	min	O
356	,	O
356	1	O
356	h	O
356	,	O
356	1	O
356	h	O
356	30	O
356	min	O
356	,	O
356	2	O
356	,	O
356	3	O
356	,	O
356	4	O
356	,	O
356	6	O
356	,	O
356	8	O
356	,	O
356	10	O
356	,	O
356	and	O
356	12	O
356	h	O
356	post	O
356	##dos	O
356	##e	O
356	.	O
356	[SEP]	O
357	[CLS]	O
357	after	O
357	50	O
357	##μ	O
357	##l	O
357	ta	O
357	(	O
357	k	O
357	##ena	O
357	##log	O
357	-	O
357	40	O
357	)	O
357	su	O
357	##pra	O
357	##chor	O
357	##oid	O
357	##al	O
357	injection	O
357	,	O
357	4	O
357	-	O
357	5	O
357	animals	O
357	at	O
357	7	O
357	time	O
357	points	O
357	were	O
357	sacrificed	O
357	for	O
357	a	O
357	##que	O
357	##ous	O
357	,	O
357	v	O
357	##it	O
357	##re	O
357	##ous	O
357	,	O
357	re	O
357	##tina	O
357	,	O
357	and	O
357	plasma	O
357	collections	O
357	.	O
357	[SEP]	O
358	[CLS]	O
358	the	O
358	half	B-PK
358	-	I-PK
358	life	I-PK
358	of	O
358	elimination	O
358	estimated	O
358	from	O
358	the	O
358	fourth	O
358	twitch	O
358	was	O
358	similar	O
358	to	O
358	that	O
358	from	O
358	the	O
358	first	O
358	twitch	O
358	.	O
358	[SEP]	O
359	[CLS]	O
359	quality	O
359	control	O
359	(	O
359	q	O
359	##c	O
359	)	O
359	samples	O
359	were	O
359	obtained	O
359	at	O
359	5	O
359	,	O
359	50	O
359	,	O
359	160	O
359	ng	O
359	/	O
359	m	O
359	##l	O
359	for	O
359	ma	O
359	##gno	O
359	##f	O
359	##lor	O
359	##ine	O
359	and	O
359	α	O
359	-	O
359	all	O
359	##oc	O
359	##ry	O
359	##pt	O
359	##op	O
359	##ine	O
359	,	O
359	at	O
359	1	O
359	,	O
359	10	O
359	,	O
359	32	O
359	ng	O
359	/	O
359	m	O
359	##l	O
359	for	O
359	ski	O
359	##mm	O
359	##ian	O
359	##ine	O
359	.	O
359	[SEP]	O
360	[CLS]	O
360	all	O
360	the	O
360	size	O
360	of	O
360	as	O
360	##l	O
360	-	O
360	m	O
360	##l	O
360	formulation	O
360	##s	O
360	were	O
360	around	O
360	170	O
360	–	O
360	200	O
360	nm	O
360	with	O
360	as	O
360	##l	O
360	-	O
360	m	O
360	##l	O
360	(	O
360	d	O
360	##pp	O
360	##g	O
360	)	O
360	smaller	O
360	than	O
360	as	O
360	##l	O
360	-	O
360	m	O
360	##l	O
360	(	O
360	h	O
360	##sp	O
360	##c	O
360	)	O
360	.	O
360	[SEP]	O
361	[CLS]	O
361	steady	O
361	state	O
361	te	O
361	##di	O
361	##zo	O
361	##lid	O
361	had	O
361	no	O
361	effect	O
361	on	O
361	the	O
361	p	O
361	##k	O
361	of	O
361	pseudo	O
361	##ep	O
361	##hed	O
361	##rine	O
361	;	O
361	the	O
361	g	O
361	##m	O
361	##r	O
361	and	O
361	90	O
361	%	O
361	c	O
361	##is	O
361	remained	O
361	within	O
361	the	O
361	no	O
361	-	O
361	effect	O
361	0	O
361	.	O
361	8	O
361	to	O
361	1	O
361	.	O
361	25	O
361	boundaries	O
361	(	O
361	table	O
361	1	O
361	)	O
361	[	O
361	15	O
361	]	O
361	.	O
361	[SEP]	O
362	[CLS]	O
362	the	O
362	accumulation	O
362	of	O
362	(	O
362	+	O
362	)	O
362	-	O
362	and	O
362	(	O
362	-	O
362	)	O
362	-	O
362	prop	O
362	##rano	O
362	##lo	O
362	##l	O
362	was	O
362	investigated	O
362	in	O
362	nine	O
362	subjects	O
362	who	O
362	received	O
362	160	O
362	mg	O
362	of	O
362	race	O
362	##mic	O
362	prop	O
362	##rano	O
362	##lo	O
362	##l	O
362	as	O
362	a	O
362	single	O
362	dose	O
362	and	O
362	then	O
362	once	O
362	daily	O
362	for	O
362	7	O
362	days	O
362	.	O
362	[SEP]	O
363	[CLS]	O
363	the	O
363	mean	O
363	cm	B-PK
363	##ax	I-PK
363	for	O
363	male	O
363	and	O
363	female	O
363	subjects	O
363	was	O
363	not	O
363	statistical	O
363	##ly	O
363	significant	O
363	but	O
363	the	O
363	extent	O
363	of	O
363	absorption	O
363	appeared	O
363	to	O
363	be	O
363	affected	O
363	by	O
363	sex	O
363	.	O
363	[SEP]	O
364	[CLS]	O
364	the	O
364	en	O
364	##cap	O
364	##sul	O
364	##ation	O
364	efficiency	O
364	(	O
364	e	O
364	##e	O
364	,	O
364	%	O
364	)	O
364	was	O
364	expressed	O
364	as	O
364	the	O
364	ratio	O
364	of	O
364	the	O
364	p	O
364	##t	O
364	##x	O
364	amount	O
364	en	O
364	##cap	O
364	##sul	O
364	##ated	O
364	by	O
364	the	O
364	g	O
364	##a	O
364	mice	O
364	##lles	O
364	and	O
364	the	O
364	total	O
364	p	O
364	##t	O
364	##x	O
364	(	O
364	100	O
364	%	O
364	)	O
364	amount	O
364	in	O
364	the	O
364	mice	O
364	##lle	O
364	suspension	O
364	,	O
364	as	O
364	described	O
364	by	O
364	equation	O
364	(	O
364	1	O
364	)	O
364	:	O
364	(	O
364	1	O
364	)	O
364	e	O
364	##e	O
364	%	O
364	=	O
364	(	O
364	1	O
364	##−	O
364	##w	O
364	##f	O
364	##w	O
364	##to	O
364	##tal	O
364	)	O
364	×	O
364	##100	O
364	%	O
364	where	O
364	w	O
364	##f	O
364	was	O
364	the	O
364	weight	O
364	of	O
364	p	O
364	##t	O
364	##x	O
364	in	O
364	the	O
364	fi	O
364	##lt	O
364	##rate	O
364	,	O
364	and	O
364	w	O
364	##to	O
364	##tal	O
364	was	O
364	the	O
364	weight	O
364	of	O
364	p	O
364	##t	O
364	##x	O
364	in	O
364	the	O
364	formulation	O
364	.	O
364	[SEP]	O
365	[CLS]	O
365	electrical	O
365	current	O
365	in	O
365	all	O
365	cases	O
365	was	O
365	44	O
365	ma	O
365	.	O
365	[SEP]	O
366	[CLS]	O
366	volunteers	O
366	receiving	O
366	delayed	O
366	-	O
366	release	O
366	me	O
366	##sal	O
366	##amine	O
366	capsule	O
366	##s	O
366	with	O
366	food	O
366	were	O
366	given	O
366	a	O
366	high	O
366	-	O
366	fat	O
366	,	O
366	high	O
366	-	O
366	ca	O
366	##lor	O
366	##ie	O
366	(	O
366	800	O
366	–	O
366	1	O
366	,	O
366	000	O
366	ca	O
366	##lor	O
366	##ies	O
366	)	O
366	breakfast	O
366	30	O
366	minutes	O
366	prior	O
366	to	O
366	dos	O
366	##ing	O
366	.	O
366	[SEP]	O
367	[CLS]	O
367	introduction	O
367	to	O
367	p	O
367	##har	O
367	##ma	O
367	##co	O
367	##kin	O
367	##etics	O
367	:	O
367	amino	O
367	##gly	O
367	##cos	O
367	##ides	O
367	in	O
367	c	O
367	##ys	O
367	##tic	O
367	fi	O
367	##bro	O
367	##sis	O
367	as	O
367	a	O
367	prototype	O
367	.	O
367	[SEP]	O
368	[CLS]	O
368	a	O
368	digital	O
368	ca	O
368	##lip	O
368	##er	O
368	was	O
368	used	O
368	to	O
368	measure	O
368	the	O
368	tumor	O
368	diameter	O
368	##s	O
368	(	O
368	in	O
368	mill	O
368	##imeter	O
368	##s	O
368	)	O
368	,	O
368	and	O
368	tumor	O
368	volumes	O
368	(	O
368	in	O
368	cubic	O
368	mill	O
368	##imeter	O
368	##s	O
368	)	O
368	were	O
368	calculated	O
368	using	O
368	the	O
368	following	O
368	formula	O
368	:	O
368	tumor	O
368	volume	O
368	=	O
368	length	O
368	##×	O
368	##wi	O
368	##dt	O
368	##h	O
368	##2	O
368	##×	O
368	##0	O
368	.	O
368	5	O
368	.	O
368	[SEP]	O
369	[CLS]	O
369	effect	O
369	of	O
369	o	O
369	##besity	O
369	on	O
369	p	O
369	##har	O
369	##ma	O
369	##co	O
369	##kin	O
369	##etics	O
369	and	O
369	bio	O
369	##log	O
369	##ic	O
369	effect	O
369	of	O
369	inter	O
369	##fer	O
369	##on	O
369	-	O
369	alpha	O
369	in	O
369	he	O
369	##pa	O
369	##titis	O
369	c	O
369	.	O
369	[SEP]	O
370	[CLS]	O
370	in	O
370	addition	O
370	to	O
370	receiving	O
370	the	O
370	study	O
370	drug	O
370	or	O
370	place	O
370	##bo	O
370	,	O
370	all	O
370	participants	O
370	receive	O
370	i	O
370	##v	O
370	p	O
370	##ca	O
370	with	O
370	h	O
370	##ydro	O
370	##mor	O
370	##phone	O
370	on	O
370	demand	O
370	to	O
370	facilitate	O
370	achieving	O
370	adequate	O
370	pain	O
370	relief	O
370	.	O
370	[SEP]	O
371	[CLS]	O
371	as	O
371	expected	O
371	,	O
371	there	O
371	was	O
371	a	O
371	significant	O
371	reduction	O
371	in	O
371	s	O
371	##t	O
371	##n	O
371	##f	O
371	-	O
371	α	O
371	in	O
371	the	O
371	as	O
371	##cite	O
371	##s	O
371	fluid	O
371	of	O
371	in	O
371	##f	O
371	##lix	O
371	##ima	O
371	##b	O
371	-	O
371	treated	O
371	mice	O
371	when	O
371	compared	O
371	to	O
371	vehicle	O
371	(	O
371	3	O
371	.	O
371	7	O
371	-	O
371	fold	O
371	reduction	O
371	,	O
371	p	O
371	<	O
371	0	O
371	.	O
371	000	O
371	##1	O
371	)	O
371	.	O
371	[SEP]	O
372	[CLS]	O
372	in	O
372	addition	O
372	,	O
372	there	O
372	was	O
372	no	O
372	wash	O
372	##out	O
372	period	O
372	prior	O
372	to	O
372	the	O
372	repeated	O
372	administration	O
372	phase	O
372	(	O
372	j	O
372	##apa	O
372	##n	O
372	pharmaceutical	O
372	information	O
372	center	O
372	registration	O
372	no	O
372	.	O
372	j	O
372	##ap	O
372	##ic	O
372	##ct	O
372	##i	O
372	‐	O
372	111	O
372	##48	O
372	##2	O
372	)	O
372	.	O
372	[SEP]	O
373	[CLS]	O
373	car	O
373	##fi	O
373	##l	O
373	##zo	O
373	##mi	O
373	##b	O
373	was	O
373	administered	O
373	on	O
373	days	O
373	1	O
373	,	O
373	2	O
373	,	O
373	8	O
373	,	O
373	9	O
373	,	O
373	15	O
373	and	O
373	16	O
373	in	O
373	28	O
373	-	O
373	day	O
373	cycles	O
373	:	O
373	15	O
373	mg	O
373	/	O
373	m	O
373	##2	O
373	(	O
373	cycle	O
373	1	O
373	)	O
373	,	O
373	20	O
373	mg	O
373	/	O
373	m	O
373	##2	O
373	(	O
373	cycle	O
373	2	O
373	)	O
373	and	O
373	27	O
373	mg	O
373	/	O
373	m	O
373	##2	O
373	(	O
373	cycles	O
373	3	O
373	+	O
373	)	O
373	.	O
373	[SEP]	O
374	[CLS]	O
374	the	O
374	results	O
374	show	O
374	a	O
374	highly	O
374	significant	O
374	increase	O
374	in	O
374	the	O
374	ex	O
374	##cre	O
374	##tion	O
374	of	O
374	f	O
374	##er	O
374	##uli	O
374	##c	O
374	,	O
374	is	O
374	##of	O
374	##er	O
374	##uli	O
374	##c	O
374	,	O
374	di	O
374	##hy	O
374	##dr	O
374	##of	O
374	##er	O
374	##uli	O
374	##c	O
374	acid	O
374	(	O
374	3	O
374	-	O
374	(	O
374	4	O
374	-	O
374	h	O
374	##ydro	O
374	##xy	O
374	-	O
374	3	O
374	-	O
374	met	O
374	##ho	O
374	##xy	O
374	##phe	O
374	##ny	O
374	##l	O
374	)	O
374	-	O
374	prop	O
374	##ion	O
374	##ic	O
374	acid	O
374	)	O
374	,	O
374	and	O
374	van	O
374	##ill	O
374	##ic	O
374	acid	O
374	posts	O
374	##up	O
374	##ple	O
374	##mentation	O
374	relative	O
374	to	O
374	the	O
374	levels	O
374	pre	O
374	##su	O
374	##pp	O
374	##lement	O
374	##ation	O
374	.	O
374	[SEP]	O
375	[CLS]	O
375	blank	O
375	na	O
375	##no	O
375	##par	O
375	##tic	O
375	##les	O
375	were	O
375	produced	O
375	in	O
375	a	O
375	similar	O
375	manner	O
375	without	O
375	adding	O
375	the	O
375	drug	O
375	.	O
375	[SEP]	O
376	[CLS]	O
376	in	O
376	v	O
376	##ivo	O
376	p	O
376	##har	O
376	##ma	O
376	##co	O
376	##kin	O
376	##etic	O
376	data	O
376	demonstrate	O
376	that	O
376	the	O
376	au	B-PK
376	##c	I-PK
376	##0	I-PK
376	-	I-PK
376	α	I-PK
376	in	O
376	trans	O
376	##der	O
376	##mal	O
376	application	O
376	(	O
376	13	O
376	,	O
376	50	O
376	##6	O
376	.	O
376	51	O
376	±	O
376	164	O
376	##9	O
376	.	O
376	92	O
376	ng	O
376	·	O
376	h	O
376	/	O
376	m	O
376	##l	O
376	)	O
376	was	O
376	~	O
376	2	O
376	times	O
376	higher	O
376	(	O
376	p	O
376	<	O
376	0	O
376	.	O
376	000	O
376	##1	O
376	)	O
376	as	O
376	compared	O
376	to	O
376	oral	O
376	dos	O
376	##age	O
376	form	O
376	.	O
376	[SEP]	O
377	[CLS]	O
377	by	O
377	comparison	O
377	p	O
377	##b	O
377	increased	O
377	c	O
377	##y	O
377	##p	O
377	##2	O
377	##b	O
377	expression	O
377	40	O
377	-	O
377	fold	O
377	.	O
377	[SEP]	O
378	[CLS]	O
378	p	O
378	##har	O
378	##ma	O
378	##co	O
378	##dynamic	O
378	##s	O
378	showed	O
378	dose	O
378	related	O
378	beta	O
378	2	O
378	responses	O
378	for	O
378	r	O
378	-	O
378	sa	O
378	##l	O
378	##but	O
378	##amo	O
378	##l	O
378	and	O
378	r	O
378	##s	O
378	-	O
378	sa	O
378	##l	O
378	##but	O
378	##amo	O
378	##l	O
378	but	O
378	not	O
378	for	O
378	the	O
378	s	O
378	is	O
378	##omer	O
378	,	O
378	and	O
378	a	O
378	plateau	O
378	in	O
378	response	O
378	was	O
378	not	O
378	reached	O
378	within	O
378	the	O
378	administered	O
378	dose	O
378	range	O
378	.	O
378	[SEP]	O
379	[CLS]	O
379	here	O
379	,	O
379	the	O
379	design	O
379	and	O
379	optimization	O
379	of	O
379	novel	O
379	[	O
379	1	O
379	,	O
379	2	O
379	,	O
379	4	O
379	]	O
379	o	O
379	##xa	O
379	##dia	O
379	##zo	O
379	##le	O
379	derivatives	O
379	as	O
379	selective	O
379	s	O
379	##1	O
379	##p	O
379	receptor	O
379	ago	O
379	##nist	O
379	##s	O
379	are	O
379	described	O
379	.	O
379	[SEP]	O
380	[CLS]	O
380	oral	O
380	##ly	O
380	administered	O
380	a	O
380	##ra	O
380	-	O
380	d	O
380	##ma	O
380	##p	O
380	was	O
380	rapidly	O
380	absorbed	O
380	.	O
380	[SEP]	O
381	[CLS]	O
381	the	O
381	more	O
381	favorable	O
381	results	O
381	obtained	O
381	with	O
381	am	O
381	##ox	O
381	##ici	O
381	##llin	O
381	compared	O
381	with	O
381	those	O
381	obtained	O
381	with	O
381	c	O
381	##ef	O
381	##uro	O
381	##xi	O
381	##me	O
381	could	O
381	be	O
381	related	O
381	to	O
381	the	O
381	anti	O
381	##mic	O
381	##ro	O
381	##bial	O
381	su	O
381	##s	O
381	##ce	O
381	##pt	O
381	##ibility	O
381	of	O
381	the	O
381	p	O
381	##ne	O
381	##um	O
381	##oc	O
381	##oc	O
381	##cal	O
381	strain	O
381	(	O
381	mi	O
381	##cs	O
381	and	O
381	minimum	O
381	b	O
381	##act	O
381	##eric	O
381	##idal	O
381	concentrations	O
381	of	O
381	1	O
381	and	O
381	1	O
381	micro	O
381	##gram	O
381	/	O
381	m	O
381	##l	O
381	and	O
381	4	O
381	and	O
381	4	O
381	micro	O
381	##gram	O
381	##s	O
381	/	O
381	m	O
381	##l	O
381	for	O
381	am	O
381	##ox	O
381	##ici	O
381	##llin	O
381	and	O
381	c	O
381	##ef	O
381	##uro	O
381	##xi	O
381	##me	O
381	,	O
381	respectively	O
381	)	O
381	as	O
381	well	O
381	as	O
381	to	O
381	the	O
381	better	O
381	p	O
381	##har	O
381	##ma	O
381	##co	O
381	##kin	O
381	##etic	O
381	parameters	O
381	obtained	O
381	with	O
381	am	O
381	##ox	O
381	##ici	O
381	##llin	O
381	.	O
381	[SEP]	O
382	[CLS]	O
382	the	O
382	c	O
382	##y	O
382	##c	O
382	##lop	O
382	##hos	O
382	##pha	O
382	##mi	O
382	##de	O
382	(	O
382	si	O
382	##gma	O
382	chemical	O
382	company	O
382	in	O
382	##c	O
382	.	O
382	,	O
382	s	O
382	##t	O
382	lo	O
382	##ui	O
382	##s	O
382	,	O
382	m	O
382	##o	O
382	,	O
382	u	O
382	.	O
382	s	O
382	.	O
382	a	O
382	.	O
382	)	O
382	was	O
382	administered	O
382	in	O
382	all	O
382	animals	O
382	from	O
382	control	O
382	(	O
382	+	O
382	)	O
382	,	O
382	ex	O
382	##p	O
382	1	O
382	(	O
382	+	O
382	)	O
382	,	O
382	and	O
382	ex	O
382	##p	O
382	2	O
382	(	O
382	+	O
382	)	O
382	groups	O
382	through	O
382	a	O
382	single	O
382	in	O
382	##tra	O
382	##per	O
382	##ito	O
382	##nea	O
382	##l	O
382	injection	O
382	only	O
382	at	O
382	29	O
382	d	O
382	of	O
382	experiment	O
382	period	O
382	.	O
382	[SEP]	O
383	[CLS]	O
383	model	O
383	selection	O
383	was	O
383	guided	O
383	by	O
383	evaluation	O
383	of	O
383	the	O
383	minimum	O
383	objective	O
383	function	O
383	and	O
383	the	O
383	weighted	O
383	residual	O
383	##s	O
383	.	O
383	[SEP]	O
384	[CLS]	O
384	in	O
384	all	O
384	cases	O
384	,	O
384	the	O
384	drug	O
384	almost	O
384	totally	O
384	disappeared	O
384	from	O
384	plasma	O
384	within	O
384	8	O
384	hours	O
384	;	O
384	drug	O
384	levels	O
384	measured	O
384	prior	O
384	to	O
384	the	O
384	first	O
384	doses	O
384	on	O
384	the	O
384	following	O
384	days	O
384	showed	O
384	und	O
384	##ete	O
384	##ct	O
384	##able	O
384	levels	O
384	.	O
384	[SEP]	O
385	[CLS]	O
385	a	O
385	maximum	O
385	of	O
385	six	O
385	cycles	O
385	were	O
385	given	O
385	.	O
385	[SEP]	O
386	[CLS]	O
386	there	O
386	was	O
386	a	O
386	good	O
386	correlation	O
386	between	O
386	r	O
386	##cc	O
386	and	O
386	p	O
386	##cc	O
386	(	O
386	r	O
386	=	O
386	0	O
386	.	O
386	7	O
386	)	O
386	.	O
386	[SEP]	O
387	[CLS]	O
387	the	O
387	in	O
387	##tra	O
387	-	O
387	ass	O
387	##ay	O
387	precision	O
387	##s	O
387	ranged	O
387	from	O
387	3	O
387	.	O
387	8	O
387	to	O
387	5	O
387	.	O
387	9	O
387	%	O
387	,	O
387	while	O
387	inter	O
387	-	O
387	ass	O
387	##ay	O
387	precision	O
387	##s	O
387	ranged	O
387	from	O
387	4	O
387	.	O
387	2	O
387	to	O
387	6	O
387	.	O
387	0	O
387	%	O
387	.	O
387	[SEP]	O
388	[CLS]	O
388	both	O
388	plasma	O
388	(	O
388	cm	B-PK
388	##ax	I-PK
388	:	O
388	0	O
388	.	O
388	54	O
388	-	O
388	1	O
388	.	O
388	10	O
388	-	O
388	3	O
388	.	O
388	12	O
388	µ	O
388	##m	O
388	)	O
388	and	O
388	u	O
388	##rina	O
388	##ry	O
388	(	O
388	cm	B-PK
388	##ax	I-PK
388	:	O
388	0	O
388	.	O
388	09	O
388	-	O
388	0	O
388	.	O
388	41	O
388	-	O
388	0	O
388	.	O
388	72	O
388	mg	O
388	/	O
388	mg	O
388	c	O
388	##rea	O
388	##tin	O
388	##ine	O
388	)	O
388	an	O
388	##ser	O
388	##ine	O
388	increased	O
388	dose	O
388	-	O
388	dependent	O
388	##ly	O
388	following	O
388	ing	O
388	##est	O
388	##ion	O
388	of	O
388	4	O
388	-	O
388	10	O
388	-	O
388	20	O
388	an	O
388	##ser	O
388	##ine	O
388	mg	O
388	/	O
388	kg	O
388	b	O
388	##w	O
388	,	O
388	respectively	O
388	.	O
388	[SEP]	O
389	[CLS]	O
389	for	O
389	in	O
389	##test	O
389	##inal	O
389	b	O
389	##d	O
389	patients	O
389	,	O
389	the	O
389	clinical	O
389	symptoms	O
389	were	O
389	scored	O
389	at	O
389	weeks	O
389	0	O
389	,	O
389	2	O
389	,	O
389	and	O
389	6	O
389	,	O
389	and	O
389	every	O
389	4	O
389	weeks	O
389	thereafter	O
389	.	O
389	[SEP]	O
390	[CLS]	O
390	the	O
390	##o	O
390	5	O
390	+	O
390	te	O
390	##r	O
390	20	O
390	,	O
390	and	O
390	the	O
390	##o	O
390	20	O
390	+	O
390	te	O
390	##r	O
390	20	O
390	enhanced	O
390	the	O
390	br	O
390	##on	O
390	##cho	O
390	##di	O
390	##lator	O
390	action	O
390	of	O
390	each	O
390	other	O
390	in	O
390	an	O
390	add	O
390	##itive	O
390	manner	O
390	.	O
390	[SEP]	O
391	[CLS]	O
391	b	O
391	##pa	O
391	##f	O
391	-	O
391	g	O
391	was	O
391	further	O
391	characterized	O
391	by	O
391	nuclear	O
391	magnetic	O
391	resonance	O
391	(	O
391	nm	O
391	##r	O
391	)	O
391	.	O
391	[SEP]	O
392	[CLS]	O
392	for	O
392	both	O
392	the	O
392	p	O
392	##ic	O
392	and	O
392	l	O
392	##f	O
392	##c	O
392	,	O
392	on	O
392	day	O
392	1	O
392	(	O
392	co	O
392	##hor	O
392	##ts	O
392	1	O
392	and	O
392	3	O
392	)	O
392	and	O
392	day	O
392	8	O
392	(	O
392	co	O
392	##hor	O
392	##t	O
392	1	O
392	only	O
392	)	O
392	,	O
392	subjects	O
392	received	O
392	l	O
392	##f	O
392	##c	O
392	(	O
392	co	O
392	##hor	O
392	##t	O
392	1	O
392	)	O
392	or	O
392	p	O
392	##ic	O
392	(	O
392	co	O
392	##hor	O
392	##t	O
392	3	O
392	)	O
392	of	O
392	p	O
392	##ex	O
392	##met	O
392	##ini	O
392	##b	O
392	with	O
392	240	O
392	m	O
392	##l	O
392	(	O
392	±	O
392	##10	O
392	m	O
392	##l	O
392	)	O
392	water	O
392	(	O
392	ambient	O
392	temperature	O
392	)	O
392	.	O
392	[SEP]	O
393	[CLS]	O
393	[	O
393	p	O
393	##har	O
393	##ma	O
393	##co	O
393	##kin	O
393	##etics	O
393	of	O
393	ca	O
393	##uli	O
393	##s	O
393	er	O
393	##y	O
393	##ci	O
393	##bes	O
393	injection	O
393	in	O
393	rabbits	O
393	]	O
393	.	O
393	[SEP]	O
394	[CLS]	O
394	summary	O
394	statistics	O
394	and	O
394	statistical	O
394	comparisons	O
394	were	O
394	,	O
394	therefore	O
394	,	O
394	not	O
394	performed	O
394	for	O
394	the	O
394	10	O
394	‐	O
394	mg	O
394	and	O
394	20	O
394	‐	O
394	mg	O
394	doses	O
394	.	O
394	[SEP]	O
395	[CLS]	O
395	z	O
395	##op	O
395	##ic	O
395	##lone	O
395	7	O
395	.	O
395	5	O
395	mg	O
395	has	O
395	been	O
395	compared	O
395	also	O
395	with	O
395	te	O
395	##ma	O
395	##ze	O
395	##pa	O
395	##m	O
395	20	O
395	mg	O
395	in	O
395	subjects	O
395	with	O
395	chronic	O
395	ins	O
395	##om	O
395	##nia	O
395	.	O
395	[SEP]	O
396	[CLS]	O
396	rates	O
396	of	O
396	v	O
396	##ld	O
396	##l	O
396	secret	O
396	##ion	O
396	were	O
396	measured	O
396	by	O
396	determining	O
396	the	O
396	rate	B-PK
396	of	I-PK
396	accumulation	I-PK
396	of	O
396	t	O
396	##rig	O
396	##ly	O
396	##cer	O
396	##ide	O
396	in	O
396	the	O
396	plasma	O
396	after	O
396	in	O
396	##tra	O
396	##ven	O
396	##ous	O
396	injection	O
396	of	O
396	anti	O
396	-	O
396	lip	O
396	##op	O
396	##rote	O
396	##in	O
396	lip	O
396	##ase	O
396	anti	O
396	##body	O
396	.	O
396	[SEP]	O
397	[CLS]	O
397	the	O
397	plasma	B-PK
397	elimination	I-PK
397	half	I-PK
397	-	I-PK
397	life	I-PK
397	of	I-PK
397	the	I-PK
397	beta	I-PK
397	-	I-PK
397	phase	I-PK
397	(	I-PK
397	t	I-PK
397	1	I-PK
397	/	I-PK
397	2	I-PK
397	beta	I-PK
397	)	I-PK
397	and	O
397	time	B-PK
397	to	I-PK
397	maximum	I-PK
397	peak	I-PK
397	plasma	I-PK
397	concentration	I-PK
397	(	I-PK
397	t	I-PK
397	##max	I-PK
397	)	I-PK
397	were	O
397	significantly	O
397	longer	O
397	in	O
397	the	O
397	elderly	O
397	than	O
397	in	O
397	the	O
397	young	O
397	:	O
397	t	B-PK
397	1	I-PK
397	/	I-PK
397	2	I-PK
397	beta	I-PK
397	,	O
397	103	O
397	.	O
397	8	O
397	+	O
397	-	O
397	40	O
397	.	O
397	6	O
397	versus	O
397	59	O
397	.	O
397	7	O
397	+	O
397	-	O
397	16	O
397	.	O
397	1	O
397	hours	O
397	;	O
397	and	O
397	t	B-PK
397	##max	I-PK
397	,	O
397	5	O
397	.	O
397	2	O
397	+	O
397	-	O
397	2	O
397	.	O
397	8	O
397	versus	O
397	3	O
397	.	O
397	4	O
397	+	O
397	-	O
397	1	O
397	.	O
397	5	O
397	hours	O
397	,	O
397	respectively	O
397	.	O
397	[SEP]	O
398	[CLS]	O
398	the	O
398	objective	O
398	of	O
398	this	O
398	study	O
398	was	O
398	to	O
398	determine	O
398	,	O
398	in	O
398	br	O
398	##oil	O
398	##ers	O
398	,	O
398	which	O
398	m	O
398	##oda	O
398	##lity	O
398	of	O
398	di	O
398	##so	O
398	##dium	O
398	f	O
398	##os	O
398	##fo	O
398	##my	O
398	##cin	O
398	(	O
398	d	O
398	##f	O
398	)	O
398	administration	O
398	and	O
398	at	O
398	what	O
398	dose	O
398	the	O
398	best	O
398	p	O
398	##har	O
398	##ma	O
398	##co	O
398	##kin	O
398	##etic	O
398	(	O
398	p	O
398	##k	O
398	)	O
398	profile	O
398	could	O
398	be	O
398	obtained	O
398	,	O
398	taking	O
398	as	O
398	reference	O
398	a	O
398	110	O
398	field	O
398	bacterial	O
398	strains	O
398	of	O
398	es	O
398	##cher	O
398	##ichi	O
398	##a	O
398	co	O
398	##li	O
398	minimum	O
398	inhibitor	O
398	##y	O
398	concentration	O
398	survey	O
398	.	O
398	[SEP]	O
399	[CLS]	O
399	in	O
399	cycle	O
399	4	O
399	,	O
399	the	O
399	mean	O
399	t	O
399	##ras	O
399	##tu	O
399	##zu	O
399	##ma	O
399	##b	O
399	exposure	O
399	over	O
399	the	O
399	24	O
399	h	O
399	following	O
399	dose	O
399	administration	O
399	was	O
399	3	O
399	,	O
399	09	O
399	##4	O
399	μ	O
399	##g	O
399	*	O
399	h	O
399	/	O
399	m	O
399	##l	O
399	,	O
399	which	O
399	increased	O
399	to	O
399	a	O
399	mean	B-PK
399	concentration	I-PK
399	of	O
399	17	O
399	,	O
399	322	O
399	μ	O
399	##g	O
399	*	O
399	h	O
399	/	O
399	m	O
399	##l	O
399	over	O
399	the	O
399	3	O
399	-	O
399	week	O
399	sampling	O
399	interval	O
399	.	O
399	[SEP]	O
400	[CLS]	O
400	the	O
400	steady	B-PK
400	-	I-PK
400	state	I-PK
400	brain	I-PK
400	-	I-PK
400	to	I-PK
400	-	I-PK
400	free	I-PK
400	plasma	I-PK
400	concentration	I-PK
400	ratio	I-PK
400	of	O
400	v	O
400	##al	O
400	##p	O
400	##roi	O
400	##c	O
400	acid	O
400	(	O
400	v	O
400	##pa	O
400	)	O
400	is	O
400	well	O
400	below	O
400	unity	O
400	,	O
400	which	O
400	suggests	O
400	that	O
400	it	O
400	is	O
400	efficiently	O
400	removed	O
400	from	O
400	the	O
400	central	O
400	nervous	O
400	system	O
400	(	O
400	c	O
400	##ns	O
400	)	O
400	by	O
400	specialized	O
400	transport	O
400	processes	O
400	.	O
400	[SEP]	O
401	[CLS]	O
401	after	O
401	the	O
401	subjects	O
401	were	O
401	pre	O
401	##tre	O
401	##ated	O
401	with	O
401	p	O
401	##r	O
401	##x	O
401	for	O
401	7	O
401	days	O
401	or	O
401	fl	O
401	##v	O
401	for	O
401	6	O
401	days	O
401	,	O
401	a	O
401	single	O
401	dose	O
401	of	O
401	a	O
401	##p	O
401	##z	O
401	was	O
401	co	O
401	##ad	O
401	##mini	O
401	##stered	O
401	with	O
401	p	O
401	##r	O
401	##x	O
401	or	O
401	fl	O
401	##v	O
401	under	O
401	fast	O
401	##ing	O
401	conditions	O
401	at	O
401	the	O
401	steady	B-PK
401	-	I-PK
401	state	I-PK
401	plasma	I-PK
401	concentration	I-PK
401	of	O
401	these	O
401	s	O
401	##s	O
401	##ris	O
401	,	O
401	then	O
401	repeated	O
401	oral	O
401	doses	O
401	of	O
401	s	O
401	##s	O
401	##ris	O
401	were	O
401	administered	O
401	for	O
401	14	O
401	consecutive	O
401	days	O
401	(	O
401	period	O
401	ii	O
401	)	O
401	(	O
401	fi	O
401	##g	O
401	.	O
401	1	O
401	)	O
401	.	O
401	[SEP]	O
402	[CLS]	O
402	internal	O
402	##ized	O
402	fraction	B-PK
402	of	I-PK
402	radio	I-PK
402	##act	I-PK
402	##ivity	I-PK
402	was	O
402	determined	O
402	after	O
402	l	O
402	##ys	O
402	##ing	O
402	the	O
402	cells	O
402	with	O
402	rip	O
402	##a	O
402	buffer	O
402	.	O
402	[SEP]	O
403	[CLS]	O
403	median	O
403	plasma	O
403	a	O
403	##g	O
403	##10	O
403	‐	O
403	a	O
403	##g	O
403	t	B-PK
403	##max	I-PK
403	was	O
403	1	O
403	hour	O
403	across	O
403	all	O
403	dose	O
403	levels	O
403	.	O
403	[SEP]	O
404	[CLS]	O
404	these	O
404	results	O
404	suggest	O
404	that	O
404	combining	O
404	the	O
404	simplified	O
404	in	O
404	##test	O
404	##inal	O
404	availability	O
404	model	O
404	and	O
404	in	O
404	v	O
404	##it	O
404	##ro	O
404	con	O
404	##ju	O
404	##gation	O
404	ass	O
404	##ay	O
404	make	O
404	it	O
404	possible	O
404	to	O
404	predict	O
404	human	O
404	f	B-PK
404	(	I-PK
404	a	I-PK
404	)	I-PK
404	f	B-PK
404	(	I-PK
404	g	I-PK
404	)	I-PK
404	regardless	O
404	of	O
404	u	O
404	##gt	O
404	is	O
404	##of	O
404	##orm	O
404	.	O
404	[SEP]	O
405	[CLS]	O
405	the	O
405	median	O
405	plasma	B-PK
405	equivalent	I-PK
405	space	I-PK
405	was	O
405	found	O
405	to	O
405	be	O
405	15	O
405	.	O
405	9	O
405	l	O
405	.	O
405	/	O
405	m	O
405	##2	O
405	,	O
405	and	O
405	volume	B-PK
405	of	I-PK
405	distribution	I-PK
405	at	I-PK
405	steady	I-PK
405	state	I-PK
405	was	O
405	40	O
405	.	O
405	2	O
405	l	O
405	.	O
405	/	O
405	m	O
405	##2	O
405	.	O
405	[SEP]	O
406	[CLS]	O
406	the	O
406	in	O
406	v	O
406	##ivo	O
406	apparent	B-PK
406	clearance	I-PK
406	##s	I-PK
406	of	O
406	these	O
406	compounds	O
406	increase	O
406	with	O
406	dose	O
406	.	O
406	[SEP]	O
407	[CLS]	O
407	patient	O
407	1	O
407	was	O
407	given	O
407	ran	O
407	##iti	O
407	##dine	O
407	once	O
407	or	O
407	twice	O
407	daily	O
407	(	O
407	table	O
407	1	O
407	)	O
407	.	O
407	[SEP]	O
408	[CLS]	O
408	we	O
408	therefore	O
408	performed	O
408	a	O
408	systematic	O
408	study	O
408	to	O
408	identify	O
408	the	O
408	per	O
408	##me	O
408	##ation	O
408	properties	O
408	of	O
408	g	O
408	##eran	O
408	##iol	O
408	across	O
408	in	O
408	##test	O
408	##inal	O
408	cells	O
408	,	O
408	and	O
408	its	O
408	p	O
408	##har	O
408	##ma	O
408	##co	O
408	##kin	O
408	##etics	O
408	and	O
408	bio	B-PK
408	##ava	I-PK
408	##ila	I-PK
408	##bility	I-PK
408	after	O
408	in	O
408	##tra	O
408	##ven	O
408	##ous	O
408	and	O
408	oral	O
408	administration	O
408	to	O
408	rats	O
408	.	O
408	[SEP]	O
409	[CLS]	O
409	there	O
409	was	O
409	no	O
409	significant	O
409	change	O
409	in	O
409	area	B-PK
409	under	I-PK
409	the	I-PK
409	curve	I-PK
409	or	O
409	in	O
409	the	O
409	elimination	B-PK
409	half	I-PK
409	-	I-PK
409	life	I-PK
409	of	O
409	to	O
409	##l	O
409	##but	O
409	##ami	O
409	##de	O
409	.	O
409	[SEP]	O
410	[CLS]	O
410	the	O
410	au	B-PK
410	##cs	I-PK
410	observed	O
410	for	O
410	the	O
410	l	O
410	##h	O
410	-	O
410	types	O
410	were	O
410	1	O
410	.	O
410	8	O
410	times	O
410	those	O
410	of	O
410	the	O
410	h	O
410	##l	O
410	types	O
410	.	O
410	[SEP]	O
411	[CLS]	O
411	high	O
411	i	O
411	##ov	O
411	on	O
411	v	B-PK
411	##1	I-PK
411	was	O
411	observed	O
411	,	O
411	indicating	O
411	important	O
411	variation	O
411	in	O
411	v	B-PK
411	##1	I-PK
411	from	O
411	day	O
411	to	O
411	day	O
411	within	O
411	this	O
411	population	O
411	.	O
411	[SEP]	O
412	[CLS]	O
412	patient	O
412	demographic	O
412	##s	O
412	and	O
412	characteristics	O
412	are	O
412	presented	O
412	in	O
412	table	O
412	1	O
412	and	O
412	supplement	O
412	##ary	O
412	table	O
412	s	O
412	##1	O
412	.	O
412	[SEP]	O
413	[CLS]	O
413	previous	O
413	models	O
413	demonstrated	O
413	that	O
413	p	O
413	##k	O
413	parameters	O
413	in	O
413	neon	O
413	##ates	O
413	and	O
413	infants	O
413	were	O
413	comparable	O
413	to	O
413	adolescent	O
413	and	O
413	adult	O
413	populations	O
413	after	O
413	com	O
413	##pen	O
413	##sat	O
413	##ing	O
413	for	O
413	both	O
413	significantly	O
413	decreased	O
413	clearance	B-PK
413	and	O
413	longer	O
413	terminal	B-PK
413	elimination	I-PK
413	half	I-PK
413	‐	I-PK
413	life	I-PK
413	(	I-PK
413	t	I-PK
413	##1	I-PK
413	/	I-PK
413	2	I-PK
413	)	I-PK
413	.	O
413	[SEP]	O
414	[CLS]	O
414	the	O
414	area	B-PK
414	under	I-PK
414	the	I-PK
414	serum	I-PK
414	concentration	I-PK
414	-	I-PK
414	time	I-PK
414	curve	I-PK
414	(	I-PK
414	au	I-PK
414	##c	I-PK
414	)	I-PK
414	,	O
414	maximum	B-PK
414	serum	I-PK
414	concentration	I-PK
414	(	I-PK
414	c	I-PK
414	(	I-PK
414	ma	I-PK
414	##x	I-PK
414	)	I-PK
414	)	I-PK
414	,	O
414	time	B-PK
414	to	I-PK
414	reach	I-PK
414	the	I-PK
414	c	I-PK
414	(	I-PK
414	ma	I-PK
414	##x	I-PK
414	)	I-PK
414	(	I-PK
414	t	I-PK
414	(	I-PK
414	ma	I-PK
414	##x	I-PK
414	)	I-PK
414	)	I-PK
414	,	O
414	half	B-PK
414	-	I-PK
414	life	I-PK
414	(	I-PK
414	t	I-PK
414	(	I-PK
414	&	I-PK
414	f	I-PK
414	##rac	I-PK
414	##12	I-PK
414	;	I-PK
414	)	I-PK
414	)	I-PK
414	,	O
414	volume	B-PK
414	of	I-PK
414	distribution	I-PK
414	(	I-PK
414	v	I-PK
414	(	I-PK
414	d	I-PK
414	)	I-PK
414	)	I-PK
414	and	O
414	total	B-PK
414	clearance	I-PK
414	(	I-PK
414	c	I-PK
414	##l	I-PK
414	)	I-PK
414	were	O
414	calculated	O
414	.	O
414	[SEP]	O
415	[CLS]	O
415	clinical	O
415	and	O
415	##la	O
415	##bor	O
415	##atory	O
415	base	O
415	##line	O
415	characteristics	O
415	of	O
415	these	O
415	83	O
415	patients	O
415	s	O
415	##tra	O
415	##ti	O
415	##fied	O
415	according	O
415	to	O
415	v	O
415	##tl	O
415	##are	O
415	presented	O
415	in	O
415	table	O
415	1	O
415	.	O
415	[SEP]	O
416	[CLS]	O
416	the	O
416	geometric	O
416	mean	O
416	vs	B-PK
416	##s	I-PK
416	(	O
416	1	O
416	mg	O
416	/	O
416	kg	O
416	:	O
416	80	O
416	.	O
416	06	O
416	##2	O
416	m	O
416	##l	O
416	/	O
416	kg	O
416	and	O
416	10	O
416	mg	O
416	/	O
416	kg	O
416	:	O
416	76	O
416	.	O
416	217	O
416	m	O
416	##l	O
416	/	O
416	kg	O
416	)	O
416	is	O
416	about	O
416	twice	O
416	the	O
416	v	B-PK
416	##1	I-PK
416	(	O
416	1	O
416	mg	O
416	/	O
416	kg	O
416	:	O
416	48	O
416	.	O
416	85	O
416	##6	O
416	m	O
416	##l	O
416	/	O
416	kg	O
416	and	O
416	10	O
416	mg	O
416	/	O
416	kg	O
416	:	O
416	44	O
416	.	O
416	260	O
416	m	O
416	##l	O
416	/	O
416	kg	O
416	)	O
416	.	O
416	[SEP]	O
417	[CLS]	O
417	au	B-PK
417	##c	I-PK
417	##0	I-PK
417	-	I-PK
417	in	I-PK
417	##finity	I-PK
417	values	O
417	for	O
417	unchanged	O
417	c	O
417	##p	O
417	-	O
417	93	O
417	,	O
417	39	O
417	##3	O
417	were	O
417	also	O
417	greater	O
417	for	O
417	pm	O
417	##s	O
417	than	O
417	for	O
417	em	O
417	##s	O
417	,	O
417	whereas	O
417	the	O
417	mean	O
417	maximum	B-PK
417	plasma	I-PK
417	concentration	I-PK
417	and	O
417	au	B-PK
417	##c	I-PK
417	##0	I-PK
417	-	I-PK
417	in	I-PK
417	##finity	I-PK
417	values	O
417	for	O
417	total	B-PK
417	radio	I-PK
417	##act	I-PK
417	##ivity	I-PK
417	were	O
417	similar	O
417	for	O
417	the	O
417	two	O
417	p	O
417	##hen	O
417	##otype	O
417	##s	O
417	.	O
417	[SEP]	O
418	[CLS]	O
418	test	O
418	conditions	O
418	were	O
418	the	O
418	same	O
418	as	O
418	described	O
418	in	O
418	the	O
418	“	O
418	flu	O
418	##ores	O
418	##cence	O
418	properties	O
418	of	O
418	compound	O
418	f	O
418	”	O
418	section	O
418	.	O
418	[SEP]	O
419	[CLS]	O
419	these	O
419	showed	O
419	that	O
419	form	O
419	##ono	O
419	##net	O
419	##in	O
419	might	O
419	still	O
419	be	O
419	a	O
419	mainly	O
419	active	O
419	ingredient	O
419	that	O
419	we	O
419	can	O
419	detect	O
419	in	O
419	rat	O
419	plasma	O
419	.	O
419	[SEP]	O
420	[CLS]	O
420	i	O
420	##v	O
420	clearance	B-PK
420	and	O
420	volume	B-PK
420	of	I-PK
420	distribution	I-PK
420	were	O
420	16	O
420	.	O
420	8	O
420	l	O
420	/	O
420	h	O
420	and	O
420	128	O
420	##5	O
420	l	O
420	,	O
420	respectively	O
420	.	O
420	[SEP]	O
421	[CLS]	O
421	dynamic	O
421	(	O
421	18	O
421	)	O
421	f	O
421	-	O
421	fl	O
421	##t	O
421	pet	O
421	imaging	O
421	was	O
421	performed	O
421	for	O
421	60	O
421	min	O
421	in	O
421	g	O
421	##lio	O
421	##ma	O
421	-	O
421	bearing	O
421	mice	O
421	(	O
421	n	O
421	=	O
421	10	O
421	)	O
421	and	O
421	in	O
421	non	O
421	-	O
421	tumor	O
421	-	O
421	bearing	O
421	control	O
421	mice	O
421	(	O
421	n	O
421	=	O
421	4	O
421	)	O
421	by	O
421	use	O
421	of	O
421	a	O
421	dedicated	O
421	small	O
421	-	O
421	animal	O
421	pet	O
421	scan	O
421	##ner	O
421	.	O
421	[SEP]	O
422	[CLS]	O
422	a	O
422	group	O
422	of	O
422	17	O
422	patients	O
422	were	O
422	enrolled	O
422	in	O
422	this	O
422	trial	O
422	.	O
422	[SEP]	O
423	[CLS]	O
423	there	O
423	is	O
423	a	O
423	wealth	O
423	of	O
423	evidence	O
423	for	O
423	the	O
423	powerful	O
423	anti	O
423	##ox	O
423	##ida	O
423	##nt	O
423	properties	O
423	in	O
423	v	O
423	##it	O
423	##ro	O
423	of	O
423	fl	O
423	##av	O
423	##ono	O
423	##id	O
423	components	O
423	of	O
423	the	O
423	diet	O
423	.	O
423	[SEP]	O
424	[CLS]	O
424	a	O
424	##rip	O
424	##ip	O
424	##raz	O
424	##ole	O
424	decreases	O
424	b	O
424	##p	O
424	and	O
424	increases	O
424	h	O
424	##r	O
424	and	O
424	q	O
424	##t	O
424	##c	O
424	interval	O
424	.	O
424	[SEP]	O
425	[CLS]	O
425	overall	O
425	,	O
425	there	O
425	appears	O
425	to	O
425	be	O
425	a	O
425	p	O
425	##har	O
425	##ma	O
425	##co	O
425	##kin	O
425	##etic	O
425	-	O
425	p	O
425	##har	O
425	##ma	O
425	##co	O
425	##log	O
425	##ic	O
425	correlation	O
425	between	O
425	trim	O
425	##op	O
425	##ros	O
425	##til	O
425	plasma	O
425	concentrations	O
425	and	O
425	in	O
425	##hibition	O
425	of	O
425	gas	O
425	##tric	O
425	acid	O
425	secret	O
425	##ion	O
425	.	O
425	[SEP]	O
426	[CLS]	O
426	a	O
426	p	O
426	##har	O
426	##ma	O
426	##co	O
426	##kin	O
426	##etic	O
426	model	O
426	was	O
426	developed	O
426	using	O
426	non	O
426	##me	O
426	##m	O
426	based	O
426	on	O
426	208	O
426	plasma	O
426	and	O
426	51	O
426	urine	O
426	samples	O
426	from	O
426	20	O
426	i	O
426	##cu	O
426	patients	O
426	during	O
426	a	O
426	median	O
426	follow	O
426	-	O
426	up	O
426	of	O
426	3	O
426	days	O
426	.	O
426	[SEP]	O
427	[CLS]	O
427	al	O
427	##iq	O
427	##uo	O
427	##ts	O
427	of	O
427	200	O
427	μ	O
427	##l	O
427	of	O
427	6	O
427	%	O
427	perch	O
427	##lor	O
427	##ic	O
427	acid	O
427	were	O
427	added	O
427	into	O
427	the	O
427	300	O
427	μ	O
427	##l	O
427	of	O
427	blank	O
427	or	O
427	plasma	O
427	sample	O
427	in	O
427	a	O
427	1	O
427	.	O
427	5	O
427	m	O
427	##l	O
427	micro	O
427	##tub	O
427	##e	O
427	to	O
427	pre	O
427	##ci	O
427	##pit	O
427	##ate	O
427	the	O
427	protein	O
427	.	O
427	[SEP]	O
428	[CLS]	O
428	the	O
428	initial	O
428	pool	O
428	sizes	O
428	of	O
428	1	O
428	##pec	O
428	##d	O
428	##f	O
428	-	O
428	derived	O
428	radio	B-PK
428	##act	I-PK
428	##ivity	I-PK
428	in	O
428	the	O
428	liver	O
428	,	O
428	muscle	O
428	,	O
428	skin	O
428	,	O
428	and	O
428	ad	O
428	##ip	O
428	##ose	O
428	tissue	O
428	were	O
428	43	O
428	,	O
428	35	O
428	,	O
428	10	O
428	,	O
428	and	O
428	7	O
428	%	O
428	of	O
428	the	O
428	administered	O
428	dose	O
428	,	O
428	respectively	O
428	.	O
428	[SEP]	O
429	[CLS]	O
429	it	O
429	is	O
429	established	O
429	that	O
429	r	O
429	##u	O
429	-	O
429	120	O
429	##5	O
429	substance	O
429	has	O
429	high	O
429	bio	B-PK
429	##ava	I-PK
429	##ila	I-PK
429	##bility	I-PK
429	(	O
429	44	O
429	.	O
429	17	O
429	and	O
429	56	O
429	.	O
429	03	O
429	%	O
429	upon	O
429	per	O
429	##oral	O
429	and	O
429	sub	O
429	##cut	O
429	##aneous	O
429	introduction	O
429	,	O
429	respectively	O
429	)	O
429	.	O
429	[SEP]	O
430	[CLS]	O
430	however	O
430	,	O
430	one	O
430	place	O
430	##bo	O
430	-	O
430	treated	O
430	individual	O
430	had	O
430	a	O
430	“	O
430	pseudo	O
430	-	O
430	ex	O
430	##ace	O
430	##rb	O
430	##ation	O
430	”	O
430	starting	O
430	on	O
430	study	O
430	day	O
430	13	O
430	characterized	O
430	by	O
430	uh	O
430	##th	O
430	##off	O
430	’	O
430	s	O
430	phenomenon	O
430	lasting	O
430	45	O
430	days	O
430	,	O
430	coincide	O
430	##nt	O
430	with	O
430	onset	O
430	of	O
430	a	O
430	u	O
430	##rina	O
430	##ry	O
430	tract	O
430	infection	O
430	for	O
430	two	O
430	weeks	O
430	and	O
430	an	O
430	overlapping	O
430	period	O
430	of	O
430	blurred	O
430	v	O
430	##ison	O
430	from	O
430	study	O
430	days	O
430	29	O
430	–	O
430	169	O
430	.	O
430	[SEP]	O
431	[CLS]	O
431	for	O
431	c	O
431	##26	O
431	##h	O
431	##22	O
431	##n	O
431	##8	O
431	##o	O
431	##6	O
431	##s	O
431	##2	O
431	:	O
431	c	O
431	,	O
431	51	O
431	.	O
431	48	O
431	;	O
431	h	O
431	,	O
431	3	O
431	.	O
431	66	O
431	;	O
431	n	O
431	,	O
431	18	O
431	.	O
431	47	O
431	;	O
431	s	O
431	,	O
431	10	O
431	.	O
431	57	O
431	;	O
431	found	O
431	:	O
431	c	O
431	,	O
431	51	O
431	.	O
431	42	O
431	;	O
431	h	O
431	,	O
431	3	O
431	.	O
431	64	O
431	;	O
431	n	O
431	,	O
431	18	O
431	.	O
431	43	O
431	;	O
431	s	O
431	,	O
431	10	O
431	.	O
431	52	O
431	.	O
431	[SEP]	O
432	[CLS]	O
432	this	O
432	study	O
432	establishes	O
432	that	O
432	a	O
432	dose	O
432	-	O
432	es	O
432	##cal	O
432	##ation	O
432	strategy	O
432	for	O
432	improving	O
432	b	O
432	##c	O
432	##nu	O
432	controlled	O
432	-	O
432	release	O
432	polymer	O
432	##s	O
432	is	O
432	more	O
432	effective	O
432	than	O
432	adjusting	O
432	the	O
432	ratio	O
432	of	O
432	c	O
432	##pp	O
432	to	O
432	sa	O
432	to	O
432	pro	O
432	##long	O
432	drug	O
432	release	O
432	.	O
432	[SEP]	O
433	[CLS]	O
433	once	O
433	a	O
433	potential	O
433	participant	O
433	was	O
433	identified	O
433	,	O
433	a	O
433	parent	O
433	was	O
433	counsel	O
433	##led	O
433	in	O
433	the	O
433	presence	O
433	of	O
433	a	O
433	senior	O
433	staff	O
433	nurse	O
433	,	O
433	and	O
433	informed	O
433	written	O
433	consent	O
433	was	O
433	obtained	O
433	.	O
433	[SEP]	O
434	[CLS]	O
434	p	O
434	##har	O
434	##ma	O
434	##co	O
434	##kin	O
434	##etics	O
434	of	O
434	c	O
434	##ef	O
434	##uro	O
434	##xi	O
434	##me	O
434	was	O
434	studied	O
434	in	O
434	patients	O
434	on	O
434	continuous	O
434	am	O
434	##bula	O
434	##tory	O
434	or	O
434	intermittent	O
434	per	O
434	##ito	O
434	##nea	O
434	##l	O
434	dial	O
434	##ys	O
434	##is	O
434	.	O
434	[SEP]	O
435	[CLS]	O
435	a	O
435	##v	O
435	##s	O
435	were	O
435	scored	O
435	by	O
435	2	O
435	independent	O
435	investigators	O
435	who	O
435	were	O
435	blinded	O
435	to	O
435	treatment	O
435	time	O
435	points	O
435	.	O
435	[SEP]	O
436	[CLS]	O
436	ch	O
436	##em	O
436	##otherapy	O
436	was	O
436	delivered	O
436	as	O
436	outlined	O
436	in	O
436	table	O
436	1	O
436	,	O
436	case	O
436	1	O
436	.	O
436	[SEP]	O
437	[CLS]	O
437	for	O
437	bio	O
437	-	O
437	distribution	O
437	of	O
437	g	O
437	##d	O
437	and	O
437	g	O
437	##d	O
437	-	O
437	t	O
437	##s	O
437	##ln	O
437	##ps	O
437	as	O
437	shown	O
437	in	O
437	fi	O
437	##g	O
437	9	O
437	##a	O
437	,	O
437	the	O
437	delivery	O
437	of	O
437	g	O
437	##d	O
437	through	O
437	t	O
437	##s	O
437	##ln	O
437	##p	O
437	into	O
437	liver	O
437	,	O
437	s	O
437	##ple	O
437	##en	O
437	or	O
437	lung	O
437	was	O
437	significantly	O
437	high	O
437	compared	O
437	with	O
437	g	O
437	##d	O
437	alone	O
437	.	O
437	[SEP]	O
438	[CLS]	O
438	to	O
438	minimize	O
438	the	O
438	risk	O
438	of	O
438	treatment	O
438	failures	O
438	,	O
438	toxic	O
438	##ities	O
438	,	O
438	and	O
438	other	O
438	drug	O
438	‐	O
438	related	O
438	adverse	O
438	events	O
438	often	O
438	associated	O
438	with	O
438	off	O
438	‐	O
438	label	O
438	p	O
438	##ediatric	O
438	dos	O
438	##ing	O
438	,	O
438	regulatory	O
438	agencies	O
438	now	O
438	require	O
438	sponsors	O
438	to	O
438	submit	O
438	p	O
438	##ediatric	O
438	trial	O
438	plans	O
438	at	O
438	the	O
438	end	O
438	of	O
438	the	O
438	phase	O
438	ii	O
438	study	O
438	(	O
438	following	O
438	the	O
438	availability	O
438	of	O
438	exposure	O
438	‐	O
438	response	O
438	data	O
438	in	O
438	adults	O
438	)	O
438	and	O
438	prior	O
438	to	O
438	the	O
438	initiation	O
438	of	O
438	phase	O
438	ii	O
438	##i	O
438	studies	O
438	as	O
438	part	O
438	of	O
438	new	O
438	drug	O
438	approval	O
438	.	O
438	[SEP]	O
439	[CLS]	O
439	in	O
439	addition	O
439	,	O
439	in	O
439	pro	O
439	##ges	O
439	##tero	O
439	##ne	O
439	-	O
439	treated	O
439	rats	O
439	,	O
439	levels	O
439	of	O
439	ben	O
439	##zo	O
439	##yle	O
439	##c	O
439	##gon	O
439	##ine	O
439	and	O
439	e	O
439	##c	O
439	##gon	O
439	##ine	O
439	met	O
439	##hyl	O
439	##ester	O
439	were	O
439	higher	O
439	at	O
439	30	O
439	min	O
439	post	O
439	-	O
439	administration	O
439	than	O
439	at	O
439	15	O
439	min	O
439	.	O
439	[SEP]	O
440	[CLS]	O
440	ha	O
440	##em	O
440	##oly	O
440	##ticus	O
440	was	O
440	less	O
440	rapid	O
440	and	O
440	marked	O
440	than	O
440	against	O
440	s	O
440	##ta	O
440	##ph	O
440	.	O
440	[SEP]	O
441	[CLS]	O
441	following	O
441	oral	O
441	administration	O
441	of	O
441	mon	O
441	##tel	O
441	##uka	O
441	##st	O
441	sodium	O
441	,	O
441	10	O
441	mg	O
441	d	O
441	-	O
441	1	O
441	(	O
441	the	O
441	therapeutic	O
441	regime	O
441	##n	O
441	for	O
441	mon	O
441	##tel	O
441	##uka	O
441	##st	O
441	sodium	O
441	)	O
441	for	O
441	7	O
441	d	O
441	,	O
441	there	O
441	was	O
441	little	O
441	difference	O
441	in	O
441	the	O
441	plasma	O
441	concentration	O
441	-	O
441	time	O
441	profiles	O
441	of	O
441	mon	O
441	##tel	O
441	##uka	O
441	##st	O
441	in	O
441	young	O
441	subjects	O
441	between	O
441	day	O
441	1	O
441	and	O
441	day	O
441	7	O
441	dos	O
441	##ing	O
441	.	O
441	[SEP]	O
442	[CLS]	O
442	the	O
442	risk	O
442	for	O
442	other	O
442	a	O
442	##es	O
442	did	O
442	not	O
442	significantly	O
442	differ	O
442	between	O
442	treatment	O
442	groups	O
442	;	O
442	however	O
442	,	O
442	de	O
442	##ute	O
442	##tra	O
442	##ben	O
442	##azi	O
442	##ne	O
442	was	O
442	associated	O
442	with	O
442	numerical	O
442	##ly	O
442	lower	O
442	risk	O
442	of	O
442	most	O
442	of	O
442	these	O
442	a	O
442	##es	O
442	compared	O
442	with	O
442	te	O
442	##tra	O
442	##ben	O
442	##azi	O
442	##ne	O
442	,	O
442	except	O
442	for	O
442	coughing	O
442	and	O
442	di	O
442	##ar	O
442	##r	O
442	##hea	O
442	.	O
442	[SEP]	O
443	[CLS]	O
443	although	O
443	sub	O
443	##cellular	O
443	fraction	O
443	##s	O
443	were	O
443	pro	O
443	##cure	O
443	##d	O
443	for	O
443	multiple	O
443	organs	O
443	,	O
443	only	O
443	the	O
443	liver	O
443	had	O
443	all	O
443	three	O
443	fraction	O
443	##s	O
443	(	O
443	c	O
443	##yt	O
443	##oso	O
443	##lic	O
443	,	O
443	micro	O
443	##so	O
443	##mal	O
443	,	O
443	and	O
443	s	O
443	##9	O
443	)	O
443	available	O
443	.	O
443	[SEP]	O
444	[CLS]	O
444	the	O
444	clinical	O
444	study	O
444	was	O
444	performed	O
444	in	O
444	accordance	O
444	with	O
444	the	O
444	principles	O
444	stated	O
444	in	O
444	the	O
444	1964	O
444	he	O
444	##ls	O
444	##ink	O
444	##i	O
444	declaration	O
444	and	O
444	its	O
444	subsequent	O
444	amendments	O
444	,	O
444	good	O
444	clinical	O
444	practices	O
444	(	O
444	g	O
444	##c	O
444	##p	O
444	;	O
444	c	O
444	##pm	O
444	##p	O
444	/	O
444	i	O
444	##ch	O
444	/	O
444	135	O
444	‐	O
444	95	O
444	)	O
444	for	O
444	trials	O
444	on	O
444	medicinal	O
444	products	O
444	and	O
444	with	O
444	h	O
444	##uri	O
444	##et	O
444	law	O
444	of	O
444	20	O
444	de	O
444	##ce	O
444	##mber	O
444	1988	O
444	,	O
444	relating	O
444	to	O
444	the	O
444	protection	O
444	of	O
444	individuals	O
444	involved	O
444	in	O
444	bio	O
444	##medical	O
444	research	O
444	in	O
444	f	O
444	##rance	O
444	and	O
444	its	O
444	subsequent	O
444	amendments	O
444	.	O
444	[SEP]	O
445	[CLS]	O
445	the	O
445	p	O
445	##eg	O
445	##yla	O
445	##ted	O
445	lip	O
445	##oso	O
445	##me	O
445	exhibited	O
445	excellent	O
445	co	O
445	##llo	O
445	##idal	O
445	stability	O
445	and	O
445	was	O
445	able	O
445	to	O
445	retain	O
445	drugs	O
445	en	O
445	##cap	O
445	##sul	O
445	##ated	O
445	,	O
445	which	O
445	were	O
445	released	O
445	in	O
445	a	O
445	slow	O
445	and	O
445	sustained	O
445	fashion	O
445	.	O
445	[SEP]	O
446	[CLS]	O
446	a	O
446	population	O
446	p	O
446	##har	O
446	##ma	O
446	##co	O
446	##kin	O
446	##etic	O
446	model	O
446	was	O
446	developed	O
446	to	O
446	investigate	O
446	the	O
446	effects	O
446	of	O
446	pregnancy	O
446	on	O
446	r	O
446	##if	O
446	##amp	O
446	##in	O
446	p	O
446	##har	O
446	##ma	O
446	##co	O
446	##kin	O
446	##etics	O
446	.	O
446	[SEP]	O
447	[CLS]	O
447	in	O
447	addition	O
447	,	O
447	these	O
447	differential	O
447	##ly	O
447	abundant	O
447	proteins	O
447	were	O
447	related	O
447	to	O
447	a	O
447	variety	O
447	of	O
447	bio	O
447	##film	O
447	structures	O
447	,	O
447	suggesting	O
447	that	O
447	as	O
447	extract	O
447	could	O
447	maintain	O
447	the	O
447	stability	O
447	of	O
447	mouse	O
447	brain	O
447	cells	O
447	’	O
447	metabolism	O
447	,	O
447	control	O
447	substances	O
447	into	O
447	and	O
447	out	O
447	of	O
447	brain	O
447	cells	O
447	,	O
447	and	O
447	play	O
447	essential	O
447	roles	O
447	in	O
447	cell	O
447	recognition	O
447	,	O
447	cell	O
447	##ula	O
447	##se	O
447	synthesis	O
447	,	O
447	or	O
447	other	O
447	functions	O
447	.	O
447	[SEP]	O
448	[CLS]	O
448	in	O
448	all	O
448	cases	O
448	car	O
448	##bo	O
448	##p	O
448	##lat	O
448	##in	O
448	was	O
448	administered	O
448	di	O
448	##lut	O
448	##ed	O
448	in	O
448	5	O
448	%	O
448	de	O
448	##x	O
448	##tro	O
448	##se	O
448	as	O
448	a	O
448	60	O
448	min	O
448	in	O
448	##tra	O
448	##ven	O
448	##ous	O
448	in	O
448	##fusion	O
448	.	O
448	[SEP]	O
449	[CLS]	O
449	the	O
449	elimination	B-PK
449	half	I-PK
449	-	I-PK
449	life	I-PK
449	(	I-PK
449	t	I-PK
449	(	I-PK
449	1	I-PK
449	/	I-PK
449	2	I-PK
449	##bet	I-PK
449	##a	I-PK
449	)	I-PK
449	)	I-PK
449	of	O
449	f	O
449	##x	O
449	was	O
449	longer	O
449	in	O
449	ducks	O
449	than	O
449	in	O
449	br	O
449	##oil	O
449	##ers	O
449	.	O
449	[SEP]	O
450	[CLS]	O
450	[	O
450	pharmaceutical	O
450	properties	O
450	of	O
450	r	O
450	##ik	O
450	##ku	O
450	##ns	O
450	##hit	O
450	##o	O
450	extract	O
450	su	O
450	##pp	O
450	##os	O
450	##itor	O
450	##y	O
450	and	O
450	bio	O
450	##e	O
450	##qui	O
450	##valence	O
450	by	O
450	p	O
450	##har	O
450	##ma	O
450	##co	O
450	##kin	O
450	##etic	O
450	parameters	O
450	and	O
450	effectiveness	O
450	against	O
450	nausea	O
450	and	O
450	vomit	O
450	##ing	O
450	and	O
450	an	O
450	##ore	O
450	##xia	O
450	in	O
450	rats	O
450	]	O
450	.	O
450	[SEP]	O
451	[CLS]	O
451	in	O
451	addition	O
451	,	O
451	on	O
451	imaging	O
451	,	O
451	non	O
451	##tar	O
451	##get	O
451	em	O
451	##bol	O
451	##ization	O
451	and	O
451	other	O
451	potential	O
451	complications	O
451	were	O
451	recorded	O
451	,	O
451	including	O
451	as	O
451	##cite	O
451	##s	O
451	,	O
451	p	O
451	##le	O
451	##ural	O
451	fluid	O
451	,	O
451	gal	O
451	##l	O
451	##bla	O
451	##dder	O
451	wall	O
451	thick	O
451	##ening	O
451	,	O
451	and	O
451	presence	O
451	of	O
451	bi	O
451	##lo	O
451	##mas	O
451	or	O
451	a	O
451	##bs	O
451	##cess	O
451	##es	O
451	.	O
451	[SEP]	O
452	[CLS]	O
452	five	O
452	to	O
452	nine	O
452	hundred	O
452	-	O
452	fold	O
452	lower	O
452	concentrations	O
452	of	O
452	t	O
452	##ro	O
452	##xa	O
452	##ci	O
452	##ta	O
452	##bine	O
452	were	O
452	required	O
452	to	O
452	in	O
452	##hibit	O
452	cell	O
452	growth	O
452	in	O
452	human	O
452	compared	O
452	with	O
452	m	O
452	##uri	O
452	##ne	O
452	tumor	O
452	and	O
452	normal	O
452	hem	O
452	##ap	O
452	##oi	O
452	##etic	O
452	cell	O
452	lines	O
452	.	O
452	[SEP]	O
453	[CLS]	O
453	z	O
453	##ile	O
453	##uto	O
453	##n	O
453	,	O
453	a	O
453	5	O
453	-	O
453	lip	O
453	##ox	O
453	##y	O
453	##gen	O
453	##ase	O
453	inhibitor	O
453	,	O
453	was	O
453	evaluated	O
453	as	O
453	an	O
453	inhibitor	O
453	of	O
453	c	O
453	##yt	O
453	##och	O
453	##rome	O
453	p	O
453	##45	O
453	##0	O
453	activity	O
453	in	O
453	human	O
453	liver	O
453	micro	O
453	##some	O
453	##s	O
453	.	O
453	[SEP]	O
454	[CLS]	O
454	for	O
454	all	O
454	study	O
454	e	O
454	##c	O
454	##gs	O
454	(	O
454	periods	O
454	1	O
454	-	O
454	4	O
454	)	O
454	,	O
454	the	O
454	over	O
454	-	O
454	reading	O
454	card	O
454	##iol	O
454	##ogist	O
454	##s	O
454	were	O
454	blinded	O
454	to	O
454	time	O
454	,	O
454	date	O
454	,	O
454	treatment	O
454	and	O
454	any	O
454	data	O
454	identifying	O
454	the	O
454	subject	O
454	.	O
454	[SEP]	O
455	[CLS]	O
455	half	B-PK
455	-	I-PK
455	life	I-PK
455	was	O
455	slightly	O
455	,	O
455	but	O
455	statistical	O
455	##ly	O
455	significantly	O
455	shorter	O
455	in	O
455	j	O
455	##apa	O
455	##nese	O
455	than	O
455	in	O
455	ca	O
455	##uca	O
455	##sian	O
455	subjects	O
455	following	O
455	single	O
455	dose	O
455	:	O
455	ratios	O
455	(	O
455	95	O
455	%	O
455	c	O
455	##i	O
455	)	O
455	were	O
455	0	O
455	.	O
455	68	O
455	(	O
455	0	O
455	.	O
455	61	O
455	-	O
455	0	O
455	.	O
455	77	O
455	)	O
455	for	O
455	single	O
455	dose	O
455	,	O
455	and	O
455	1	O
455	.	O
455	00	O
455	(	O
455	0	O
455	.	O
455	79	O
455	-	O
455	1	O
455	.	O
455	26	O
455	)	O
455	for	O
455	multiple	O
455	dose	O
455	.	O
455	[SEP]	O
456	[CLS]	O
456	the	O
456	aim	O
456	of	O
456	this	O
456	study	O
456	was	O
456	to	O
456	assess	O
456	the	O
456	population	O
456	p	O
456	##har	O
456	##ma	O
456	##co	O
456	##kin	O
456	##etics	O
456	(	O
456	p	O
456	##k	O
456	)	O
456	of	O
456	in	O
456	##tra	O
456	##ven	O
456	##ous	O
456	p	O
456	##oly	O
456	##my	O
456	##xin	O
456	b	O
456	in	O
456	patients	O
456	with	O
456	variable	O
456	total	O
456	body	O
456	weights	O
456	and	O
456	create	O
456	a	O
456	population	O
456	model	O
456	for	O
456	clinical	O
456	use	O
456	.	O
456	[SEP]	O
457	[CLS]	O
457	in	O
457	contrast	O
457	,	O
457	do	O
457	##xy	O
457	##cy	O
457	##cline	O
457	pre	O
457	-	O
457	treatment	O
457	increased	O
457	the	O
457	sensitivity	O
457	of	O
457	c	O
457	##s	O
457	##cs	O
457	to	O
457	radiation	O
457	by	O
457	up	O
457	to	O
457	4	O
457	.	O
457	5	O
457	-	O
457	fold	O
457	.	O
457	[SEP]	O
458	[CLS]	O
458	after	O
458	this	O
458	method	O
458	was	O
458	proven	O
458	to	O
458	be	O
458	applicable	O
458	in	O
458	the	O
458	detection	O
458	of	O
458	b	O
458	##hm	O
458	##c	O
458	in	O
458	rat	O
458	plasma	O
458	by	O
458	giving	O
458	accurate	O
458	and	O
458	precise	O
458	results	O
458	,	O
458	it	O
458	will	O
458	be	O
458	further	O
458	applied	O
458	in	O
458	future	O
458	research	O
458	to	O
458	determine	O
458	the	O
458	absolute	B-PK
458	bio	I-PK
458	##ava	I-PK
458	##ila	I-PK
458	##bility	I-PK
458	,	O
458	as	O
458	well	O
458	as	O
458	the	O
458	metabolism	O
458	,	O
458	distribution	O
458	and	O
458	ex	O
458	##cre	O
458	##tion	O
458	of	O
458	b	O
458	##hm	O
458	##c	O
458	in	O
458	rats	O
458	to	O
458	give	O
458	a	O
458	thorough	O
458	overview	O
458	on	O
458	the	O
458	p	O
458	##har	O
458	##ma	O
458	##co	O
458	##kin	O
458	##etic	O
458	profile	O
458	of	O
458	b	O
458	##hm	O
458	##c	O
458	since	O
458	the	O
458	major	O
458	problems	O
458	of	O
458	cu	O
458	##rc	O
458	##umi	O
458	##n	O
458	are	O
458	associated	O
458	with	O
458	its	O
458	rapid	O
458	clearance	B-PK
458	from	O
458	the	O
458	body	O
458	and	O
458	low	O
458	bio	B-PK
458	##ava	I-PK
458	##ila	I-PK
458	##bility	I-PK
458	in	O
458	plasma	O
458	.	O
458	[SEP]	O
459	[CLS]	O
459	this	O
459	facilitate	O
459	##s	O
459	relatively	O
459	straightforward	O
459	##st	O
459	##ructural	O
459	characterization	O
459	by	O
459	nm	O
459	##r	O
459	s	O
459	##pect	O
459	##ros	O
459	##copy	O
459	.	O
459	[SEP]	O
460	[CLS]	O
460	these	O
460	data	O
460	support	O
460	the	O
460	use	O
460	of	O
460	single	O
460	-	O
460	dose	O
460	lip	O
460	##eg	O
460	##fi	O
460	##l	O
460	##gra	O
460	##st	O
460	##im	O
460	6	O
460	mg	O
460	in	O
460	subsequent	O
460	phase	O
460	ii	O
460	##i	O
460	trials	O
460	as	O
460	prop	O
460	##hyl	O
460	##actic	O
460	treatment	O
460	for	O
460	patients	O
460	receiving	O
460	my	O
460	##elo	O
460	##su	O
460	##pp	O
460	##ress	O
460	##ive	O
460	ch	O
460	##em	O
460	##otherapy	O
460	.	O
460	[SEP]	O
461	[CLS]	O
461	in	O
461	subjects	O
461	with	O
461	moderate	O
461	re	O
461	##nal	O
461	imp	O
461	##air	O
461	##ment	O
461	,	O
461	the	O
461	g	O
461	##me	O
461	##an	O
461	au	B-PK
461	##c	I-PK
461	##last	I-PK
461	of	O
461	94	O
461	##8	O
461	ng	O
461	·	O
461	h	O
461	/	O
461	m	O
461	##l	O
461	was	O
461	slightly	O
461	increased	O
461	compared	O
461	with	O
461	the	O
461	value	O
461	of	O
461	77	O
461	##6	O
461	ng	O
461	·	O
461	h	O
461	/	O
461	m	O
461	##l	O
461	in	O
461	matched	O
461	healthy	O
461	controls	O
461	;	O
461	g	O
461	##me	O
461	##an	O
461	cm	B-PK
461	##ax	I-PK
461	values	O
461	were	O
461	similar	O
461	at	O
461	28	O
461	.	O
461	7	O
461	and	O
461	28	O
461	.	O
461	4	O
461	ng	O
461	/	O
461	m	O
461	##l	O
461	,	O
461	respectively	O
461	.	O
461	[SEP]	O
462	[CLS]	O
462	the	O
462	op	O
462	##ti	O
462	##mized	O
462	oral	O
462	films	O
462	were	O
462	almost	O
462	neutral	O
462	to	O
462	eliminate	O
462	any	O
462	possibility	O
462	of	O
462	irritation	O
462	to	O
462	the	O
462	b	O
462	##uc	O
462	##cal	O
462	m	O
462	##uc	O
462	##osa	O
462	during	O
462	administration	O
462	.	O
462	[SEP]	O
463	[CLS]	O
463	p	O
463	##har	O
463	##ma	O
463	##co	O
463	##kin	O
463	##etic	O
463	studies	O
463	of	O
463	a	O
463	single	O
463	oral	O
463	dose	O
463	of	O
463	u	O
463	##bs	O
463	##10	O
463	##9	O
463	in	O
463	mice	O
463	revealed	O
463	that	O
463	peak	B-PK
463	plasma	I-PK
463	concentrations	I-PK
463	were	O
463	reached	O
463	at	O
463	0	O
463	.	O
463	5	O
463	hours	O
463	post	O
463	-	O
463	dose	O
463	(	O
463	t	B-PK
463	##max	I-PK
463	)	O
463	with	O
463	average	B-PK
463	plasma	I-PK
463	concentrations	I-PK
463	(	I-PK
463	cm	I-PK
463	##ax	I-PK
463	)	I-PK
463	of	O
463	131	O
463	and	O
463	248	O
463	ng	O
463	/	O
463	m	O
463	##l	O
463	for	O
463	oral	O
463	doses	O
463	of	O
463	50	O
463	and	O
463	150	O
463	mg	O
463	/	O
463	kg	O
463	,	O
463	respectively	O
463	.	O
463	[SEP]	O
464	[CLS]	O
464	the	O
464	p	O
464	##har	O
464	##ma	O
464	##co	O
464	##kin	O
464	##etic	O
464	profiles	O
464	of	O
464	me	O
464	##lo	O
464	##xi	O
464	##cam	O
464	following	O
464	an	O
464	oral	O
464	administration	O
464	of	O
464	me	O
464	##lo	O
464	##xi	O
464	##cam	O
464	or	O
464	its	O
464	ethanol	O
464	##amine	O
464	salts	O
464	were	O
464	also	O
464	evaluated	O
464	in	O
464	rats	O
464	.	O
464	[SEP]	O
465	[CLS]	O
465	treatment	O
465	via	O
465	this	O
465	regime	O
465	##n	O
465	resulted	O
465	in	O
465	complete	O
465	re	O
465	##gression	O
465	of	O
465	the	O
465	tumor	O
465	in	O
465	all	O
465	animals	O
465	by	O
465	day	O
465	22	O
465	;	O
465	complete	O
465	re	O
465	##gression	O
465	(	O
465	c	O
465	##r	O
465	)	O
465	occurred	O
465	in	O
465	4	O
465	of	O
465	6	O
465	treated	O
465	animals	O
465	within	O
465	31	O
465	days	O
465	of	O
465	post	O
465	-	O
465	treatment	O
465	observation	O
465	(	O
465	fi	O
465	##g	O
465	.	O
465	6	O
465	##a	O
465	)	O
465	.	O
465	[SEP]	O
466	[CLS]	O
466	regardless	O
466	of	O
466	the	O
466	optimal	O
466	ratio	O
466	selected	O
466	,	O
466	g	O
466	##ati	O
466	##f	O
466	##lo	O
466	##xa	O
466	##cin	O
466	had	O
466	a	O
466	higher	O
466	probability	O
466	of	O
466	achieving	O
466	the	O
466	au	B-PK
466	##c	I-PK
466	:	I-PK
466	mi	I-PK
466	##c	I-PK
466	target	O
466	than	O
466	did	O
466	le	O
466	##vo	O
466	##f	O
466	##lo	O
466	##xa	O
466	##cin	O
466	.	O
466	[SEP]	O
467	[CLS]	O
467	in	O
467	this	O
467	study	O
467	,	O
467	we	O
467	directly	O
467	incorporated	O
467	a	O
467	p	O
467	##ediatric	O
467	co	O
467	##var	O
467	##iate	O
467	model	O
467	for	O
467	the	O
467	g	O
467	##lu	O
467	##cu	O
467	##ron	O
467	##ida	O
467	##tion	O
467	of	O
467	m	O
467	##or	O
467	##phine	O
467	into	O
467	a	O
467	p	O
467	##ediatric	O
467	population	O
467	model	O
467	for	O
467	z	O
467	##ido	O
467	##vu	O
467	##dine	O
467	g	O
467	##lu	O
467	##cu	O
467	##ron	O
467	##ida	O
467	##tion	O
467	.	O
467	[SEP]	O
468	[CLS]	O
468	the	O
468	n	O
468	##s	O
468	##5	O
468	##b	O
468	s	O
468	##28	O
468	##2	O
468	##t	O
468	amino	O
468	acid	O
468	substitution	O
468	,	O
468	associated	O
468	with	O
468	al	O
468	-	O
468	335	O
468	in	O
468	v	O
468	##it	O
468	##ro	O
468	resistance	O
468	,	O
468	was	O
468	not	O
468	observed	O
468	by	O
468	sang	O
468	##er	O
468	population	O
468	se	O
468	##quencing	O
468	in	O
468	any	O
468	of	O
468	the	O
468	subjects	O
468	,	O
468	either	O
468	at	O
468	base	O
468	##line	O
468	or	O
468	emerging	O
468	at	O
468	the	O
468	end	O
468	of	O
468	dos	O
468	##ing	O
468	or	O
468	at	O
468	the	O
468	end	O
468	of	O
468	follow	O
468	-	O
468	up	O
468	(	O
468	day	O
468	21	O
468	)	O
468	.	O
468	[SEP]	O
469	[CLS]	O
469	strict	O
469	ad	O
469	##herence	O
469	to	O
469	the	O
469	university	O
469	of	O
469	lo	O
469	##ui	O
469	##sville	O
469	institutional	O
469	animal	O
469	care	O
469	and	O
469	use	O
469	committee	O
469	(	O
469	i	O
469	##ac	O
469	##uc	O
469	111	O
469	##10	O
469	)	O
469	approved	O
469	protocol	O
469	was	O
469	maintained	O
469	.	O
469	[SEP]	O
470	[CLS]	O
470	the	O
470	patches	O
470	consisted	O
470	of	O
470	1	O
470	)	O
470	the	O
470	backing	O
470	layer	O
470	made	O
470	of	O
470	a	O
470	water	O
470	-	O
470	ins	O
470	##ol	O
470	##ub	O
470	##le	O
470	polymer	O
470	,	O
470	2	O
470	)	O
470	the	O
470	drug	O
470	-	O
470	carrying	O
470	layer	O
470	composed	O
470	of	O
470	ca	O
470	##ffe	O
470	##ine	O
470	and	O
470	a	O
470	gel	O
470	-	O
470	forming	O
470	polymer	O
470	,	O
470	and	O
470	3	O
470	)	O
470	the	O
470	enter	O
470	##ic	O
470	polymer	O
470	membrane	O
470	.	O
470	[SEP]	O
471	[CLS]	O
471	the	O
471	outcomes	O
471	of	O
471	this	O
471	animal	O
471	study	O
471	are	O
471	expected	O
471	to	O
471	serve	O
471	as	O
471	a	O
471	basis	O
471	for	O
471	development	O
471	of	O
471	clinical	O
471	guidelines	O
471	on	O
471	total	O
471	p	O
471	##eon	O
471	##y	O
471	g	O
471	##lu	O
471	##cos	O
471	##ides	O
471	usage	O
471	.	O
471	[SEP]	O
472	[CLS]	O
472	is	O
472	##onia	O
472	##zi	O
472	##d	O
472	,	O
472	r	O
472	##if	O
472	##amp	O
472	##in	O
472	,	O
472	et	O
472	##ham	O
472	##but	O
472	##ol	O
472	,	O
472	and	O
472	p	O
472	##yra	O
472	##zin	O
472	##ami	O
472	##de	O
472	p	O
472	##har	O
472	##ma	O
472	##co	O
472	##kin	O
472	##etics	O
472	and	O
472	treatment	O
472	outcomes	O
472	among	O
472	a	O
472	predominantly	O
472	hi	O
472	##v	O
472	-	O
472	infected	O
472	co	O
472	##hor	O
472	##t	O
472	of	O
472	adults	O
472	with	O
472	tuberculosis	O
472	from	O
472	b	O
472	##ots	O
472	##wana	O
472	.	O
472	[SEP]	O
473	[CLS]	O
473	the	O
473	other	O
473	α	O
473	‐	O
473	ad	O
473	##rene	O
473	##rg	O
473	##ic	O
473	receptor	O
473	block	O
473	##er	O
473	that	O
473	has	O
473	been	O
473	used	O
473	during	O
473	pregnancy	O
473	is	O
473	p	O
473	##hen	O
473	##ox	O
473	##y	O
473	##ben	O
473	##zam	O
473	##ine	O
473	that	O
473	binds	O
473	i	O
473	##rre	O
473	##vers	O
473	##ibly	O
473	3	O
473	.	O
473	[SEP]	O
474	[CLS]	O
474	the	O
474	p	O
474	##har	O
474	##ma	O
474	##co	O
474	##kin	O
474	##etic	O
474	and	O
474	p	O
474	##har	O
474	##ma	O
474	##co	O
474	##dynamic	O
474	profiles	O
474	of	O
474	in	O
474	##tra	O
474	##ven	O
474	##ous	O
474	and	O
474	oral	O
474	do	O
474	##xa	O
474	##zo	O
474	##sin	O
474	were	O
474	investigated	O
474	in	O
474	6	O
474	norm	O
474	##ote	O
474	##ns	O
474	##ive	O
474	volunteers	O
474	.	O
474	[SEP]	O
475	[CLS]	O
475	additional	O
475	studies	O
475	are	O
475	required	O
475	to	O
475	further	O
475	investigate	O
475	c	O
475	##y	O
475	##p	O
475	##45	O
475	##0	O
475	p	O
475	##oly	O
475	##mor	O
475	##phism	O
475	effects	O
475	on	O
475	et	O
475	##ham	O
475	##but	O
475	##ol	O
475	p	O
475	##har	O
475	##ma	O
475	##co	O
475	##kin	O
475	##etics	O
475	.	O
475	[SEP]	O
476	[CLS]	O
476	group	O
476	i	O
476	received	O
476	twice	O
476	daily	O
476	250	O
476	mg	O
476	of	O
476	metro	O
476	##ni	O
476	##da	O
476	##zo	O
476	##le	O
476	(	O
476	supplied	O
476	as	O
476	250	O
476	mg	O
476	tablets	O
476	v	O
476	##agi	O
476	##mi	O
476	##d	O
476	)	O
476	.	O
476	[SEP]	O
477	[CLS]	O
477	in	O
477	a	O
477	survey	O
477	of	O
477	290	O
477	patients	O
477	with	O
477	pm	O
477	##d	O
477	,	O
477	muscle	O
477	weakness	O
477	,	O
477	chronic	O
477	fatigue	O
477	,	O
477	exercise	O
477	into	O
477	##ler	O
477	##ance	O
477	,	O
477	gas	O
477	##tro	O
477	##int	O
477	##est	O
477	##inal	O
477	problems	O
477	,	O
477	and	O
477	balance	O
477	problems	O
477	were	O
477	the	O
477	5	O
477	most	O
477	common	O
477	symptoms	O
477	experienced	O
477	in	O
477	>	O
477	75	O
477	%	O
477	of	O
477	patients	O
477	.	O
477	7	O
477	primary	O
477	mitochondrial	O
477	my	O
477	##op	O
477	##athy	O
477	(	O
477	pm	O
477	##m	O
477	)	O
477	is	O
477	a	O
477	pm	O
477	##d	O
477	affecting	O
477	predominantly	O
477	,	O
477	but	O
477	not	O
477	exclusively	O
477	,	O
477	skeletal	O
477	muscle	O
477	.	O
477	8	O
477	pm	O
477	##m	O
477	can	O
477	be	O
477	very	O
477	di	O
477	##sa	O
477	##bling	O
477	and	O
477	adverse	O
477	##ly	O
477	affects	O
477	patients	O
477	'	O
477	quality	O
477	of	O
477	life	O
477	##9	O
477	,	O
477	10	O
477	with	O
477	no	O
477	available	O
477	treatments	O
477	to	O
477	be	O
477	used	O
477	aside	O
477	from	O
477	p	O
477	##all	O
477	##ia	O
477	##tive	O
477	approaches	O
477	.	O
477	1	O
477	,	O
477	9	O
477	,	O
477	11	O
477	[SEP]	O
478	[CLS]	O
478	the	O
478	ass	O
478	##ay	O
478	ranges	O
478	from	O
478	25	O
478	to	O
478	500	O
478	ng	O
478	/	O
478	m	O
478	##l	O
478	with	O
478	a	O
478	functional	O
478	sensitivity	O
478	(	O
478	at	O
478	20	O
478	%	O
478	coefficient	O
478	of	O
478	variation	O
478	)	O
478	of	O
478	30	O
478	ng	O
478	/	O
478	m	O
478	##l	O
478	.	O
478	[SEP]	O
479	[CLS]	O
479	we	O
479	investigated	O
479	the	O
479	f	O
479	##eas	O
479	##ibility	O
479	of	O
479	using	O
479	sa	O
479	##liva	O
479	for	O
479	compliance	O
479	monitoring	O
479	of	O
479	z	O
479	##ido	O
479	##vu	O
479	##dine	O
479	(	O
479	z	O
479	##d	O
479	##v	O
479	)	O
479	,	O
479	la	O
479	##mi	O
479	##vu	O
479	##dine	O
479	(	O
479	3	O
479	##t	O
479	##c	O
479	)	O
479	and	O
479	ne	O
479	##vir	O
479	##ap	O
479	##ine	O
479	(	O
479	n	O
479	##v	O
479	##p	O
479	)	O
479	in	O
479	29	O
479	hi	O
479	##v	O
479	-	O
479	1	O
479	infected	O
479	patients	O
479	from	O
479	r	O
479	##wan	O
479	##da	O
479	.	O
479	[SEP]	O
480	[CLS]	O
480	the	O
480	post	O
480	##ulated	O
480	role	O
480	of	O
480	p	O
480	-	O
480	g	O
480	##p	O
480	suggests	O
480	that	O
480	c	O
480	##el	O
480	is	O
480	clinical	O
480	##ly	O
480	active	O
480	,	O
480	and	O
480	advise	O
480	##s	O
480	caution	O
480	in	O
480	designing	O
480	combinations	O
480	of	O
480	p	O
480	##t	O
480	##x	O
480	with	O
480	other	O
480	drugs	O
480	that	O
480	are	O
480	substrate	O
480	for	O
480	p	O
480	-	O
480	g	O
480	##p	O
480	.	O
480	[SEP]	O
481	[CLS]	O
481	data	O
481	were	O
481	best	O
481	described	O
481	by	O
481	a	O
481	two	O
481	-	O
481	compartment	O
481	model	O
481	with	O
481	first	O
481	order	O
481	absorption	O
481	and	O
481	parallel	O
481	linear	O
481	and	O
481	non	O
481	##linear	O
481	elimination	O
481	pathways	O
481	.	O
481	[SEP]	O
482	[CLS]	O
482	the	O
482	ass	O
482	##ay	O
482	was	O
482	linear	O
482	up	O
482	to	O
482	400	O
482	ng	O
482	/	O
482	m	O
482	##l	O
482	of	O
482	s	O
482	##n	O
482	-	O
482	38	O
482	in	O
482	tissue	O
482	ho	O
482	##mo	O
482	##gen	O
482	##ates	O
482	,	O
482	and	O
482	may	O
482	be	O
482	extended	O
482	to	O
482	120	O
482	micro	O
482	##g	O
482	/	O
482	m	O
482	##l	O
482	by	O
482	proper	O
482	di	O
482	##lution	O
482	of	O
482	samples	O
482	over	O
482	the	O
482	upper	O
482	limit	O
482	of	O
482	q	O
482	##uant	O
482	##itation	O
482	.	O
482	[SEP]	O
483	[CLS]	O
483	in	O
483	stage	O
483	i	O
483	##v	O
483	patients	O
483	,	O
483	the	O
483	onset	O
483	of	O
483	toxic	O
483	##ities	O
483	was	O
483	also	O
483	delayed	O
483	with	O
483	p	O
483	##k	O
483	monitoring	O
483	(	O
483	p	O
483	=	O
483	.	O
483	06	O
483	##0	O
483	##5	O
483	)	O
483	.	O
483	[SEP]	O
484	[CLS]	O
484	actual	O
484	p	O
484	##har	O
484	##ma	O
484	##co	O
484	##kin	O
484	##etic	O
484	sampling	O
484	times	O
484	were	O
484	used	O
484	in	O
484	the	O
484	p	O
484	##har	O
484	##ma	O
484	##co	O
484	##kin	O
484	##etic	O
484	analysis	O
484	;	O
484	data	O
484	points	O
484	with	O
484	missing	O
484	dos	O
484	##ing	O
484	or	O
484	sampling	O
484	time	O
484	information	O
484	were	O
484	excluded	O
484	from	O
484	the	O
484	analysis	O
484	.	O
484	[SEP]	O
485	[CLS]	O
485	r	O
485	-	O
485	125	O
485	##5	O
485	##28	O
485	is	O
485	a	O
485	plasma	O
485	meta	O
485	##bol	O
485	##ite	O
485	and	O
485	is	O
485	cleared	O
485	solely	O
485	by	O
485	c	O
485	##y	O
485	##p	O
485	##2	O
485	##d	O
485	##6	O
485	despite	O
485	its	O
485	acid	O
485	##ity	O
485	.	O
485	[SEP]	O
486	[CLS]	O
486	est	O
486	##imation	O
486	of	O
486	met	O
486	##had	O
486	##one	O
486	clearance	B-PK
486	:	O
486	application	O
486	in	O
486	the	O
486	management	O
486	of	O
486	cancer	O
486	pain	O
486	.	O
486	[SEP]	O
487	[CLS]	O
487	h	O
487	/	O
487	m	O
487	##l	O
487	,	O
487	respectively	O
487	,	O
487	which	O
487	were	O
487	three	O
487	##fold	O
487	higher	O
487	than	O
487	those	O
487	of	O
487	s	O
487	##yn	O
487	-	O
487	286	O
487	##9	O
487	.	O
487	[SEP]	O
488	[CLS]	O
488	te	O
488	##rb	O
488	##ina	O
488	##fine	O
488	and	O
488	dem	O
488	##eth	O
488	##yl	O
488	##ter	O
488	##bina	O
488	##fine	O
488	are	O
488	only	O
488	ex	O
488	##cre	O
488	##ted	O
488	as	O
488	trace	O
488	amounts	O
488	in	O
488	urine	O
488	.	O
488	[SEP]	O
489	[CLS]	O
489	sample	O
489	preparation	O
489	involved	O
489	only	O
489	protein	O
489	precipitation	O
489	without	O
489	any	O
489	complicated	O
489	extraction	O
489	procedures	O
489	decreasing	O
489	analysis	O
489	time	O
489	.	O
489	[SEP]	O
490	[CLS]	O
490	as	O
490	for	O
490	the	O
490	c	O
490	.	O
490	-	O
490	154	O
490	##7	O
490	##t	O
490	>	O
490	g	O
490	variant	O
490	,	O
490	similar	O
490	to	O
490	the	O
490	s	O
490	##p	O
490	##1	O
490	em	O
490	##sa	O
490	ass	O
490	##ay	O
490	,	O
490	we	O
490	confirmed	O
490	the	O
490	position	O
490	of	O
490	the	O
490	d	O
490	##na	O
490	-	O
490	us	O
490	##f	O
490	##1	O
490	complex	O
490	in	O
490	competition	O
490	or	O
490	super	O
490	##shi	O
490	##ft	O
490	ass	O
490	##ays	O
490	after	O
490	in	O
490	##cu	O
490	##bation	O
490	of	O
490	nuclear	O
490	proteins	O
490	with	O
490	32	O
490	##p	O
490	-	O
490	labeled	O
490	us	O
490	##f	O
490	##1	O
490	consensus	O
490	o	O
490	##li	O
490	##gon	O
490	##uc	O
490	##leo	O
490	##tide	O
490	##s	O
490	(	O
490	lanes	O
490	1	O
490	–	O
490	3	O
490	,	O
490	fi	O
490	##g	O
490	.	O
490	2	O
490	##b	O
490	)	O
490	.	O
490	[SEP]	O
491	[CLS]	O
491	the	O
491	disposition	O
491	characteristics	O
491	of	O
491	(	O
491	-	O
491	)	O
491	-	O
491	q	O
491	##uin	O
491	##uc	O
491	##lid	O
491	##in	O
491	##yl	O
491	ben	O
491	##zy	O
491	##late	O
491	(	O
491	q	O
491	##n	O
491	##b	O
491	)	O
491	were	O
491	investigated	O
491	in	O
491	rats	O
491	,	O
491	and	O
491	a	O
491	physiological	O
491	##ly	O
491	based	O
491	p	O
491	##har	O
491	##ma	O
491	##co	O
491	##kin	O
491	##etic	O
491	model	O
491	was	O
491	established	O
491	using	O
491	its	O
491	linear	O
491	and	O
491	non	O
491	##linear	O
491	tissue	O
491	binding	O
491	parameters	O
491	.	O
491	[SEP]	O
492	[CLS]	O
492	β	O
492	-	O
492	car	O
492	##ote	O
492	##ne	O
492	supplement	O
492	##ation	O
492	with	O
492	50	O
492	,	O
492	000	O
492	i	O
492	##u	O
492	per	O
492	day	O
492	for	O
492	28	O
492	days	O
492	also	O
492	resulted	O
492	in	O
492	a	O
492	significant	O
492	increase	O
492	in	O
492	the	O
492	c	O
492	##d	O
492	##4	O
492	+	O
492	%	O
492	and	O
492	c	O
492	##d	O
492	##4	O
492	+	O
492	:	O
492	c	O
492	##d	O
492	##8	O
492	+	O
492	ratio	O
492	in	O
492	our	O
492	subjects	O
492	none	O
492	of	O
492	which	O
492	had	O
492	a	O
492	base	O
492	##line	O
492	car	O
492	##ote	O
492	##ne	O
492	deficiency	O
492	.	O
492	[SEP]	O
493	[CLS]	O
493	blood	O
493	samples	O
493	were	O
493	collected	O
493	in	O
493	s	O
493	##ter	O
493	##ile	O
493	p	O
493	##oly	O
493	##p	O
493	##rop	O
493	##yle	O
493	##ne	O
493	tubes	O
493	for	O
493	24	O
493	hours	O
493	after	O
493	each	O
493	f	O
493	##ent	O
493	##any	O
493	##l	O
493	administration	O
493	.	O
493	[SEP]	O
494	[CLS]	O
494	the	O
494	samples	O
494	were	O
494	son	O
494	##ica	O
494	##ted	O
494	for	O
494	5	O
494	minutes	O
494	to	O
494	dissolve	O
494	the	O
494	pre	O
494	##ci	O
494	##pit	O
494	##ate	O
494	,	O
494	and	O
494	the	O
494	drug	O
494	concentration	O
494	in	O
494	each	O
494	sample	O
494	was	O
494	determined	O
494	by	O
494	hp	O
494	##l	O
494	##c	O
494	ass	O
494	##ay	O
494	as	O
494	mentioned	O
494	above	O
494	.	O
494	[SEP]	O
495	[CLS]	O
495	the	O
495	two	O
495	o	O
495	##me	O
495	##pra	O
495	##zo	O
495	##le	O
495	products	O
495	failed	O
495	to	O
495	show	O
495	bio	O
495	##e	O
495	##qui	O
495	##valence	O
495	,	O
495	with	O
495	the	O
495	observed	O
495	differences	O
495	being	O
495	even	O
495	more	O
495	apparent	O
495	after	O
495	multiple	O
495	doses	O
495	,	O
495	as	O
495	post	O
495	##ulated	O
495	.	O
495	[SEP]	O
496	[CLS]	O
496	au	B-PK
496	##c	I-PK
496	(	I-PK
496	0	I-PK
496	–	I-PK
496	t	I-PK
496	)	I-PK
496	was	O
496	increased	O
496	by	O
496	40	O
496	%	O
496	(	O
496	90	O
496	%	O
496	c	O
496	##i	O
496	29	O
496	.	O
496	1	O
496	,	O
496	52	O
496	.	O
496	0	O
496	)	O
496	,	O
496	but	O
496	there	O
496	was	O
496	no	O
496	effect	O
496	on	O
496	cm	B-PK
496	##ax	I-PK
496	(	O
496	table	O
496	2	O
496	)	O
496	.	O
496	[SEP]	O
497	[CLS]	O
497	p	O
497	##t	O
497	##x	O
497	-	O
497	l	O
497	##pps	O
497	with	O
497	mass	O
497	median	O
497	a	O
497	##ero	O
497	##dynamic	O
497	diameter	O
497	(	O
497	mm	O
497	##ad	O
497	)	O
497	of	O
497	5	O
497	.	O
497	74	O
497	±	O
497	0	O
497	.	O
497	09	O
497	μ	O
497	##m	O
497	,	O
497	high	O
497	en	O
497	##cap	O
497	##sul	O
497	##ation	O
497	efficiency	O
497	and	O
497	good	O
497	a	O
497	##ero	O
497	##sol	O
497	##isation	O
497	properties	O
497	were	O
497	produced	O
497	using	O
497	am	O
497	##mon	O
497	##ium	O
497	bi	O
497	##car	O
497	##bon	O
497	##ate	O
497	as	O
497	p	O
497	##oro	O
497	##gen	O
497	.	O
497	[SEP]	O
498	[CLS]	O
498	we	O
498	recently	O
498	proposed	O
498	a	O
498	p	O
498	##oly	O
498	-	O
498	p	O
498	##k	O
498	strategy	O
498	to	O
498	character	O
498	##ize	O
498	the	O
498	concentration	O
498	-	O
498	time	O
498	profile	O
498	and	O
498	the	O
498	metabolic	O
498	response	O
498	profile	O
498	of	O
498	multi	O
498	##com	O
498	##po	O
498	##nent	O
498	h	O
498	##ms	O
498	using	O
498	an	O
498	integrated	O
498	p	O
498	##hy	O
498	##to	O
498	##chemical	O
498	and	O
498	meta	O
498	##bol	O
498	##omi	O
498	##cs	O
498	approach	O
498	.	O
498	[SEP]	O
499	[CLS]	O
499	a	O
499	prominent	O
499	decrease	O
499	in	O
499	ps	O
499	was	O
499	observed	O
499	,	O
499	along	O
499	with	O
499	improved	O
499	en	O
499	##tra	O
499	##pment	O
499	efficiency	O
499	,	O
499	collectively	O
499	(	O
499	figure	O
499	1	O
499	##c	O
499	)	O
499	.	O
499	[SEP]	O
